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-secretase is an important protease complex responsible for the cleavage of over 100 substrates 
within their transmembrane domains. Among these substrates is the AMYLOID BETA (A4) 
PRECURSOR PROTEIN (APP), which is most well-known for its involvement in Alzheimer’s 
disease (AD) pathology and the p75 neurotrophin receptor (p75NTR). 
This thesis aimed to investigate γ-secretase and its substrates, p75NTR and APP, in a number of 
ways; Aim 1) to dissect the structural determinants contributing to selection of substrates by γ-
secretase using an assay-based system, Aim 2) to investigate the molecular effects of fAD-like and 
null mutations in zebrafish appa and appb, by generating mutations in endogenous genes with 
genome editing technologies, and Aim 3) to investigate the aggregation propensity of Aβ-42-like 
peptides of Appa and Appb using predictive software. 
How -secretase cleavage site specificity is determined is still unclear. A previous study 
investigating the proteolytic processing of p75NTR and its homolog NRH1 (neurotrophin receptor 
homolog 1) found that transmembrane cleavage of NRH1 was not sensitive to the -secretase 
inhibitor DAPT, suggesting that it is not processed by -secretase. We have previously identified 
zebrafish orthologues of the p75NTR and Nrh1 genes and have developed in-vivo assays to assess 
cleavage of the p75NTR and Nrh1 proteins.  
To address Aim 1, we first improved upon our previous assay system by switching out the internal 
reference standard mCherry for a second GFP sequence. A chimeric construct was then designed, 
in which the Nrh1 transmembrane domain was replaced with the transmembrane domain of 
p75NTR, to allow us to determine whether this domain can confer -secretase cleavage susceptibility 
to Nrh1. Our results indicate that the p75NTR transmembrane domain alone is not sufficient to 
confer γ-secretase susceptibility to Nrh1. 
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Missense mutations in the APP gene cause approximately 15% of dominantly inherited familial 
Alzheimer’s Disease (fAD). Currently 59 mutations are known and are listed on Alzforum 
(https://www.alzforum.org/mutations/app). The human APP gene has two co-orthologues in 
zebrafish, appa and appb. To address Aim 2, we attempted to utilise genome editing technology 
to generate fAD-like and null mutations in these zebrafish genes. Despite the various challenges 
associated with this project, a putative null mutation of the zebrafish appb gene was ultimately 
generated.  
Hypoxia is thought to be a risk factor for AD. A previous study in our laboratory measured the 
hypoxic response of 6-month-old zebrafish carrying fAD-like mutations in psen1 and observed an 
increased hypoxic response in these mutants under normoxia and a further increase under hypoxia. 
We measured the hypoxic response in our 6-month-old heterozygous appb putative null mutant 
zebrafish. However, there was no observable difference in the hypoxic response of our mutants 
compared to 6-month-old wildtypes. In future, our appb null mutation should serve to elucidate 
the role of this gene in neural function and its interactions with the other fAD genes.  
Aβ is proposed to be a key pathogenic molecule in AD. It is unknown whether APP genes in 
zebrafish form aggregation prone Aβ42-like peptides as occurs in the aging human brain. To 
address Aim 3 a bioinformatics approach was employed. Analyses using multiple software 
revealed that the predicted Aβ-42-like peptide of Appa zebrafish had similar aggregation 
propensity potential to that of human Aβ-42. The peptides we analysed consistently showed two 
domains of high aggregation propensity, one at the C-terminus and one in the middle of the peptide. 
Interestingly, the Aβ-42-like peptide of zebrafish Appb had comparable aggregation potential to 
human Aβ-42 in its C-terminal end but not in its mid-peptide region, suggesting that this peptide 
may not be as aggregation prone as human Aβ-42. 
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Chapter 1 – Literature Review 
1.1 γ-secretase is a protease complex that is responsible for the cleavage of many 
substrates 
γ-secretase is an important multi-subunit membrane-bound aspartyl protease complex that is 
responsible for the cleavage of more than 100 substrates, including; Amyloid Precursor Protein 
(APP), Notch and the p75 neurotrophin receptor (p75NTR) [reviewed in 1, 2]. γ-secretase is a 
member of the intramembrane cleaving protease family (I-CLiP), which cleave type 1 membrane 
proteins enzymatically via a process termed regulated intramembrane proteolysis (RIP) [reviewed 
in 1, 2].   
The most studied function of γ-secretase amongst the literature is its processing of APP. This is 
due to the seemingly critical role of APP in Alzheimer’s disease (AD) etiology. γ-secretase’s 
involvement in the sequential cleavage of APP can lead to increased Amyloid β-42 residue (Aβ-
42) deposition. Aβ-42 is a neurotoxic peptide that aggregates and eventually forms senile/neuritic 
plaques (extracellular deposits of Aβ) in the central nervous system (CNS) [3]. This intensive 
research into γ-secretase processing of APP has been performed in the hopes of devising a potential 
method of treatment for AD [1, 4].  
p75NTR, also known as the ‘low-affinity nerve growth factor receptor’ (LNGFR), is another of the 
many substrates that is subject to cleavage within its transmembrane domain by -secretase [5]. 
p75NTR is involved in development and maintenance of the nervous system through its interaction 
with the neurotrophins and Trk receptors [6, 7]. p75NTR has also been implicated in AD [8], where 
it is hypothesised to play a role in cholinergic neuron loss via the Aβ peptide, which acts as a ligand 
for p75NTR [8]. γ-secretase cleavage also has a crucial role in the processing of Notch. The Notch 
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receptor is a very well characterised signalling molecule. Notch signalling is vital for the 
determination of cell fate during embryogenesis and development [9, 10]. 
 
Components of the γ-secretase complex 
The structure and mechanism of proteolysis by γ-secretase is still not completely characterised 
[11]. The multi-subunit -secretase complex is comprised of four major components (Figure 1.1), 
originally identified in Caenorhabditis elegans [12, 13]. They include; PRESENILINs (either 
PSEN1 or PSEN2), Nicastrin (NCSTN), Anterior pharynx defective-1 (Aph-1a or Aph-1b) and 
Presenilin enhancer-2 (PSENEN or Pen-2). These integral membrane proteins provide the minimal 
requirement for a functional -secretase complex and exist in 1:1:1:1 stoichiometry [reviewed in 
1, 2, 11, 14]. Previous studies using Saccharomyces cerevisiae confirmed these four components 
to be necessary and sufficient for -secretase activity [reviewed in 2]. The γ-secretase complex can 
exist in at least eight different possible compositions, as both PSEN and APH-1 can exists in two 
forms (PSEN1 and PSEN2 and APH-1a and APH-1b) and Aph-1a is also able to generate two 
individual isoforms due to alternative splicing events (APH1aS and APH-1aL) [15]. These 
multiple compositions may have a number of different possible functions, including; substrate 
affinity, diversity in activities and/or implications for different subcellular localisations [2, 14].  
NCSTN is a type 1 membrane protein which has a large, heavily glycosylated extracellular 
domain. Originally, NCSTN was thought to recruit γ-secretase substrates through interaction 
between a conserved glutamate residue in its ectodomain and the N-terminal stub of the substrate 
[16]. However, experiments demonstrated that mutation of this glutamate residue does not result 
in loss of substrate attraction and binding by γ-secretase [17]. Also, a γ-secretase complex of 
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PSEN1/PSENEN/Aph1a was found to cleave APP and Notch in the absence of NCSTN [18]. Such 
findings suggest that while NCSTN may be involved in stabilisation of the complex, it is not 
indispensable for recognition of substrates. More recent findings suggest that NCSTN may operate 
as a gatekeeper for substrates of γ-secretase by sterically barring substrates that have not undergone 
ectodomain shedding from accessing the PRESENILIN active site [19] 
 
 
Figure 1.1. The multi-subunit γ-secretase complex. Presenilin provides catalytic activity of the complex. 
Presenilin, Nicastrin, APH-1 and PEN2 together are necessary and sufficient for γ–secretase activity 
[Adapted from 27]. 
 
PSENEN is a small (~12kDa) membrane protein with a hairpin-like structure. It is thought to be 
integral in stabilisation of the complex, which has been determined by mutagenesis studies [20, 
21]. PSENEN directly interacts with the fourth transmembrane domain (TMD4) of PSEN1 [22, 
23], and is also thought to assist PSENs in endoproteolysis [20, 24]. Aph-1 is a ~30kDa 
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transmembrane protein that associates with Nct and PSENs [12]. Aph-1 binds to immature Nct via 
its GxxxG motif and traffics this protein to the immature PSEN holoprotein [25]. Aph-1 is also 
thought to stabilise the γ-secretase complex [26].  
 
The role of PRESENILINS in γ-secretase activity 
The PSEN1 and PSEN2 proteins both undergo endoproteolysis to produce two fragments: a C-
Terminal fragment (CTF) and an N-terminal fragment (NTF). This self-cleavage of PSENs has 
been shown to be promoted by PSENEN [28]. The two PSEN fragments associate to form a 
functional heterodimer, the active form of PSEN [reviewed in 14]. This heterodimer exists in the 
γ-secretase complex and makes up the catalytic core of this membrane anchored protease [16, 29]. 
Research into the PSENs has a complex history and for many years there was doubt as to whether 
the PSENs were responsible for γ-secretase cleavage activity. Early investigations in the lower 
eukaryote Pichia pastoris revealed that a lack of PSENs does not impede γ-secretase-like 
proteolytic processing of APP, suggesting that PSENs were not necessary for this function [30]. A 
study involving the processing of another γ-secretase substrate Notch, suggested that while PSENs 
do play a role in Notch processing they are not necessarily responsible for the direct cleavage of 
this substrate [31]. Another study found that small changes in pH conditions of an in vitro assay 
for γ-secretase can result in changes in the ability to inhibit a γ-secretase-like cleavage of APP 
[32]. A paper published by Ahn et al (2010) demonstrated that PSEN1 does have γ-secretase 
catalytic function [28]. They demonstrated that recombinant PSEN (rPS) exhibits γ-secretase 
activity and that rPS mutants lacking the catalytic aspartate residues lose this activity [28]. 
Furthermore, rPS harbouring familial Alzheimer’s disease (fAD) causing mutations led to elevated 
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Aβ42-40 ratio produced from a wild type APP [28]. Supplementing this are PSEN1 knockout 
studies conducted in mice by De Strooper et al (1998), in which secretion of Aβ peptide was 
strongly inhibited. There was also accumulation of APP C-terminal fragments in PSEN1 deficient 
mouse neurons. Taken together, these findings provide a firm argument that PSEN is indeed 
responsible for the catalytic activity observed in γ-secretase [33]. Lending further support to this 
argument is the finding by Wolfe et al (1999), that two aspartate residues in PSENs are vital, both 
for endoproteolysis of PSEN and γ-secretase cleavage of substrates [34].  
 
The mystery of substrate recognition and selection by γ-secretase 
The specific nature of substrate selection by γ-secretase is still not clearly defined. γ-secretase 
substrates are typically derived from large precursor proteins that undergo a prerequisite removal 
of their ectodomain prior to γ-secretase cleavage, in a process termed “ectodomain shedding” [2]. 
Indeed, γ-secretase substrate recognition and cleavage are much more efficient for ectodomains 
with fewer than ~50 remaining amino acid residues [9]. In early studies, the only other observed 
prerequisite was that the substrate must be a type 1 membrane protein [16]. Later studies suggested 
that dimerization of substrates and/or the structure of substrate α-helices may regulate γ-secretase 
activity [35]. More recently, cryo-electron microscopy (cryo-EM) has been utilised to solve 
structures of the γ-secretase complex [36]. Unfortunately, the findings of this study did not reveal 
further details of how the γ-secretase complex interacts with its substrates. However, subsequent 
studies utilising cryo-EM improved the resolution of the human γ-secretase complex and revealed 
conformational flexibility upon substrate binding [37, 38]. Furthermore, a cryo-EM study by Bai 
et al (2015) seemingly supports that the previously mentioned glutamate residue (Glu333), along 
with a tyrosine residue (Try337), of NCSTN likely play a role in substrate recruitment [38, 39]. 
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Other recent findings suggested a mechanism whereby γ-secretase trims substrates within their 
transmembrane domains (TMD) from within three substrate binding pockets (S1′, S2′ and S3′). 
These three substrate binding pockets trim peptides in intervals of three amino acids [19]. Even 
more recently, there have been two studies published that utilised cryo-EM to resolve structures 
of the γ-secretase complex bound to either Notch or APP [40, 41]. Both studies reported similar 
confirmations in binding of their respective substrate, where, the initial two-thirds of the TMD 
formed a helical conformation and the final third was unwound into a β-strand to engage the active 
site. Moreover, specific TMDs of PRESENILIN changed conformationally in order to interact 
with both substrates [19]. These findings are a great step forward in our understanding of γ-
secretase substrate recognition, however, there remains much unknown about this process. 
 
1.2 The p75 neurotrophin receptor (p75NTR) 
The p75 neurotrophin receptor (p75NTR), also known as the ‘low-affinity nerve growth factor 
receptor’ (LNGFR), is one of the 100+ substrates that is subject to cleavage within its 
transmembrane domain by γ-secretase. p75NTR is a member of the tumour necrosis factor 
(TNF)/nerve growth factor (NGF) superfamily [5]. As its name suggests, p75NTR acts as a receptor 
for the neurotrophins (NT’s), both in their pro-NT (immature) and mature forms [reviewed in 6]. 
Neurotrophins are a family of protein growth factors, vital in the maintenance and development of 
the nervous system. The four neurotrophins are; 1. Nerve growth factor (NGF), 2. Brain derived 
neurotrophic factor (BDNF), 3. Neurotrophin-3 (NT-3) and 4. Neurotrophin-4 (NT-4) [reviewed 




P75NTR has an ECD (extracellular domain) containing a signal peptide and a cysteine-rich motif of 
four repeats. It has a transmembrane domain which is the site of γ-secretase cleavage and through 
which it has been found to form a homodimer at the cell surface [35]. This homodimer is thought 
to be involved in receptor-ligand interactions. It also has an ICD with a ‘death domain’ motif that 
shares similarity to the TNF (tumour necrosis factor) family of proteins. The ICD also contains a 
PEST sequence, an indicative character for proteins that undergo proteasome degradation [6, 35]. 
More recently, the p75ECD has been shown to be neuroprotective in mouse brain [44]. 
The ICD (intracellular domain) of p75NTR can promote both apoptosis and cell survival upon 
release into the cytosol [43]. There are several described protein interactions which alter the final 
product of p75NTR signalling. Promotion of neuronal survival is achieved through p75NTR binding 
with TrkA in the presence of NGF (Figure 1.2) [reviewed in 6, 42]. Another interaction is p75NTR 
with sortilin (SORT1) (Figure 1.2). Interaction of the p75NTR/SORT1 heterodimeric complex with 
proNGF or proBDNF leads to apoptosis [reviewed in 6, 43]. 
 
p75NTR proteolysis is carried out by α- and γ-secretases 
The proteolysis of p75NTR (Figure 1.3) is very similar to that of two of γ-secretase other substrates, 
APP and Notch. Initially p75NTR is subject to cleavage 15 amino acids N-terminal to the 
transmembrane domain by α-secretase, leaving a membrane-anchored CTF [45]. This α-secretase 
cleavage of p75NTR is mediated by a member of the ‘A Disintegrin and Metalloproteinase’ 
(ADAM) family [45]. Whether this cleavage is mediated by ADAM10 or ADAM17 has not been 
firmly established. Experiments by Kanning et al (2003) suggest that it is ADAM10 which 
provides the primary cleavage event [5]. However, evidence provided by Weskamp et al (2003) 
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and Forsyth et al (2014), suggests that ADAM17 that is responsible for ECD shedding [46, 47]. It 
is possible that both ADAM10 and ADAM17 can cleave p75NTR. Following the shedding of the 
p75NTR ectodomain there is a firmly established cleavage event by γ-secretase [5, 6]. This occurs 
within the transmembrane domain of p75NTR although the specific position has not been well 
defined. This cleavage releases the ICD into the cytoplasm, which is responsible for downstream 
signalling leading to either cell survival or apoptosis [42, 43]. The processing of p75NTR by γ-




Figure 1.2. p75NTRcan interact with both Sortilin and TrkA receptors to promote cell death or survival 




p75NTR has two homologues with distinct cleavage properties 
Our interest in the issue of γ-secretase-like cleavage activities was piqued by a paper published by 
Kanning et al (2003) investigating the proteolytic processing of p75NTR, along with what they 
described as the “neurotrophin receptor homologs” (NRH), NRH1 and NRH2 [5]. Database and 
EST searches have established that these two genes show greater sequence similarity to p75NTR 
than its previously known closest relative sequences. Kanning et al (2003) found that NRH 
subfamily members share approximately 30% identity in their ICD across species, whereas only 
13% identity is shared with the ICD of p75NTR next nearest known relative sequence, human 
TNFR1 [5]. p75NTR and the NRH genes are described as a subfamily of the nerve growth factor 
(NGF)/tumour necrosis factor (TNF) family. NRH2 exists only in mammals and NRH1 exists only 
in amphibians, fish and chickens. Alignment of p75NTR with both homologs revealed a high degree 
of similarity in ICD and transmembrane domains [5]. 
Experiments investigating the proteolytic processing of p75NTR confirmed its processing by α- and 
γ-secretase. Results from Western blot analysis of NRH1 and NRH2 indicated that they are both 
cleaved within the transmembrane domain [5]. Using proteasome inhibitors, particularly the 
commonly used γ-secretase inhibitor DAPT, Kanning et al (2003) observed that DAPT had no 
effect on the cleavage of NRH1 or NRH2, suggesting that transmembrane cleavage of these 
proteins is not by γ-secretase [5]. Inconsistencies within the literature pertaining to this conclusion 
do exist. For example, a paper published by Zampieri et al (2005) stated that NRH2 is a target of 
both α- and γ-secretase activities [45]. However, no references or experimental data were provided 
as evidence for this statement [45]. It is true that the presence or absence of α-secretase cleavage 
of both NRH1 and NRH2 was not clearly assessed by Kanning et al (2003) [5]. However, their 
experimental procedures and controls addressing γ-secretase cleavage were sound and convincing. 
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As such it is increasingly clear that this cleavage must arise from another, currently unknown 
processing event. It would be interesting to investigate further the events which are involved in the 
processing of NRH1 that eventually lead to the release of its ICD. 
 
 
Figure 1.3. Cleavage events of p75NTR and its homolog NRH1. Both p75NTR and NRH1 are cleaved first 
in the extracellular domain by α-secretase and then in the transmembrane domain. While p75NTR is 
cleaved in the TMD by γ-secretase, the enzyme that cleaves NRH1 at this position remains unknown. 
 
The p75NTR homolog of greatest interest to this thesis is NRH1, as this is the p75NTR homolog in 
zebrafish. We have previously observed that zebrafish NRH1 is not subject to γ-secretase-
dependent cleavage [48]. However, the nature of primary cleavage events, although potentially 
mediated by α-secretase, remains uncertain [5]. The high sequence and structural similarity 
between NRH1 and p75NTR [5] makes the lack of γ-secretase-dependent cleavage of NRH1 
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particularly intriguing, since the genes coding for these proteins must have arisen by duplication 
of a common ancestor. Further investigation of NRH1 processing events would be of interest, as 
this may give us some insight into; 1) the evolution of γ-secretase cleavage of p75NTR and 2) 
substrate selection by γ-secretase in general. 
 
1.3 Epidemiology, history and etiology of Alzheimer’s disease 
As previously mentioned, γ-secretase is most studied for its role in APP processing, through which 
production of the neurotoxic Aβ-42 peptide is thought to contribute to the observed 
neurodegeneration in AD. Alzheimer’s is the most common form of dementia, with 50-70% of all 
dementia cases in Australia diagnosed as AD. More than 413,000 Australians are living with some 
form of dementia and it has been estimated that, by 2050, 1,000,000 Australians will be living with 
dementia. There is currently no cure for AD, even though it is the second leading cause of death 
in Australia (https://alzheimers.com.au/about-alzheimers/). As there is currently no cure, there is 
an intense research effort into all aspects of AD biology to attempt to identify one. 
In 1901 at the Frankfurt Psychiatric Hospital, Alois Alzheimer began treating a 51 year old female 
patient, Auguste Deter. She had been admitted to hospital for symptoms that are associated with 
AD to this day; paranoia, sleep disorder, memory disturbance, aggressive behaviour and confusion 
[49]. After her death in 1906, Alzheimer performed post-mortem analysis on brain tissue from 
Auguste. His published observations described the presence of senile plaques and neurofibrillary 
tangles (NFT) within her cerebral cortex [50]. The presence of these two types of brain lesions has 
become widely accepted as the basis of characterisation of the disease. More than a century later, 
patients are still not confirmed as having had AD without displaying a similar brain pathology. 
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The characteristic senile plaques and NFT of AD are located in both the temporal neocortex and 
hippocampus [51, 52]. Plaques and NFT are a downstream effect of abnormal deposition of the 
Aβ peptide and hyperphosphorylated tau protein respectively. The deposition of these proteins 
results in neuronal loss and neurotoxicity by unknown mechanisms [53]. Aβ peptides are believed 
to be capable of triggering oxidative stress, which is extensively observed in AD [54, 55]. This 
stimulation can occur both directly and indirectly. Aβ peptides are able to produce hydrogen 
peroxide directly and also generate free radicals via the reduction of metal ions [56, 57]. Aβ 
peptides can also influence the generation of free radicals through binding Aβ-binding alcohol 
dehydrogenase (ABAD), which forms a direct link between Aβ and mitochondria [58]. 
Neuroinflammation is another mechanism through which Aβ peptides produce oxidative stress. 
Many studies have supported the implication of neuroinflammation’s role in AD pathogenesis 
[59]. The neuronal death observed in AD is, in part, accredited to microglial and astrocyte 
activation. Both of these brain cell types are involved in the inflammatory and immune response 
to deposition of Aβ, and both have neuroprotective and neurodegenerative roles [60]. Studies have 
indicated that astrocytes are able to degrade Aβ deposits both in vitro and in situ, which suggests 
they may be involved in the clearance of Aβ aggregates [61]. Clustering of astrocytes at amyloid 
deposition sites lends further support to this proposed role. When activated, both microglia and 
astrocytes are known to release pro-inflammatory molecules. Microglia in particular have been 
shown to release proteases, cytokines (chemokines) and reactive oxygen species (ROS) in response 
to activation by Aβ, all of which are potentially neurotoxic [62]. 
There are two recognised forms of AD. Familial AD (fAD) also known as ‘early onset’ AD 
(EOAD) occurs in patients between the ages of 40 and 65 years of age. fAD is thought to represent 
approximately 2% of all AD. Sporadic AD (SAD) or ‘late onset’ AD (LOAD) occurs in patients 
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over the age of 65 and accounts for the majority of AD cases. Approximately 10% of fAD cases 
present a clear autosomal dominant inheritance pattern [63]. However, a more complex pattern of 
inheritance is observed in most cases of both forms of AD [64]. 
 
Genes implicated in familial Alzheimer’s disease 
There are currently three loci for autosomal dominant mutations associated with the rare familial 
form of AD (fAD). The first of these loci to be identified was APP, which encodes the Aβ peptide 
that is accumulated into amyloid plaques. 59 fAD contributing mutations have been described for 
the APP gene (https://www.alzforum.org/mutations/app). The methods by which APP mutations 
contribute to fAD will be discussed in more detail later. Linkage analysis identified that the two 
related genes known as PSEN1 and PSEN2 are also associated with fAD [65]. Mutations in PSEN1 
are the major contributor to fAD, with 300+ fAD mutations in this gene currently described. There 
are approximately 45 fAD-causing mutations in the gene encoding PSEN2 
(https://www.alzforum.org/mutations).  
Most fAD causing mutations are found in the PSEN1 gene. PSEN1 mutations are spread 
throughout the open reading frame of the gene but are more concentrated in sequences coding for 
trans-membrane (TM) domains 1-6 [66]. Both in vitro and in vivo studies have shown that PSEN 
mutations increase Aβ-42 or decrease Aβ-40, which leads to an altered Aβ-42/Aβ-40 ratio [67-
69]. However, studies using cell culture systems, while confirming an increase in Aβ42/Aβ40, 
showed that this was due to a decrease in Aβ-40 peptide levels [70]. Furthermore, Cacquevel et al 
(2012) confirmed that fAD-linked pathogenic mutations in PSEN1 result in a loss of γ-secretase 
activity that reduces Aβ-40 levels, thereby increasing the Aβ-42/Aβ-40 ratio [71]. Another study 
showed that the cerebral spinal fluid (CSF) of PSEN1 mutation carriers had much lower levels of 
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Aβ-42 than sporadic early onset AD patients [72]. These observations and others suggest that 
PSEN1 mutations can result in the observed altered ratio of Aβ peptides in a wide variety of ways. 
One question that remains is what the increased Aβ-42/Aβ-40 ratio observed for these PSEN1 
mutations mean in the context of AD development. Interestingly, Sun et al (2016) used an in vitro 
method to measure the production of Aβ-40 and Aβ-42 peptides from γ-secretase variants, where 
each variant carried 1 of 138 individual PSEN1 AD mutations [69]. Their study aimed to address 
the question of whether the Aβ-42/Aβ-40 ratio resulting from these different PSEN1 mutations, 
correlated with the mean age of onset of AD observed for each mutation. While they observed no 
such correlation, they also observed that some of the PSEN1 mutations increased γ-secretase 
activity rather than decreasing it (as had been observed in the studies above), further complicating 
the question of the role of PSEN1 mutations in AD [69]. 
 
Genes implicated in Late Onset Alzheimer’s Disease 
The gene with the strongest confirmed association to LOAD is apolipoprotein E (APOE). The 
polymorphic APOE gene has three allelic variants; ε2, ε3 and ε4. These isoforms are defined by 
variations in the amino acid residues at two positions in the 299 amino acid residue APOE protein, 
(112 and 158) that can alter its structure; ε2 allele (112 Cys, 158 Cys), ε3 allele (112 Cys, 158 Arg) 
and ε4 allele (112 Arg, 158 Arg) [reviewed in 73]. While the ε4 allele contributes increased 
susceptibility to AD, it is not necessary nor sufficient to cause this disease [74]. There is, however, 
a gene dosage effect associated with ε4. Carriers who are homozygous for the ε4 allele develop 
AD earlier than those who are heterozygous at this locus and may also have a greater burden of 
Amyloid [75]. Interestingly, while the ε4 allele seems to promote AD pathology, the ε2 allele is 
thought to be neuroprotective [76].  
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Regarding APOE’s role in AD risk there are several observations to consider. Firstly, APOE has 
been described to have a direct interaction with Aβ protein in vitro [77]. Furthermore, stimulation 
of APP endocytosis and metabolism by the ε4 allele, both in vitro and in vivo, can potentially 
enhance Aβ production [78, 79] and APOE can also potentially modulate Aβ toxicity [80]. Finally, 
there is strong evidence suggesting that extracellular clearance of in Aβ the brain is regulated by 
APOE [81] and that the ε4 allele has a reduced ability to clear aggregated amyloid in plaques [82]. 
 
LOAD risk factors identified during the GWAS era 
GWAS studies have been successfully used in the past to identify risk factors associated with 
complex disorders such as diabetes and Macular degeneration [83]. Since 2009, several Genome-
wide association studies (GWAS) have identified more than 40 novel genetic loci associated with 
AD risk, including; CLU, PICALM, and SORL1 [84].  
Early GWAS identified variants of clusterin (CLU) and two polymorphisms in 
Phosphatidylinositol binding clathrin assembly protein (PICALM) associated with LOAD [85]. 
CLU is expressed in cerebrospinal fluid, amyloid plaques and is up regulated in the brains of AD 
affected patients [86]. Interaction of CLU with soluble Aβ has been implicated by studies in guinea 
pig, which suggest the complexes formed are able to cross the blood brain barrier [87]. The 
function of CLU binding to Aβ and chaperoning it across the blood brain barrier may be to prevent 
formation of Aβ oligomers and fibrils [83]. Furthermore, there is a potential role for CLU in 
protecting cells against apoptosis and oxidative stress [83]. PICALM is expressed ubiquitously in 
all tissue types but most prominently in neurons [85]. PICALM has also been implicated in 
endocytosis of APP and generation of Aβ and increased cleavage and aggregation of this peptide 
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may also result from underexpression of PICALM [88]. Recently, evidence from in vitro and in 
vivo studies has implicated PICALM in Aβ transcytosis and clearance at the BBB [89]. 
Other potential AD susceptibility genes identified by GWAS analyses can be found on the 
“AlzGene” database (http://www.alzgene.org) [90]. These genes have a range of roles in AD 
neuropathology progression through regulation of Aβ. Other roles related to AD pathology include 
suppression of Tau phosphorylation and NFT formation, involvement in lipid metabolism, 
impaired inflammation and other cellular pathways [83]. Other AD risk genes, such as TREM2, 
have also been identified by both next generation sequencing (NGS) and the Alzheimer’s disease 
sequencing project (ADSP) [84]. 
 
The SORL1 gene potentially associates with both forms of AD 
In the preceding sections we discussed genes known to associate specifically with either fAD or 
LOAD, however, SORL1 is associated with both forms of AD. SORL1 was first identified to have 
an association with AD through microarray screening of AD patient lymphoblasts [91]. Since then 
it has been implicated in both LOAD through GWAS analysis [92, 93] and fAD through exome 
sequencing [94]) and a candidate gene approach [95]. Rare missense variants of SORL1 have now 
been identified that co-segregate with autosomal dominantly inherited AD [96]. Interestingly, 
these rare variants SORL1 are also often observed to co-occur with an APOE ε4 homozygous 
genotype, suggesting that, in these families, the cause of AD might be oligogenic [96].  
SORL1 is thought to act as an AD risk factor through trafficking and processing of APP [97]. 
Studies of mutant SORL1 variants demonstrated its ability to bind and traffic APP in two ways 
that potentially impair Aβ production. One of SORL1’s normal functions is to retrogradely sort 
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APP into the retromer recycling pathway, shuttling it from endosomes to the trans-Golgi network 
(TGN) [98]. Consequently, overexpressing SORL1 has been confirmed to decrease Aβ production 
in cell lines [95]. Conversely, suppression of SORL1 increased the levels of Aβ with subsequent 
increase in senile plaques in AD mouse models [99]. This suggests a second role for SORL1 in 
moving APP anterogradely into the endosome, which is where APP is processed to release Aβ. 
From there SORL1 has also been shown to direct Aβ to lysosomes to be degraded, thereby 
potentially protecting the brain by reducing Aβ levels [97, 100]. Another possible explanation for 
Aβ accumulation in response to SORL1 suppression might be that SORL1 competes with APP as 
a substrate for γ-secretase. Bohm et al (2006) previously demonstrated that SORL1 is also a 
substrate of γ-secretase, therefore it’s possible that a reduction of SORL1 levels in the brain would 
lead to increased processing of APP, consequently increasing Aβ [101] 
 
The Amyloid cascade hypothesis is the prevailing hypothesis for AD 
A complete understanding of the etiology of AD continues to prove elusive. The most commonly 
accepted hypothesis for the development of AD pathology is the ‘Amyloid Cascade’, originally 
described by Hardy and Higgins in 1992 [102]. This hypothesis suggests that missense mutations 
in APP, PSEN1 or PSEN2 trigger Aβ plaque and neurofibrillary tangle formation, which eventually 
leads to neuronal cell death and dementia [102, 103]. The key factor in this hypothesis is the 
production of the Aβ peptide. Depending on the positions of cleavage by multiple enzymes 
associated with the processing of APP, Aβ peptides of between 39-42 amino acid residues in length 
can be generated. Soluble Aβ-40 peptide is the major species present in normal brain. The less 
soluble Aβ-42 isoform of the Aβ peptide is thought to be the most prone to aggregation in the 
brain. Aβ-42 has been implicated as the major component of senile/neuritic plaques which are 
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deposited in brain parenchyma. As previously mentioned, these plaques are considered to be a 
histological hallmark of AD [104]. 
 
Figure 1.4. The proteolytic processing of APP. APP can be cleaved by α-, β- and γ-secretases; the cleavage 
sites of these proteases are indicated in the full-length APP shown in the centre of the figure. 
Oligomerisation of Aβ is proposed to make up the senile/neuritic plaques in the brains of AD patients 
(reproduced without permission from [107]). 
 
Processing of APP to form aggregation-prone Aβ-42 peptide occurs in a sequential manner (Figure 
1.4). Firstly, there must be removal of the extracellular domain (ECD) of the protein, termed 
‘shedding’. This is required in order for it to be processed by γ-secretase [9]. There are two 
pathways in which APP can be processed. In the amyloidogenic pathway the APP ECD is shed by 
β-secretase (BACE1) before cleavage by γ-secretase to produce Aβ. In the non-amyloidogenic 
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pathway, shedding is performed by α-secretase (ADAM10 or ADAM17) and, after γ-secretase 
cleavage, produces the p3 peptide instead of Aβ [2, 10, 66]. Shedding initially leaves a membrane 
bound C-terminal fragment. Shedding via α-secretase leaves C83. Shedding via β-secretase leaves 
C99. The C99 fragment then undergoes subsequent cleavage by γ-secretase to release the 
neurotoxic Aβ-42 peptide [105, 106]. Downstream effects of the increased production of Aβ-42 
peptide and its subsequent deposition as diffuse plaques include the activation of microglia and 
astrocytes as discussed above. 
 
Alternative hypotheses for Alzheimer’s disease 
Although the Amyloid cascade hypothesis remains the most popular hypothesis for AD, there are 
many who doubt its veracity. There is a limit to which this hypothesis can accurately explain AD 
progression. Reviews by David Drachman and Jack de la Torre discuss this issue in detail [108, 
109]. Many AD sufferers never develop Aβ plaques and/or NFTs while many non-AD elderly 
individuals do exhibit these histological features. These among other observations call into 
question the ability of the amyloid cascade hypothesis to accurately describe AD pathogenesis. 
There are a great number of alternative hypotheses that attempt to describe the pathogenic nature 
of AD [reviewed in 110, 111]. Here I will discuss in detail a select few that are most relevant to 
this review’s theme. If the reader is interested in other alternative hypotheses not discussed in this 
review, such as; the cholinergic hypothesis, the cell cycle hypothesis, the aluminium hypothesis, 
the inflammatory hypothesis, or the calcium hypothesis, they might be interested in the following 




The Presenilin hypothesis 
The presenilin hypothesis (Figure 1.5) posits that the many pathogenic missense mutations in 
PSEN that are distributed throughout the protein result in a loss of protein function, potentially due 
to destabilisation of its overall structure. It is well documented that not all cases of 
neurodegenerative dementias have amyloid pathology as is observed in AD (eg. FTD). There are 
also mouse models that overexpress mutant APP and in which there is overproduction of Aβ 
peptides and subsequent deposition of this peptide but no apparent neurodegeneration [112]. These 
two observations led Shen and Kelleher to challenge the Amyloid cascade hypothesis and present 
their own alternative hypothesis, “the presenilin hypothesis” [113]. As mentioned above, the 
presenilins are involved in the γ-secretase-mediated cleavage of many substrates. There is a 
substantial body of evidence supporting the opinion that mutations in PSEN that are pathogenic 
may cause partial impairment of PSEN function, disturbing both γ-secretase-independent and -
dependent actions. For example, the first study in a vertebrate system to show reduction of PSEN 
activity via pathogenic mutations, examined the effects of six FAD-linked PSEN mutations on 
generation of the Notch intracellular domain (NICD). All six mutations resulted in reduced 
proteolytic release of NICD [114]. PSENs are involved in γ-secretase-independent down-
regulation of the Wnt signalling pathway by interacting with and destabilising β-catenin [115]. 
FAD-linked PSEN mutations have been found to impair this function of PSENs, leading to 
increased β-catenin stability and β-catenin-dependent signalling [116, 117]. 
Shen and Kelleher proposed that loss of PSEN protein function occurs via a dominant negative 
mechanism, whereby mutant PSEN interferes with the function of wildtype PSEN. This is 
supported by the nature and distribution of these mutations [113]. In order to incorporate the 
observation that APP mutations alone are sufficient to cause AD into this “PSEN loss of function” 
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hypothesis, the effects of Aβ peptide on PSEN function must be considered. Shen and Kelleher 
suggest that Aβ-42 overproduction in both PSEN and APP FAD mutations may enhance the PSEN 
impairment observed by way of a “product-based negative feedback mechanism” [113]. As γ-
secretase has such a relaxed specificity for its substrates, longer forms of Aβ (42/43) containing 
potential cleavage sites (that would generate shorter forms), may fill the active site. It is probable 
that these Aβ species would be ineffective substrates for cleavage, as they lack downstream 
residues important for substrate-active site interactions. Due to this they would block the γ-




Figure 1.5. The Presenilin Hypothesis of AD. (Reproduced without permission from [113]). 
 
A combination of PSEN inactivation and increased Aβ result in reduced cAMP-response element 
(CRE)-dependent gene expression and number of synaptic NMDA receptors [113]. Furthermore, 
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expression of both the PSEN1 and PSENEN encoding genes are CRE-dependent [113]. When 
PSEN function in the adult mammalian brain is lost this results in a pathogenic cascade, which 
ultimately triggers widespread and progressive neuronal atrophy and death (aka neurodegeneration 
resembling AD neuropathology) [113].  
 
The vascular hypothesis of AD 
First and foremost, the vascular hypothesis of AD attempts to step away from the amyloid cascade 
hypothesis. This hypothesis postulates that Alzheimer’s is primarily a vascular disorder, and that 
the neurodegeneration observed in the ageing brain is a downstream effect of vascular dysfunction 
and subsequent cerebral hypoperfusion [118]. This hypothesis is supported by the discovery of 
vascular AD risk factors in the elderly, including; diabetes 2, hypertension, heart disease, smoking, 
obesity, atherosclerosis. These risk factors coupled with the ageing process can introduce a mild 
ischemia/hypoxia state that is sustained in the brain [118]. Hypoxia/ischemia refers to a state in 
which there is insufficient blood flow to a tissue and therefore insufficient oxygen supply. The cell 
responds to hypoxia by activating the transcriptional regulator, hypoxia-inducible factor 1-alpha 
(HIF-1α) [119]. HIF-1α has been demonstrated to activate both β-secretase (BACE1) and γ-
secretase (PSEN1), which leads to this increased production of Aβ in the brain and 
cerebrovasculature [120]. Furthermore, hypoxia also stimulates oxidative stress that can produce 
both reactive oxygen species (ROS) and reactive nitrogen species (RNS). Peroxynitrite, one of 
these RNS, promotes nitrotyrosination of PSEN1, consequently shifting production of Aβ to 




1.4 The Amyloid Precursor Protein 
The γ-secretase substrate APP is a highly conserved type 1 transmembrane protein (Figure 1.6) 
encoded by a gene on chromosome 21 [122]. There are orthologues in all mammals that have been 
studied as well as some non-mammals, such as zebrafish and Drosophila. APP is a member of a 
large protein family, along with transmembrane and secreted proteins (APLP’s) [123]. 
 
Figure 1.6. The domain structure of APP family members is conserved across species. The domain 
structure of human (H. sapiens) APP and its homologs in the mouse (M. musculus), zebrafish (D. rerio), 
worm (C. elegans) and fruit fly (D. melanogaster) is shown. The extracellular region contains an E2 
domain, an acidic (Ac) domain, a copper-binding domain (CuBD) and a heparin-binding domain (HBD), 
all of which are conserved across species. A Kunitz protease inhibitor (KPI) domain, which is subject to 
alternative splicing, is also found in APP and APLP2. The intracellular domain shows the highest homology 
and contains the YENPTY motif that is conserved across homologs. The Aβ sequence is only present in APP 
(reproduced without permission from [107]). 
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The structure and heterogeneity of APP 
There are three major APP isoforms (Figure 1.7), which are the result of alternative splicing of 
exons 7 and 8 of the APP gene [124]. Both the 770 and 751 amino acid residue splice variants are 
expressed in non-neuronal and CNS tissues. The 695 residue splice variant is expressed almost 
exclusively in the CNS [123]. APP770 represents the full length protein. APP751 results from 
exclusion of exon 8. APP695 results from exclusion of both exons 7 and 8. Exon 7 encodes a 
Kunitz type serine protease inhibitor (KPI) homologous 56-amino acid domain [125]. Those APP 
isoforms with a KPI domain found in human platelets are involved in the coagulation cascade via 
inhibition of IXa, X and Xia factors [126]. Exon 8 encodes the 19aa OX-2 domain, the function of 
which is largely unknown [127]. Post-translational modifications of APP also contribute to its 
heterogeneity, such modifications include addition on sulfates, phosphates and N- and O-linked 
sugars [reviewed in 128]. 
 
Figure 1.7. Diagram representing three proteins from the APP family and their main domains. APP 
770 contains all domains, APP 751 carries only the KPI domain and APP 695 lacks both the KPI and 




Normal (non-pathogenic) functions of APP 
As mentioned previously, research involving APP has been heavily focussed on its association 
with AD, hence its normal functions are much less well understood. APP is ubiquitously expressed 
and is highly evolutionarily conserved [129]. APP is thought to play roles in neurogenesis, neurite 
outgrowth and guidance, axonal transport and synaptogenesis and morphogenesis [107, 130]. 
Furthermore, the full length APP holoprotein has been proposed to have roles in cell-cell 
interactions [131] and neuronal precursor migration during brain development [132]. The many 
other suggested roles of APP are attributed to its cleavage products. APP has two well described 
processing fates, amyloidogenic and non-amyloidogenic. There are three fragments that can be 
generated by non-amyloidogenic processing of APP. Initial cleavage by α-secretase generates the 
soluble sAPPα fragment and a membrane bound C-terminal fragment (CTF). This CTF then 
undergoes cleavage by γ-secretase to release the p3 peptide and the APP intracellular domain 
(AICD) [2]. Each of these fragments have suggested roles in the brain. 
 
sAPPα is both neurotrophic and neuroprotective 
sAPPα is both neurotrophic and neuroprotective [129]. sAPPα carries a cysteine-rich domain 
resembling that of other growth factor domains, which suggests a function for sAPPα as a growth 
factor receptor ligand [107, 133]. Furthermore, sAPPα has more recently been found to inhibit 
collapse of the growth cone [130]. Early studies demonstrated stimulation of neural stem cells 
(NSCs) by sAPPα in rat [107]. Others found that a reduction of NSC proliferation in the brains of 
adult mice could be rescued by infusion of sAPPα [134]. Supplementing this was a study that 
showed inhibition of α-secretase decreased NSC proliferation in vitro, which was rescued by 
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adding sAPPα to the culture medium [135]. This same study found that sAPPα regulates 
proliferation of not only NSCs but also mesenchymal stem cells (MSCs) and human decidua 
parietalis placenta stem cells (hdpPSCs) [135]. Combined evidence suggests that sAPPα is a 
necessary proliferation factor for non-neural and neural adult stem cells. Findings of Hartl et al 
also support a role of sAPPα in regulating CDK5 signalling [136]. sAPPα was able to reduce the 
expression and activity of CDK5, which is a known inducer of neurodegeneration. Interestingly, 
SORL1 is a known sAPPα receptor. Hartl et al demonstrated that, in SORL1 deficient neurons, 
sAPPα was no longer able to regulate CDK5 [136]. This combined evidence suggests that sAPPα 
functions as a neuroprotective factor. 
 
APP has also been shown to be neuroprotective in the immediate period following traumatic brain 
injury (TBI) [137]. The sAPPα fragment of the APP695 isoform has four domains. One of these 
domains, D1, spans residues APP96-110 and has been shown to be involved in recovery from TBI 
[138]. The D1 domain is a growth factor like domain that contains heparin binding sites (HSBs). 
These sites in APP96-110 confer ability to bind heparin sulphate proteoglycans (HSPGs). Binding 
of HSBs to HSPGs promotes neurite outgrowth, a neurotrophic property. Corrigan et al (2014) 
demonstrated that the neuroprotective activity of APP96-110 is exerted via its heparin binding 
properties [138]. 
 
The APP AICD is involved in nuclear signalling 
Aside from a proposed role of the AICD in AD neurodegeneration this fragment is thought to play 
a role in nuclear signalling. Von-Rotz et al (2004) identified transactivation activity for AICD 
using a yeast GAL4 transcription factor fused to both APP and AICD independently [139]. This 
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was dependent on Fe65, an APP-adaptor protein [140] and the Fe65-binding nuclear histone 
acetylase, Tip60 [7]. It has been shown that Fe65 can stabilise AICD, which localises to the nucleus 
with Fe65 [141].  
Fe65 contains a WW domain along with two phosphotyrosine interaction domains (PID) [142]. 
Only PID2 in Fe65 is involved in binding APP, leaving PID1 and the WW domain free for other 
binding partners [142]. AICD can also be bound by the XII protein though its PID [142]. XII has 
been shown to regulate APP by slowing cellular APP processing and reducing secretion of Aβ-40 
and Aβ-42 [143] by preventing translocation of APP into β- and γ-secretase-rich lipid rafts [144].  
Fe65 and XII may compete for binding, as they both bind to the same motif of AICD. Many lines 
of evidence suggest that it is important for APP regulation (and possibly function) that there is a 
functional balance between Fe65 and XII [142]. A third APP binding protein, mDAB1, also binds 
to the same region as Fe65 and XII. Fe65 and mDAB1 interact with mammalian Ena (mEna) [145], 
which is found in areas of actin remodelling. mEna’s interaction with APP through its binding 
proteins forms a potential molecular link between APP and the cytoskeleton [146]. This link to 
mEna may also explain the proposed functions of APP in cell adhesion, growth cone outgrowth 
and axon guidance [146]. The interaction with mEna has been implicated in a role for AICD 
signalling, in synaptic plasticity and memory [147]. 
 
The non-amyloidogenic APP pathway product p3 
There is little known of the normal functional role of the non-amyloidogenic APP pathway product 
p3. It has, however, recently been demonstrated by one group to be neuroprotective [148]. Han et 
al compared the proteolytic products of APP and phenotypes between two mouse models, BACE1-
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deficient and PSENs conditional double knockout (cDKO). Their findings suggest that p3 may be 
a neurotrophic factor deficient in cDKO mice and may play a neuroprotective role [148]. 
 
APP is also processed by lesser known secretases 
Although most research into APP proteolysis focuses on the well-established processing by α-, β- 
and γ-secretases (and on the fragments generated by these cleavages), several other secretases have 
been discovered that process APP [reviewed in 149]. Aparagine endopeptidase or δ-secretase 
cleaves APP within its ectodomain at two positions, N373-E374 and N585-I586, to produce three 
different fragments that can then be further processed by β- and γ-secretases (Figure 1.8). Of the 
three possible fragments sAPP1-373 alone was observed to be toxic to primary cultured neurons. 
Interestingly, when knocking out AED in AD mouse models, a reduced amount of Aβ was 
deposited along with a reduction of other AD features [reviewed in 149]. 
Another lesser-known APP processing secretase is the matrix metalloproteinase MT5-MMP aka 
η-secretase. η-secretase cleaves APP between position N504-M505, resulting in a ~80–95 kDa 
soluble fragment and a membrane bound CTFη. This CTFη fragment is further processed by either 
α- or β-secretase to release two additional fragments, termed Aη-α and Aη-β. These two fragments 
have been identified in mouse brain and human CSF at levels 5 times that of Aβ. Furthermore, 
knockout of MT5-MMP in AD mouse models reduces Aβ deposition within the brain [reviewed 
in 149]. Discovery of these additional secretase activities, along with our emerging understanding 
of other APP fragments (discussed above), further highlights the need for a greater understanding 




Figure 1.8. APP proteolysis by three distinct proteases. A) both amyloidogenic and non-amyloidogenic γ-
secretase processing of APP, B) δ-secretase processing of APP, and C) η-secretase processing of APP. 
Each of the fragments generated by these cleavage processes are presented in the right-hand section of the 
figure (reproduced without permission from [149]). 
 
 
Mutations in the APP gene contribute to fAD 
APP has a proposed role in AD through its cleavage to form the Aβ peptide. Missense mutations 
in the APP gene can lead to dominantly inherited fAD. Currently 59 mutations are known and are 
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listed on Alzforum (https://www.alzforum.org/mutations/app). These mutations alter amino acid 
residues predominantly clustered around the Aβ peptide region of APP and are thought to cause 
approximately 15% of all cases of fAD. Furthermore, mutations in the APP gene are generally 
associated with an observed increase in the total levels of both Aβ-40 and Aβ-42, as well as an 
increase in the Aβ-42/Aβ-40 ratio. These factors lead to increased accumulation of the insoluble 
form of the Aβ peptide and, as a result, increased aggregation and formation of neurotoxic Aβ 
protofibrils. Generally, APP mutations are known to enhance AD pathology and cause a very early 
age of AD onset. In the next few sections we will discuss in detail mutations that are relevant to 
this thesis. 
 
 The Austrian mutation 
One mutation of APP with an onset age as young as 36 years, is the “Austrian” mutation T714I. 
Kumar-Singh et al (2000) originally described an Austrian family with an autosomal dominant 
early-onset AD inheritance pattern [150]. The mutation exists in exon 17 of APP (T714I, according 
to APP770 isoform numbering) at the site of Aβ-42 cleavage. Analysis of brain sections of the 
proband revealed a huge load of non-neuritic/diffuse cotton-wool plaques (like patients with 
PSEN1 Δ9 causing mutations that present with both AD and spastic paraparesis [151]), with N-
truncated Aβ-42 composition [150]. Accumulation of hyperphosphorylated tau was also observed 
in neurites and there was a close association between blood vessels and fibrillar amyloid deposits 
[150]. Patients with this mutation presented with an early age of onset (approximately 36 years), 
rapid disease progression and early death (approximately 42 years), like PSEN1 AD mutations. 
Experiments found that Hek293T cells transiently transfected with T714I APP cDNA showed 
increased Aβ42 (3.5 fold) and decreased Aβ40 (68%) leading to a (10.8 fold) increase in the overall 
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ratio compared to wild type. Patient plasma had a 2.5 fold increase in ratio compared to the 
unaffected father and 1.7 fold compared to controls [150]. 
 
The Leuven mutation 
The “Leuven” APP mutation was discovered in a Belgian patient presenting with early onset AD. 
This mutation (E682K), within exon 16 of the APP transcript, affects the alternative BACE1 
cleavage site, β’-secretase [152]. BACE1 cleaves at both the β-secretase (Met671-Asp672) and β’-
secretase (Tyr681-Glu682) sites in human APP [153], the latter of which is much less well-
characterised. Cleavage at the β’-secretase site produces a C89 fragment which, when processed 
by the subsequent γ-secretase steps, generates truncated Aβ species [152]. Zhou et al (2011) found 
that the Aβ42/40 ratio was significantly increased in both mouse primary neurons and CHO cells 
harbouring this mutation [152]. Also, overall levels of both Aβ40 and Aβ42 were increased 2-3 
fold. The E682K mutation prevents generation of Aβ40/Aβ42 species from the β’ site, instead 
enhancing generation of these species from the β site [152]. Previous studies have indicated that 
low BACE1 levels result in an increase in cleavage at the β-site, whereas, at high BACE1 levels, 
cleavage at the β’-site becomes more predominant [154, 155]. Supplementing this is the finding 
that BACE1 has a much higher enzymatic efficiency towards peptides containing the β site than 
the β’ site [156]. It is interesting to note that cleavage of endogenous APP at the β’ site in rodents 
does not result in spontaneous development of amyloid plaques [152]. This may suggest that APP 
processing at the β’ site may be important for normal APP metabolism [152]. Furthermore, these 
data suggest that processing of the β’ site is anti-amyloidogenic, impeding amyloidogenic β site 
cleavage of APP. Processing of APP by BACE1 is disrupted when the β’ cleavage site is blocked, 
which leads to increased generation of full length Aβ [152]. 
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The Arctic mutation 
The “Arctic” Alzheimer mutation, E693G, affects exon 17 of the APP open reading frame. 
Nilsberth et al (2001) found a decrease of 22-33% in the Aβ42/Aβ40 ratio in HEK293 cells 
transiently transfected with APP carrying the Arctic mutation [157]. In an Arctic mutation mouse 
model, enhanced accumulation of Aβ was observed inside neurons, strongly facilitating 
extracellular amyloid plaque deposition with age progression. Arctic Aβ peptides were observed 
to more easily form soluble protofibrils in vitro, leading to enhanced Aβ protofibril formation 
[158]. Experiments in HEK293 cells assessing the effects of the Arctic mutation on α-secretase 
cleavage revealed a reduction of APP abundance at the cell surface [157]. α-secretase cleavage is 
believed to occur at the cell surface but also in the trans-Golgi network [159, 160]. Hence, this 
mutation probably results in an inability of α-secretase to cleave APP, rather than representing a 
reduction in the enzymatic efficiency of APP processing by α-secretase. Due to reduced levels of 
fragments from α-secretase, there is a shift towards β-secretase cleavage, resulting in increased Aβ 
production [161]. β-secretase (BACE1) cleavage is thought to occur in acidified vesicles, primarily 
in the trans-Golgi network and in endosomal pathways [162]. 
 
1.5 Animal models of AD and related genes 
The use of model organisms in experimental biology is an immensely informative research 
strategy. Model organisms provide effective in vivo systems in which the cellular biology involved 
in many complex diseases can be investigated. This is opposed to in vitro studies that are limited 
in their reproducibility of complex cellular system environments. In the following sections we will 
review the use of model animals specifically for AD research. 
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Invertebrate models of AD 
Drosophila and C.elegans are well established model systems that have also been employed as 
tools for investigating AD neuropathology. Both model systems have orthologues of the presenilin 
gene [163]. Drosophila and C.elegans also have an APP-like protein (APPL) which has conserved 
function with vertebrate APP family members but lacks the Aβ domain [164]. 
As mentioned earlier C.elegans was instrumental in the identification of two of the γ-secretase 
components, APH-1 and PSENEN. C.elegans also contains three human presenilin orthologues, 
sel-12, hop-1 and spe-4 [165-167]. Human PSEN1 and PSEN2 are able to substitute for SEL-12 
activity in C.elegans, suggesting SEL-12 protein has complete presenilin function [166]. As 
C.elegans APPL does not have an Aβ region, Link et al developed a transgenic model that 
expresses human Aβ (hAβ) in muscle cells of C.elegans [168]. Larvae of the hAβ transgenics 
presented with a muscle paralysis phenotype, which is likely due to increased toxicity in muscle 
cells [168]. Although Aβ expression is limited to muscle cells in this model, it can still be used to 
establish a link between Aβ expression and toxicity. Another study, using transgenic C.elegans 
lines, found that substituting Leu at position 17 for Pro and Met at positon 35 for Cys of Aβ resulted 
in no amyloid deposition, suggesting the importance of these single residues in the formation of 
amyloid [169]. C.elegans have also been used to confirm that the oxidative stress induced by Aβ 
(through generation of reactive oxygen species (ROS)) is related to Aβ toxicity [170].  
Drosophila possess APPL (a member of the large family that includes APP and the APLP’s (Figure 
1.6)) and orthologues for all the major γ-secretase components [171]. Larval brains of transgenic 
Drosophila, expressing either wildtype (WT) or mutant human APP (hAPP), showed increased 
cell death [172]. Both Aβ and AICD of APP were required to induce this toxicity [172]. Crowther 
et al applied a more direct approach to look at Aβ-42 toxicity using Drosophila [173]. They found 
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that Aβ-42 expressed neuronally resulted in a reduced lifespan, locomotion defects and 
neurotoxicity [173]. Finelli et al generated Drosophila lines that express Aβ peptides. 
Overexpression of Aβ-40 and Aβ-42 was induced in neuronal cells of these lines [174]. Using 
similar transgenic Drosophila lines, Iijima et al, demonstrated that age-dependent learning 
deficiency, diffuse amyloid deposits and neurodegeneration were caused by Aβ-42 expression 
[175]. Similar learning deficits, without amyloid aggregation and neurodegeneration, were caused 
by Aβ-40 induction [175]. Furthermore, when PSEN mutations were introduced into Drosophila 
PSEN, the differences in activity in Drosophila of the mutant presenilins correlated with the age 
of onset of AD in humans [176]. Drosophila are also useful for screening potential AD drugs, such 
as γ-secretase inhibitors. In particular, the binding site of the γ-secretase inhibitor DAPT is 
conserved in Drosophila [177]. There have been numerous other studies utilising Drosophila to 
investigate the effects of Aβ in the context of AD. For a more comprehensive review of this topic 
please see the following book chapter [178].  
 
Mouse models of AD 
The mouse is the most commonly used animal model for the research into human 
neurodegenerative disease. Being a mammal, the mouse is more closely related to humans than 
invertebrate models. There are many transgenic mice that have been developed to model AD-
related phenotypes [179]. Transgenic mice that express hAPP are some of the oldest and most 
widely used models. Transgenic hAPP mouse lines generally present with amyloid pathology and 
deficiency in memory [179]. These models of AD are complicated by the many factors that must 
be considered when using APP. One example of this is that hAPP lines can have different 
promoters to drive expression. There also are many hAPP isoforms, which further complicates 
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comparative analysis [179]. The different hAPP transgenic lines also express different AD 
associated mutations. A few lines have mutations that model those at the γ-secretase site. However, 
a majority of the mouse lines currently used express the Swedish double mutation 
(K670N/M671L) which exists at the β-secretase cleavage site [179]. Other lines either combine a 
γ-secretase cleavage site mutation with the Swedish mutation or add a mutation within the Aβ 
sequence (such as the E693G Arctic mutation discussed earlier). 
Mouse models based on the FAD PSEN mutations have also been used for AD research. PSEN 
mutant transgenic mice show an increase in Aβ-42 levels, while Aβ-40 is unaffected [179]. 
However, these mice do not develop cognitive defects or AD pathology. This is probably due to 
the Aβ region in mouse APP (mAPP) being different to that of hAPP. Cleavage of mouse Aβ gives 
a shorter product than human Aβ and mouse Aβ peptides are much less efficient at aggregation 
[179]. It appears that development of AD phenotypes in mice requires human Aβ expression [179]. 
To test this, PSEN mutant mice were crossed to mice with either transgenic hAPP or mAPP [179]. 
When crossed to a mouse line overexpressing mAPP offspring have no AD pathology or cognitive 
deficits. When crossed to a hAPP transgenic mouse line offspring have extensive plaque deposition 
and behavioural deficits [179]. The hAPP/PSEN1 lines that are more commonly used today are 
generated via co-injection of PSEN and hAPP transgenes. A line containing the Swedish mutation 
and PSEN1 harbouring the ΔE9 mutation (APPswe/PS1ΔE9 mice) develops behavioural deficits 
and amyloid plaques at approximately 6-7 months of age. The 5XFAD line combines multiple 
FAD mutations, 2 in PSEN1 and 3 in APP. These mice express Aβ-42 at high levels, develop 
amyloid plaques and cognitive deficits at around 4 months. 5XFAD mice also develop neuron loss, 
which most other hAPP/PSEN1 and hAPP models do not [179]. Contrary to the mouse models 
overexpressing hAPP described above, Saito et al developed simple models that overproduce Aβ-
43 
 
42 without overexpressing hAPP [180]. One of these mouse lines, carrying a combination of the 
Arctic, Swedish and Beyreuther/Iberian mutations, displayed aggressive Aβ amyloidosis in an 
age-dependent manner [180]. The amyloid deposition pattern of these mice was consistent with 
human Arctic mutation carrier pathology. These mice should provide an interesting tool for 
investigating select features of AD biology. 
For a more extensive review of AD mouse models please see the following reference [178]. It is 
also worth mentioning here that, while transgenic mouse models have been useful in investigating 
certain aspects of the disease, the transcriptomic profiles of these mouse models are not consistent 
with those of human AD [181]. This observation suggests that these transgenic mouse models are 
not necessarily the best way to model AD moving forward. 
 
Zebrafish as a model for AD 
Danio rerio, commonly known as Zebrafish, are a useful model for the study of genetic 
diseases/conditions as they contain orthologues of many human genes. Zebrafish embryos can be 
readily manipulated, allowing for knockdown of gene expression with morpholino 
oligonucleotides (MO) or overexpression of genes by injection of sense RNA [182]. Zebrafish are 
also genetically malleable, allowing for more precise genome manipulations by employing 
genome engineering technologies, which will be discussed in more detail in below. Furthermore, 
the zebrafish genome has been sequenced completely, which makes it very accessible for genetic 
screens. In addition to this, short generation times and large numbers of offspring enable 
significantly larger screens over time frames much shorter than could be accomplished using 
rodent models. Zebrafish provide an additional benefit over mice due to low maintenance costs, as 
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well as the potential to visualise developmental processes through their transparent embryos. Most 
importantly, as a vertebrate, they provide many of the benefits of invertebrate models such as C. 
elegans (worm) and D. melanogaster (fruit fly) while maintaining much greater homology to 
humans. 
Zebrafish contain orthologues of many of the human genes implicated in AD pathogenesis. 
Orthologues of Human PSEN1 and PSEN2 orthologues identified in zebrafish are psen1 [183] and 
psen2 [184] respectively. An orthologue of human SORL1 also exists in zebrafish, sorl1 [185]. 
Zebrafish form a part of the Teleost infraclass of bony fishes and as such their genomes contain 
many duplicated genes [186]. The human APP gene has two co-orthologues in zebrafish, appa and 
appb [187]. Zebrafish appa is more closely related to longer isoforms of APP (770 and 752), while 
appb is closer to APP695 [187]. Zebrafish Appa and Appb have approximately 70% identity to 
human APP695 at the amino acid level, with 80% identity to the Aβ region and 95% identity within 
the transmembrane domain [187]. Orthologues of the other key components of γ-secretase also 
exist in the zebrafish genome; PSENEN (psenen) [13], NCTN (ncstn) [188, 189] and APH1b 
(aph1b) [16]. β-secretase orthologues have also been found in zebrafish, bace1 [190] and bace2 
[191].  
Zebrafish have been used extensively as a model for research into fAD and other 
neurodegenerative diseases [178, 192]. The two PSEN gene orthologues in zebrafish are expressed 
ubiquitously during embryo development [183, 184]. The residues that give PSEN1 catalytic 
function are also conserved in zebrafish [193]. Studies conducted in vitro demonstrated that psen1 
is able to functionally replace PSEN1 and produces Aβ-42 from fAD Swedish mutant APP in an 
efficient manner [183]. A study in which a psen1 translation-blocking MO was injected into 
fertilised embryos, revealed a reduction in the Notch target gene hairy-related 1 (her1). This 
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indicated that loss of psen1 caused a reduction of Notch signalling [193]. Hence zebrafish psen1 
shows conserved function with human PSEN1. Having only recently been identified as a genetic 
risk factor for fAD, sorl1 has not been as extensively investigated using zebrafish. However, Lee 
et al (2017) found that zebrafish Sorl1 protein is highly conserved with human SORL1 [185]. They 
also placed sorl1 expression in neural tissue in 72 hours post fertilisation (hpf) zebrafish [185]. 
Zebrafish orthologues of the other γ-secretase components have not been thoroughly analysed. 
However, Campbell et al (2006) demonstrated that blocking translation of both psenen and aph1b 
in zebrafish produced loss of Notch signalling phenotypes. Blockage of psenen also destabilised 
Psen1 protein and increased apoptotic induction [194]. Furthermore, Lim et al (2015) observed 
ncstn in the developing embryo and found it to be expressed most highly in ventricular cells of the 
developing brain at 24hpf [189]. 
Zebrafish co-orthologues of APP, appa and appb, are both widely expressed in the developing 
embryo from the mid-gastrulation stage [187]. 24 hour old embryos express both genes in the 
developing forebrain and elsewhere, appb alone is expressed in the spinal cord [187]. The function 
of Appa and Appb proteins have also been investigated using translation-blocking MOs [195]. 
Inhibition of Appb conferred a defect in convergent extension movements and reduced body 
length. This could be rescued by injection of mRNA encoding human APP into Appb deficient 
embryos [195]. Defective neural development including defective axonal outgrowth and synapse 
formation have also been demonstrated by loss of Appb activity [196]. Such studies as described 
above demonstrate the usefulness of zebrafish embryos in analysing different fAD genes.  
Finally, while both brain-derived neurotrophic factor (BDNF) and TrkB have been analysed using 
zebrafish [197], studies investigating p75NTR in the zebrafish are limited to a handful of papers 
where it has been utilised to investigate Nogo/Nogo receptor complex signalling [198, 199]. We 
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could find no studies to suggest that zebrafish NRH1 has been investigated previously using this 
animal model. 
Our laboratory is the leading group using zebrafish to model AD. We have previously investigated 
extensively the roles of the zebrafish orthologues of PSEN1 and PSEN2 in various biological 
processes. The laboratory’s current goal is to generate a catalogue of fAD-like and non-fAD 
mutations in the zebrafish psen1, psen2, appa, appb and sorl1 genes for transcriptomic analyses 
in the hopes of identifying a molecular “signature” of AD. Thus far, mutations have been generated 
in psen1, psen2 and sorl1 (published [200-202] and unpublished) and some early analyses have 
revealed interesting effects on the hypoxic response and brain energy production in these model 
fish. In order to contribute to this wider laboratory project, the work presented in this thesis aimed 
to generate both fAD-like and null mutations in zebrafish appa and appb. This was attempted 
through generating mutations in endogenous zebrafish appa and appb genes with genome editing 
technologies, which will be introduced in the following section. 
 
1.6 Techniques for genome engineering in the zebrafish 
As we have just discussed, zebrafish are a useful genetic tool for studying molecular mechanisms 
and disease pathogenesis. Zebrafish embryos are easy to manipulate by injection with a variety of 
genome engineering tools. Morpholinos can be used for antisense gene knockdown [192] or to 
interfere with intron splicing [203] resulting in aberrant protein products. Conversely, direct 
injection of sense mRNA allows for overexpression of a gene of interest. While these two methods 
are successful in interfering with regular expression of a gene, their effects only persist for a short 
time. Targeted induced local lesions in genomes (TILLING) was the first approach for reverse 
genetic engineering in zebrafish that was successful in generating germline mutations in a specific 
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gene [204]. TILLING enabled the recovery of rare genomic mutations that can be analysed 
phenotypically at a later date [204]. Transposons are another useful reverse genetic approach. The 
Tol2 transposon system is used to generate transgenic zebrafish with germline mutations via 
transposition. A cell-type specific enhancer/promoter placed upstream of green fluorescence 
protein (gfp) on a Tol2 construct allows for the insertion of genes that can be visualised by 
expression of GFP in a cell-type specific manner [205]. The GAL4-UAS and Cre/loxP systems 
can be used to generate conditionally expressed transgenic zebrafish lines [204]. Both systems use 
a bipartite approach, in which two separate transgenic lines are generated and must be crossed in 
order to elicit the transgenes event. GAL4 can be driven in a temperature inducible manner using 
the heat shock protein 70 (hsp70) in zebrafish [204]. Research using zebrafish originally applied 
the Cre/LoxP system for the conditional expression of oncogenes. The system also used hsp70 
promoter to induce Cre expression. Additionally, the temporal activity of Cre can be controlled 
through its fusion with a modified estrogen receptor that binds tamoxifen [204]. Early use of 
zebrafish for transgenic analyses was at a disadvantage relative to mice, due to the inability to 
generate targeted mutations. Recently, three techniques for targeted modification of genomes have 
been established. 
 
Zinc finger nucleases (ZFNs) and Transcription activator-like effector nucleases (TALENs) 
ZFNs and TALENs are both comprised of a nonspecific DNA cleavage segment and 
programmable, sequence-specific DNA-binding units [206]. The ZFNs and TALENs cause the 
targeted induction of double-stranded breaks (DSBs) that stimulate cellular DNA repair 
mechanisms such as Non Homologous End Joining (NHEJ) and Homology Directed Repair 
(HDR) [206]. ZFNs and TALENS are useful tools for the generation of targeted mutations. They 
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are both versatile due to the ability to engineer the DNA binding domains, which can be customised 
for the recognition of practically any sequence [206]. 
ZNFs are a chimeric fusion of a Cys2His2 zinc finger array and a Fok1 endonuclease cleavage 
domain [204]. The Cys2His2 array of a zinc finger contributes specificity for the DNA site of 
interest [204]. The target sites of ZFNs are comprised of two zinc finger binding sites separated 
by a 5-7bp spacer sequence, which is recognised by Fok1 for cleavage [206]. A pair of ZFNs is 
required, due to the necessity of Fok1 of dimerise in order to exert its cleavage ability [204, 206]. 
A pair of ZFNs must bind correctly to their target sequence in order to generate a DSB [204]. A 
ZFN normally has 3-6 fingers and each finger recognises 3bp of DNA. When combined, a pair of 
ZFNs can recognise 18-36bp of DNA sequence, which is dependent on the number of fingers. This 
large recognition site length means a ZFN has specificity within 68billion bp of DNA [204, 206]. 
Occasionally introduction of unwanted indels at the cleavage site occurs, due to repair by NHEJ. 
There can also be off target effects. ZFNs are limited by their inability to generate DNA changes 
with high in vivo activity [204]. 
Transcription activator-like effector nucleases (TALENs) have more recently been used as an 
alternative to ZFNs for editing genomes by the induction of DSBs. Like ZFNs, TALENs consist 
of a non-specific FokI endonuclease domain, which is fused to a customisable and site-specific 
DNA-binding transcription activator-like effector (TALE) domain from the plant pathogenic 
bacterial species Xanthomonas [207]. This TALE domain is made up of a sequence of TALE 
repeats that each recognise one specific nucleotide of DNA [208]. Each highly conserved repeat 
is 32-35 amino acids long, with residues 12 and 13 (known as repeat variable di-residues or RVDs) 
enabling the TALEN to specifically bind a single DNA nucleotide [206-208]. Due to the nature of 
TALE proteins, a 5’ T immediately upstream of the binding site is required for function [207, 209]. 
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TALE repeat RVDs have been identified that can recognise each of the four DNA nucleotides. 
These can be assembled in such a way that virtually any DNA sequence that starts with a 5’ T can 
be targeted and bound by TALENs [207]. Similarly to ZFNs, a pair of customised TALENs is 
needed to cleave a target site due to the dimerization requirements of Fok1. An optimal spacer 
length is required between a pair of TALENs so that Fok1 is in the correct position to dimerise 
and facilitate cleavage [208]. Spacer lengths for TALENs can vary between 12-20bp [206]. Hwang 
et al (2014) have found that spacer lengths of 16-18bps are effective in zebrafish [208]. Reyon et 
al suggest that TALENs comprised of 14.5-16.5-repeat arrays are most likely to be effective [210]. 
This length array would recognise 16-18 nucleotides in total (including the 5’ T). 
 
Compared to ZFNs, the method of target recognition and binding of TALENs is much simpler and 
more predictable, making it a good alternative to ZFNs [209]. TALENs have been used previously 
to successfully induce disruption of different zebrafish genes in a targeted manner [207]. However, 
there was only germline transmission for two of the genes [207]. Hwang et al (2014) managed to 
successfully mutate their target sites in zebrafish more than 80% of the time [208]. Somatic cells 
were found to be mutated by TALENs at rates of as high as 76%. Furthermore, they also found 
that TALENs efficiently induced heritable mutations in zebrafish [208]. 
  
Better sequence targeting specificity could be achieved by constructing TALENs that target more 
than 12bp of DNA. However, the highly repetitive nature of TALE repeats makes this practically 
impossible [209]. TALENs and ZFNs function in a similar way in that they both can induce indel 
mutations in the spacer region between binding sites. However, while ZFNs and TALENs can 
cleave DNA with similar efficiency when directed to the same target, TALENs usually have a 
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higher targeting efficiency and fewer off-target effects [209]. A study by Bedell et al (2012) used 
TALENs in conjunction with a short single stranded oligonucleotide donor to precisely insert a 
mutation into the genome of zebrafish [211]. TALENs are simple to design, have robust activity 
and are nearly limitless in their targeting range making them a very attractive platform for genome 
editing [207]. 
 
Clustered regulatory interspersed short palindromic repeats (CRISPRs) 
A recently identified whole genome editing technique has also been adopted for use in the 
zebrafish, mouse, maize, drosophila and many others as an alternative to ZFNs and TALENS. This 
technique makes use of the CRISPR and CRISPR associated (Cas) proteins, which originally 
functioned as a form of protection for bacteria and archaea against invading viruses and plasmids 
[212]. In these organisms the CRISPR system acts as a form of “genetic memory” of the viral 
infection, allowing them to recognise and remove viruses that have attacked in the past [212]. Six 
different CRISPR–Cas types and at least 29 subtypes have now been discovered [213]. The type 
II CRISPR/Cas system is most commonly used for genome editing and consists of 4 cas genes 
originally identified in Streptococcus pyogenes [212]. The most heavily utilised of these, Cas9, is 
commonly employed to cleave the DNA target sequence [214, 215]. 
CRISPR RNA (crRNA) is an array of repeats interspaced by short variable sequences 
(protospacers) (Figure 1.9, 1). In bacteria and archaea, the first stage of the CRISPR process 
involves the acquisition of virus DNA and these “protospacers” represent short segments of DNA 
from the invading virus or plasmid [212]. It is thought that the protospacer adjacent motif (PAM) 
may be involved in protospacer acquisition, which results in PAM flanking the protospacers on 
the 3’ side of this ‘foreign DNA’ within the crRNA in this type II system [212, 216]. PAM is 
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required for Cas9 activity, although the specific mechanism behind this remains unknown [215]. 
Due to the positioning of PAM (3’ of each protospacer) it is possible that it’s function is to help 
Cas9 determine the spacer orientation within the crRNA, providing a “polarity” for Cas9 to 
recognise substrates for cleavage (Figure 1.9, 4) [212]. 
The adapted crRNA that is used for genome editing encodes a single 20bp guide RNA (gRNA) 
sequence to direct Cas9 to a 20bp target site [214]. This gRNA immediately precedes the (type II) 
PAM sequence NGG [217]. Deep sequencing of RNA from the (type II) bacteria S.pyogenes 
crRNA revealed the presence of trans-acting antisense RNA (tracrRNA) [212]. This tracrRNA 
serves two functions in the type II CRISPR system; tracrRNA forms a duplex with pre-crRNA and 
recruits RNAse III an enzyme which processes the tracrRNA/pre-crRNA duplex to form mature 
crRNA (Figure 1.9, 2). tracrRNA also recruits Cas9 to the site of interest allowing for the invading 
virus/plasmid to be cleaved and degraded [215]. In the zebrafish editing system the tracrRNA is 
included with the gRNA in a single transcript which is given the abbreviation “sgRNA” [217]. 
sgRNA is already in the form of a mature crRNA and can direct cas9-mediated cleavage of target 
DNA [217]. 
Cas9 cleavage functions by generating double-stranded breaks (DSBs) (Figure 1.9, 6) [218]. These 
DSBs are repaired by either error prone non-homologous end-joining (NHEJ) resulting in 
insertions or deletions (indels) or, alternatively, homologous recombination (HR) [218]. Repair by 
HR requires co-injection of a single strand oligonucleotide (SSO) as a donor template, which 





Figure 1.9. Summary of the bacterial type II CRISPR system. 1) generation of the pre-crRNA, 2) 
tracrRNA recruits RNase III and Cas9 to process pre-crRNA into crRNA, 3) tracrRNA:Cas9:crRNA 
complexes are formed, 4) tracrRNA, as a part of the crRNA:tracrRNA:Cas9 complex, directs Cas9 to the 
DNA region complementary to the crRNA, only when there is a directly adjacent PAM (3’ of the crRNA 
binding site), 5&6) Induction of a DSB by Cas9. (reproduced without permission from 
https://www.addgene.org/crispr/history/). 
 
Using genome engineering tools to generate mutations of interest  
There are both advantages and disadvantages for the use of CRISPR’s over ZFN’s and TALEN’s 
for genome modifications. One such advantage is that a single customised gRNA is required to 
target a specific sequence, compared to the need to design and assemble two TALENs or ZFNs 
for each site [217]. One disadvantage is that there are additional constraints when designing and 
using CRISPRs. For successful utilisation of the Cas9 to recognise target sequence, a protospacer 
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adjacent motif (PAM) sequence is required 3’ of the gRNA and upstream of the crRNA binding 
region [217]. Also, the use of the T7 promoter to make gRNAs means that GG is required at the 
5’ end of the transcript, which reduces the range of targetable sequences [217]. Taken together 
these constraints would mean that any sequence of the form 5’ GG-N(18)-NGG 3’ is available for 
targeting by CRISPR/Cas9, occurring once in every 128bps of random DNA sequence [217]. 
However, a later study by Hwang et al (2013) found that this targeting range could be expanded 
to once in every 8bps by relaxing the T7 promoter rule [219]. This was accomplished by the 
addition of GG to the 5’ end of the 20nt gRNA sequence that were not complimentary to the 
genomic DNA target sequence [219]. Another common problem with the current system (and 
ZFNs and TALENs) is the occurrence and frequency of possible off target effects, due to binding 
at sites of less than complete homology [220]. Shen et al (2014) looked at the potential for using 
Cas9 nickase rather than endonuclease to reduce the prevalence of these off target effects in vivo 
using mouse embryos [221]. Nickase creates a “nick” in a single strand of the genomic DNA which 
allows it to be corrected by the endogenous base-excision repair pathway [221]. 
Many studies have attested to the usefulness and adaptability of CRISPRs as a genetic tool. 
Genome editing with CRISPR/Cas9 in two separate studies demonstrated that multiplex gene 
knockouts can be performed both simultaneously and highly efficiently in a single step using stem 
cells and mice [222, 223]. In this single step process, co-injection of two sgRNAs is performed 
into a target cell. Both of these studies resulted in biallelic gene conversions or inactivation’s [222, 
223]. Results presented by Wang et al (2013) suggest that injection with a single sgRNA results 
in up to 95% of mice carrying biallelic mutations in the targeted gene, whereas co-injection of two 
different sgRNAs, results in up to 80% of mice carrying biallelic mutations in both target genes 
[222]. Jao et al (2013) showed that mutations could be efficiently transmitted through the germline 
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into the F1 generation of zebrafish [223]. Another study, by Yang et al (2013), also demonstrated 
one step generation of mutants at multiple gene loci using mouse embryos [224]. Hruscha et al 
(2013) adapted the CRISPR protocol to synthesise gRNA without cloning and demonstrated 
efficient mutagenesis, knock-in (KI), and transmission to the germline that was comparable to ZFN 
and TALEN approaches [225]. They also provided evidence that off-target effects were limited, 
and that KI was efficient, particularly when they pre-selected founder fish [225]. 
One interesting utilisation of the CRISPR system in mice demonstrated CRISPR/Cas9-mediated 
correction of Fah mutation in hepatocytes in an adult mouse model of the human disease hereditary 
tyrosinemia (HTI) [226]. Adult FAHmut/mut mice were given hydrodynamic tail vein injections with 
ssDNA oligonucleotide, plus a pX330 vector expressing Cas9 and one of three individually cloned 
sgRNA’s (FAH1-3) targeting the Fah locus. This study demonstrated that CRISPR/Cas9 could 
functionally rescue the Fah deficiency-induced liver damage in mice, demonstrating a potential 
for this system to correct disease genes in vivo in adult mouse liver using a CRISPR-Cas9 system 
[226]. Transient expression of Cas9, sgRNA and a co-injected ssDNA by non-viral hydrodynamic 
injection was sufficient to restore the weight loss of a mouse model of HTI [226]. This study 
demonstrated a previously unrealised potential of the CRISPR system to correct mutant gene 
phenotypes in adult specimens. 
The discovery and application of CRISPR-Cas9 has transformed the field of genome engineering 
and further development of this technology is rapidly progressing. A recent review highlights 
further advances in the technology [213]. Some of these advances that can be applied to genome 





γ-secretase is a protease complex that is important for the processing of more than 100 substrates. 
Processing of APP by γ-secretase is thought to be a critical component of AD pathogenesis. 
Although much research has been undertaken to identify the effects of γ-secretase in AD, the 
specific mechanism through which it recognises and selects its substrates remains elusive. The 
similar sequence and structure, but distinct transmembrane cleavage events, of p75NTR and its 
homolog NRH1 may allow us to further investigate this mechanism. Furthermore, 59 mutations in 
APP have been identified that are thought to cause fAD. However, the mechanism through which 
AD develops and progresses remains incompletely understood and there is still no single 
hypothesis that accurately predicts disease susceptibility. The zebrafish is an excellent model for 
us to further investigate the molecular effects of fAD-like mutations, in the hopes of better 
understanding what specific factors inevitably results in AD. 
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Chapter 2 – Developing in vivo assays for investigating p75NTR and NRH1 
transmembrane cleavage events using zebrafish embryos 
2.0 Declaration 
Within this chapter a portion of the results described in 2.2, namely, 1) the tblastn searches 
described in paragraph 1, below subheading Identification of p75NTR and NRH1gene orthologues 
in zebrafish, 2) the mCherry construct designs described in paragraphs 2, 3 and 5, below 
subheading Design of p75NTR and Nrh1 γ-secretase cleavage assay constructs, 3) microinjections 
through to western immunoblots of mCherry constructs described in paragraph 6, below 
subheading Design of p75NTR and Nrh1 γ-secretase cleavage assay constructs, and 4) DAPT 
treatments and western immunoblots described in paragraph 1, below the subheading Investigating 
differential cleavage properties of zebrafish p75NTF and Nrh1 and presented in Figure 2.3, are from 
work that was previously completed and submitted by myself within a thesis for the Honours 
Degree of Bachelor of Science at the University of Adelaide. 
As this chapter has been written with the intention to submit to a journal for publication, it was 




γ-secretase is a multi-subunit membrane-bound aspartyl protease complex responsible for cleavage 
of over 100 substrates including Amyloid Precursor Protein (APP), Notch and the p75 
neurotrophin receptor (p75NTR) [1]. γ-secretase has been identified as a member of the 
intramembrane cleaving protease family (I-CLiP). I-CLiPs cleave type 1 membrane proteins 
67 
 
enzymatically via a process termed regulated intramembrane proteolysis (RIP) [2, 3]. The most 
studied function of γ-secretase is processing of APP. This is due to the seemingly critical role of 
APP in Alzheimer’s disease (AD) etiology. Although numerous publications have discussed the 
perceived role of γ-secretase in AD, the specific nature of substrate selection by this protease is 
still not clearly defined.  
 
γ-secretase substrates are typically derived from large precursor proteins that undergo a 
prerequisite removal of their ectodomain/lumenal domain prior to γ-secretase cleavage [3] Early 
research suggested that the only other prerequisite was that the substrate must be a type 1 
transmembrane protein [4]. Further studies have now shown that additional factors may guide 
substrate selection by γ-secretase. It has previously been suggested that dimerisation of substrates 
and/or the structure of substrate α-helices may regulate γ-secretase activity [5]. γ-secretase 
substrate recognition and cleavage is also much more efficient for ectodomains with fewer than 
~50 remaining amino acid residues [6]. Previous studies have attempted to elucidate Notch and 
APP residues that are required for γ-secretase cleavage [7]. However, a distinct cleavage site for 
γ-secretase within the transmembrane domains of its target proteins has not been defined [2].  
p75NTR, also known as the ‘low-affinity nerve growth factor receptor’ (LNGFR), is one of the 
many substrates of γ-secretase subject to cleavage within its transmembrane domain [8]. p75NTR 
has been implicated in neuronal survival, myelination and neurite outgrowth among other 
pathways during vertebrate nervous system development, through its interactions with 
neurotrophins and Trk receptors [9]. Also, the Aβ peptide can act as a ligand for p75NTR and is 
proposed to play a role in cholinergic neuron loss, implicating this protein in AD [10, 11]. Kanning 
et al (2003) investigated the proteolytic processing of p75NTR, along with what they described as 
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the “neurotrophin receptor homologs” (NRH), NRH1 and NRH2 [8]. Database and EST searches 
have established that these two genes show greater sequence similarity to p75NTR than any other 
homologous genes [8]. Experiments by Kanning et al (2003) confirmed processing of p75NTR by 
α-secretase (ADAM10) and γ-secretase. Western blot analysis of NRH1 and NRH2 indicated that 
these are both cleaved within their transmembrane domains [8]. However, Kanning et al (2003) 
observed that the commonly used inhibitor of γ-secretase activity, DAPT, had no effect on the 
cleavage of NRH1 or NRH2, suggesting that transmembrane cleavage of these proteins is not by 
γ-secretase [8].  
 
The possible lack of sensitivity to γ-secretase inhibitors of the p75NTR homologs NRH1 and NRH2 
may have interesting applications. p75NTR and its homologs share high sequence similarity in their 
transmembrane domain, where γ-secretase cleavage occurs [8] and comparison of the 
transmembrane domains of p75NTR and NRH1 might allow definition of transmembrane domain 
characteristics critical to permit cleavage by γ-secretase. We have developed an in vivo zebrafish 
assay that can be used to investigate the structural differences in the transmembrane domains of 
these two proteins that cause their differential sensitivity to γ-secretase. 
 
2.2 Results and Discussion 
Identification of p75NTR and NRH1gene orthologues in zebrafish 
Of the two NRH genes, NRH1 has coding sequences more similar in length to p75NTR and is the 
only know NRH gene with a putative orthologue in zebrafish. To investigate p75NTR and NRH1 
cleavage in vivo using zebrafish, we previously validated the orthology of these genes [12]. A 
tblastn search performed against the zebrafish genome using the entire putative protein sequence 
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of human p75NTR, constrained to “RefSeq_RNA”, returned candidate orthologues of the human 
p75NTR gene on zebrafish chromosomes 3, 12 and 16. At the time of the original analysis 
chromosome 12 appeared to hold two almost identical copies of the gene at different loci 
(supplementary file S1, Figure S1) which we suspected was due to a recent duplication event. The 
position of the duplicate appears to have been revised to chromosome 3 in the latest genome build 
(GRCz11) (supplementary file S1, Figure S2). The top tblastn hit, nerve growth factor receptor b 
(ngfrb), on chromosome 12, has the greatest query cover (percentage of the sequence aligned to a 
sequence in GenBank) to human p75NTR (93%) (supplementary file S1, Figure S2), so we 
tentatively named this “zebrafish p75”. A tblastn search performed against the zebrafish genome 
using NRH1 from Xenopus laevis (GenBank accession AF131890.1) returned the computer 
predicted sequence for neurotrophin receptor associated death domain (nradd) on chromosome 
16 (also returned as a best hit in the human p75NTR tblastn search described above) with 100% 
query coverage to Xenopus NRH1. The only other strong zebrafish Nrh1 candidate returned was 
ngfrb, which we had already established most likely represents p75NTR in zebrafish. Therefore, we 
predict that nradd is most likely a Nrh1 orthologous gene in zebrafish.  
 
NRH1 belongs to a subfamily of vertebrate p75NTR-related proteins which also contains NRH2. 
NRH2 exists only in mammals while NRH1 exists only in amphibians, fish and birds [8]. The 
return of the predicted sequence nradd when searching for NRH1 within the zebrafish genome is 
consistent with previous knowledge that NRH2 is also known as NRADD in mouse and rat (mouse 
NCBI Gene ID: 67169, rat NCBI Gene ID: 246143). Therefore, we eliminated nradd as a zebrafish 




To confirm our identification of zebrafish p75NTR and Nrh1 orthologues we next conducted 
phylogenetic analyses using the Geneious software suite [13]. Zebrafish p75NTR and Nrh1 
candidate amino acid sequences along with p75NTR amino acid sequences from Xenopus laevis, 
Gallus gallus (chicken), mouse and human and NRH1 amino acid sequences from Xenopus 
tropicalis, Xenopus laevis and chicken were aligned using the Geneious alignment tool, and trees 
were built using both Bayesian and Maximum likelihood methods. We included the amino acid 
sequences of NRH2 from mouse and human in these analyses as these are the mammalian 
equivalents of NRH1 [8]. Accession numbers for all sequences used can be found in supplementary 
data File S2, Table S1. Branchiostoma floridae (lancelet) was used as an out-group as this was the 
most distant relative to zebrafish that returned a result when conducting tblastn searches using 
human p75NTR and X. laevis NRH1. Interestingly, tblastn searches of the lancelet genome using 
both p75NTR and NRH1 returned the same gene in lancelet (supplementary data File S2, Table S1). 
As the chicken genome contains both p75NTR and NRH1-like sequences, tblastn searches of the 
lancelet genome using both full-length chicken sequences were performed to confirm the 
preliminary findings. These searches returned results identical to those using human p75NTR and 
X. laevis NRH1. This supports that there is only a single p75NTR- and NRH1-like gene in this basal 
chordate and that p75NTR and NRH1 arose from a gene duplication event early in vertebrate 
evolution. A dendrogram modelling the phylogenetic relationships of p75NTR and its homologs 
demonstrated p75NTR proteins clustering together and NRH1 proteins clustering together in 
separate clades (Figure 2.1). This supports that the sequence nradd on chromosome 16 of zebrafish 






Figure 2.1. Phylogenetic tree of p75NTR and NRH1 proteins. This tree was generated using the Geneious 
software suite to perform Bayesian analysis (MrBayes). Numbers represent the aLRT branch-support 
values. 
 
It was difficult to discern which of the remaining three possible zebrafish p75NTR protein sequences 
was most likely to represent the true p75NTR in zebrafish from the phylogenetic analyses, although 
the sequence that we designated zebrafish p75-like-chr3 appeared to be marginally more similar 
to human p75NTR (Figure 2.1). The sequence we designated zebrafish p75, known as ngfrb in the 
NCBI database, is the only gene with a coding sequence not derived by computer-prediction from 
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genomic DNA sequence. It was thereby judged to be the most likely to be accurate and was 
selected for construction of an assay. 
 
Design of p75NTR and Nrh1 γ-secretase cleavage assay constructs 
In order to be recognised as a cleavage substrate by γ-secretase, proteins must first undergo 
truncation of the extracellular domain [6]. This preliminary shedding of large extracellular 
domains by α- or β-secretase may be rate-limiting, creating problems for an in vivo assay as the 
rate of cleavage may be dependent on these events rather than γ-secretase itself. To overcome this 
in our assay, we proposed to produce artificially truncated forms of both proteins similar to a 
strategy we had adopted previously for zebrafish APP in another γ-secretase assay [14]. 
 
To truncate p75NTR and Nrh1 to mimic approximately α-secretase-cleaved forms of these proteins, 
we first needed to identify the transmembrane domains of both p75NTR and Nrh1. As the 
transmembrane domains of zebrafish p75NTR and Nrh1 genes had not yet been defined, we had 
previously employed online prediction programs “TMHMM server, v. 2.0” 
(http://www.cbs.dtu.dk/services/TMHMM/) [15], “TMpred Server” (https://embnet.vital-
it.ch/software/TMPRED_form.html) and “DAS” (https://tmdas.bioinfo.se/DAS/index.html, [15]) 
to determine the location of the transmembrane region within each protein (supplementary data 
File S3, Figure S3) [12]. The success of this approach was confirmed by comparing our predicted 
transmembrane domains to the defined transmembrane domain of human p75NTR [5]. It has 
previously been established that γ-secretase cleavage of p75NTR is dependent on shedding of the 
N-terminal extracellular domain by the α-secretase, A DISINTEGRIN AND 
METALLOPROTEINASE DOMAIN 17 (ADAM17). A previous study of p75NTR suggested that 
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this cleavage occurs five amino acids before the N-terminal of the transmembrane [5]. Another 
study found that a large deletion of 15 amino acid residues within the juxtamembrane domain 
(before the N-terminal of the transmembrane) of p75NTR led to substantial decrease in shedding, 
while a third study found that a stub of 15 amino acids N-terminal to the transmembrane domain 
was sufficient for γ-secretase cleavage [17, 18]. We elected to remove most of the extracellular 
domain, leaving only 15 amino acids immediately adjacent the N-terminal end of the membrane. 
The C-terminal intracellular domain was left at its original length as it has not been found to affect 
cleavage [17]. When attempting to visualise cleaved and uncleaved protein fragments on a western 
blot this small 15 residue N-terminal stub may have posed a problem. Post γ-secretase cleavage 
we would be left with a very short N-terminal fragment and a much larger C-terminal fragment, 
which would presumably be difficult to resolve on the same western immunoblot. 
 
To overcome this, previous work in our laboratory fused 3 FLAG tags [19] in tandem to the N-
terminals of both p75NTR and Nrh1 [12]. The efficiency of processing by γ-secretase is not reduced 
unless the number of amino acids in the extracellular domain exceeds 50, so processing and 
cleavage should not be affected by the FLAG tags [6]. Single, silent, point mutations were 
introduced into both the second and third tandem FLAG tag repeats to inhibit recombination in 
bacteria during cloning [20]. The fourth codon in the second repeat was altered from GAT to GAC, 
and the sixth codon in the third from GAC to GAT respectively. The highly active HMM+38 
secretory signal sequence was added N-terminal to the FLAG repeats to ensure insertion of the 
p75NTR and Nrh1 proteins into lipid bilayers [21]. This signal sequence is cleaved off upon reaching 
the target site and is not involved in the metabolism of the final translated protein, hence does not 
alter the mature protein structure [21]. Destabilised green fluorescent protein (dGFP) was included 
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at the C-terminus of p75NTR and Nrh1 to allow for visualisation of expression in vivo and via 
western immunoblot analysis. As these constructs contain a truncated, C-terminal fragment of the 
original p75NTR and Nrh1 proteins we describe them as ssFLAG-p75NTRC201-dGFP and ssFLAG-
Nrh1C191-dGFP respectively.  
 
Injection of transposon-based vector DNA into fertilised zebrafish eggs can give variable results 
in terms of the amount of DNA delivered and the subsequent degree of transposition and transgene 
expression. Therefore, when examining the stability of a protein expressed from an injected 
transgene, it can be useful to have an internal reference standard against which the quantity of the 
protein can be compared. In a previous study assaying γ-secretase activity by monitoring cleavage 
of zebrafish Appa fused to dGFP (also expressed from the Tol2 transgene vector, 
pT2AL200R150G), we co-injected a similar Tol2 vector expressing free GFP, as an internal 
reference standard [14]. However, this strategy might still be somewhat subject to variability as 
the free GFP vector might not transpose into the genome at a constant rate relative to the Appa 
construct.  
 
The viral 2A (v2A) peptide ribosomal-skip mechanism allows for expression of two different 
proteins independently of one another. The skip mechanism occurs within the v2A sequence when 
a peptide bond fails to form between the penultimate (glycine) and final (proline) residue. 
Translation continues despite this failure, and tandem protein products are produced in a 
stoichiometric manner [22]. In order to express truncated p75NTR or Nrh1 simultaneously with 
an internal reference standard from the same expression vector, we previously included a v2a 
sequence at the C-terminal of ssFLAG-p75NTRC201-dGFP and ssFLAG-Nrh1C201-dGFP 
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followed by coding sequence for the red fluorescence protein, mCherry [12]. We describe these 
Tol2-based expression constructs as pT2ALssFLAG-p75NTFC201-dGFP-v2a-mCherry and 
pT2ALssFLAG-Nrh1C191-dGFP-v2a-mCherry (Figure 2.2, 1). For simplicity, we will henceforth 
refer to them as p75NTFC201-dGFP and Nrh1C191-dGFP respectively. This design enables 
stoichiometric production of p75NTFC201-dGFP or Nrh1C191-dGFP simultaneously with 
mCherry, allowing for normalisation of protein expression between successive batches of injected 
embryos. 
 
Previous work in our laboratory investigating γ-secretase cleavage of both p75NTFC201-dGFP and 
NRH1C191-dGFP, saw each expression vector co-injected with transposase mRNA into single-
cell stage zebrafish embryos [12]. At 24 hours post fertilisation (hpf) embryos displaying GFP 
fluorescence under UV light were selected, their yolks removed, and protein extracted by lysis in 
SDS buffer. Protein lysates were separated by SDS polyacrylamide gel electrophoresis and then 
subjected to western immunoblotting to detect GFP. Uncleaved p75NTFC201-dGFP and 
Nrh1C191-dGFP proteins were visible as bands of ~61kDa and ~57kDa respectively and could be 
assessed by densitometry, while their intra-membrane domain cleavage products could not be 
observed (presumably due to their instability, data not shown). Stripping and probing of the blot 
to detect mCherry followed by densitometry allowed normalisation of the GFP signals to facilitate 




Figure 2.2 Overview of all construct designs and assay process. 1) Overview of pT2ALssFLAG-
p75NTFC201-dGFP-v2a-mCherry and pT2ALssFLAG-Nrh1C191-dGFP-v2a-mCherry constructs. 2) 
pT2ALssFLAG-p75NTFC201-dGFP-v2a-GFP and pT2ALssFLAG-Nrh1C191-dGFP-v2a-GFP. 3) 
Overview of pT2ALssFLAG-A2C-dGFP-v2a-GFP. 4) Anticipated assay process. A) the position and 
mechanism of the ribosomal skip is indicated by arrows, B) TMD cleavage of constructs is represented by 




Investigating differential cleavage properties of zebrafish p75NTF and Nrh1 
Previous experiments performed by Kanning et al (2003) indicated that both the p75NTR and NRH1 
proteins are cleaved within their transmembrane domains. However, treatment with the known γ-
secretase inhibitor DAPT had no effect on NRH1 cleavage, suggesting that NRH1 is not processed 
by γ-secretase [8]. To test whether p75NTFC201-dGFP and Nrh1C191-dGFP cleavage displayed 
differential sensitivity to inhibition of γ-secretase activity in vivo, batches of injected embryos were 
divided into two groups. Half of a batch injected with either p75NTFC201-dGFP or Nrh1C191-
dGFP was treated with 100μM of the γ-secretase inhibitor DAPT from 4hpf until 24hpf (as was 
previously optimised [14]), while the other half was left untreated. DAPT is a potent γ-secretase 
cleavage inhibitor, hence we expected that treatment with DAPT would result in an accumulation 
of uncleaved substrates of γ-secretase [18]. This was observed on p75NTFC201-dGFP-injected 
embryos treated with DAPT (Figure 2.3, A), suggesting that zebrafish p75NTR is, indeed, processed 
by γ-secretase. However, when this was normalised to mCherry across three replicates, the p-value 
(0.1697) of this observed increase did not support the likelihood that uncleaved zebrafish p75NTR 
is consistently accumulated when treated with DAPT (Figure 2.3, B). This accumulation of 
substrate was not observed when Nrh1C191-dGFP was subjected to DAPT treatment (Figure 2.3, 
A), suggesting that zebrafish Nrh1 is not sensitive to the γ-secretase inhibitor DAPT. This result 
supports the observation made by Kanning et al (2003) that NRH1 is not a substrate of γ-secretase 
[8]. 
 
As was previously observed in a similar γ-secretase assay, both p75NTFC201-dGFP and Nrh1C191-
dGFP appeared to induce developmental abnormalities in embryos [14]. When injected, embryos 
displayed increased mortality (~46% vs. ~5-10% in uninjected controls) and a range of 
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developmental abnormalities, which were increased by DAPT treatment (~57% mortality) (data 
not shown). This toxicity may be due to excessive generation of p75NTF and Nrh1 intracellular 
domains (ICDs), both of which carry a death domain [5, 8]. This increase in ICD carrying death 
domains may result in premature embryo death. p75NTF is also known to form a heterodimer with 
the protein SORTILIN which then interacts with proNGF or proBDNF proteins leading to 
apoptosis [23, 24]. Treatment of embryos with DAPT may inadvertently facilitate this interaction 
by causing accumulation of uncleaved p75NTR. Another factor to consider is the nature of the 
vectors used to express the assay constructs. Tol2 is a transposase vector that inserts randomly into 
the genome. If the Tol2-based constructs were to disrupt essential/housekeeping genes this would 
also affect the survival of embryos [25].  
 
Zebrafish caspase 3 plays an important role in apoptosis signalling [26]. To overcome the toxicity 
of assay construct expression, we treated zebrafish embryos with 100μM of the caspase 3 inhibitor 
Z-DEVD-FMK (as was shown in a PhD dissertation [27]). However, treatment with this inhibitor 
did not reduce the degree of lethality observed (data not shown). Therefore, to overcome the 
problem of the lethality, an increased number of embryos were injected in each batch with only 
the most phenotypically normal embryos being selected for western blot analysis (after 




Figure 2.3. Western immunoblot analysis of p75NTFC201-dGFP and Nrh1C191-dGFP. A) Western 
immunoblots from p75NTFC201-dGFP and Nrh1C191-dGFP injected embryos at 24hpf with and without 
DAPT treatment. + indicates embryos were treated with DAPT. The additional band observed below the 
bands indicated by arrows are most likely degradation products. B) Ratios of p75NTFC201-dGFP/free 
mCherry in p75NTFC201-dGFP injected embryos at 24hpf, with (+) (n = 3) or without (-) (n = 3) DAPT 
treatment. C) Ratios of Nrh1C191-dGFP /free mCherry in Nrh1C191-dGFP injected embryos at 24hpf, 





Replacing mCherry with GFP reduces variability in the western immunoblot analyses 
An apparent trend of accumulation of p75NTFC201-dGFP due to γ-secretase inhibition was 
observed by western immunoblotting. However, statistical analysis of the densitometry 
measurements did not indicate significance due to the considerable variability between samples 
(Figure 2.3, B and C). A contributor to this variability may have been the necessity to strip and re-
probe the western blot with the anti-mCherry antibody. To overcome this, the red fluorescence 
gene mCherry was excised from the constructs and replaced with a second GFP gene downstream 
of the C-terminal of v2a, producing vectors pT2ALssFLAG-p75NTFC201-dGFP-v2a-GFP and 
pT2ALssFLAG-Nrh1C191-dGFP-v2a-GFP (Figure 2.2, 2).  For simplicity, we will henceforth 
refer to them as p75NTFC201-dGFPx2 and Nrh1C191-dGFPx2 respectively. This minor adjustment 
in construct design allows for the internal expression standard to be visualised using the same anti-
GFP antibody as detects the p75NTFC201-dGFP and Nrh1C191-dGFP fusions. 
 
To evaluate the effectiveness of the modified assay constructs we performed injections on 
numerous batches of embryos and then ran protein samples on multiple western blots. Analysis 
using the new assay constructs consistently displayed an increase in accumulation of the 
p75NTFC201-dGFPx2 substrate when treated with the γ-secretase inhibitor DAPT. This result was 
confirmed statistically by combining band intensity data from across all western blots and 






Figure 2.4. Western immunoblot analysis of p75NTFC201-dGFPx2 and Nrh1C191-dGFPx2. Ratios from 
western immunoblots of p75NTFC201-dGFPx2/free GFP in p75NTFC201-dGFPx2 injected embryos at 24hpf, 
with (+) (n = 8) or without (-) (n = 8) DAPT treatment. C) Ratios of Nrh1C191-dGFPx2 /free GFP in 
Nrh1C191-dGFPx2 injected embryos at 24hpf, with (+) (n = 8) or without (-) (n = 8) DAPT treatment. 
p value was calculated using an unpaired, two-tailed t-test. 
 
Conversely, there was no observed increase in Nrh1C191-dGFP substrate accumulation in 
response to DAPT treatment. Statistical analysis found no significant difference between the 
treated and untreated samples (p =0.9037) (Figure 2.4, B). Although the p75NTR western 
immunoblot data was similar across numerous blots there was a high degree in variability in the 
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normalised values across Nrh1 immunoblots. This variability was unexpected and seems to be due 
to variation in the amount of free GFP on each blot. It is possible that GFP stability may play a 
role in this. Regardless of this we are confident that Nrh1 is not responsive to DAPT, as when 
looking at each blot individually there was consistently no accumulation in response to this 
inhibitor among replicates (data not shown).  
 
γ-secretase cleavage is not conferred to Nrh1 by the p75NTF transmembrane domain 
The sequence similarity of p75NTR and its homolog Nrh1 imply that these two genes share a 
relatively recent evolutionary origin through duplication of an ancestral p75NTR/Nrh1-like gene. 
Therefore, if p75NTR is a substrate of γ-secretase, then Nrh1 would most probably also be cleaved 
by it. The observed lack of γ-secretase-dependent cleavage of zebrafish Nrh1 in our assay is 
consistent with the results of Kanning et al (2003) [8]. The existence of this pair of closely related 
genes/proteins, one of which is cleaved by γ-secretase and one of which is not, presents us with a 
unique opportunity to dissect the structural basis of γ-secretase cleavage substrate specificity. 
 
To begin dissection of γ-secretase cleavage substrate specificity using our assay, we designed a 
chimaeric construct in which Nrh1’s transmembrane domain was replaced with the transmembrane 
domain from p75NTR. The new construct, termed pT2ALssFLAG-A2C-dGFP-v2a-GFP (Figure 
2.2 3), simplified to A2C-dGFPx2, was injected into one cell stage embryos which were 
subsequently treated as previously with or without DAPT. Protein samples were then collected at 
24 hpf for analysis by western immunoblot. This did not reveal an accumulation of substrate when 
γ-secretase was inhibited (Figure 2.5). This suggests that the p75NTR transmembrane domain alone 
is not sufficient to confer γ-secretase susceptibility and that structures outside of this domain are 
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also required. It is possible that altering the protein by swapping entire domains may disrupt its 
ability to form homo- or heterodimers, which have previously been found to be important for γ-
secretase cleavage [5]. A detailed further analysis replacing Nrh1 amino acid residues with those 
not shared by p75NTR in this chimaeric construct should allow definition of the structures critical 
to conferring γ-secretase susceptibility. 
 
 
Figure 2.5. Western immunoblot analysis of A2C-dGFPx2. Ratios from western immunoblots of A2C-
dGFPx2 /free GFP in A2C-dGFPx2 injected embryos at 24hpf, with (+) (n = 5) or without (-) (n = 5) 
DAPT treatment. 
 
Further analysis of p75NTR and Nrh1 transmembrane domains 
Recent studies have shown that the α-helices of γ-secretase substrates Notch and APP unwind 
when they interact with the active site of PRESENILIN (the catalytic core of γ-secretase) [28-30]. 
A study investigating the conformation of the rhomboid substrate Gurken during cleavage by the 
archaeal homologue of PRESENILIN, MCMJR1, found that Gurken underwent a conformational 
change into a β-strand when interacting with MCMJR1 [31]. Proline residues have previously been 
found to disrupt transmembrane helices. Therefore, Brown et al (2018) altered the Pro252 TMD 
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residue of Gurken and found that it was no longer a substrate of MCMJR1. They suggested that 
the proline residue, through its perturbation of the α-helical conformation, effectively allows for 
this helix to unwind into the β-strand conformation that is preferred by MCMJR1 [31]. They also 
observed that so called “noncleavable” variants (i.e. those that cannot enter a β-strand 
conformation) could still bind to MCMJR1 with equal affinity to the cleavable substrates.  
 
We aligned the TMDs of zebrafish p75NTR and Nrh1 to investigate whether either of these 
sequences contain a proline residue that would allow them to unwind from an α-helix to a β-strand, 
as was observed for Gurken. Interestingly, while the TMD of zebrafish p75NTR contains a proline 
close to the N-terminal end, zebrafish Nrh1 does not contain a proline within its TMD (Figure 2.6). 
 
 
Figure 2.6. Alignment of the zebrafish p75NTR and Nrh1 transmembrane domains. Red box indicates the 
proline residue in p75NTR that is absent in Nrh1. 
 
2.3 Conclusions and Future directions 
In this study we identified the p75NTR and Nrh1 orthologues in zebrafish suitable for design of an 
assay system in which to test γ-secretase cleavage of these proteins in vivo. We observed that, 
while cleavage of zebrafish p75NTR by γ-secretase is sensitive to DAPT, zebrafish Nrh1 is not 
sensitive to this γ-secretase inhibitor. This finding is consistent with a previous study in which 
human p75NTR and Xenopus NRH1 were investigated in vitro [8]. Furthermore, our analysis of a 
chimeric Nrh1 protein in which the Nrh1 transmembrane domain is replaced by that of p75NTR 
revealed that this domain alone is not sufficient to confer γ-secretase cleavage susceptibility. This 
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is not completely unexpected as there is evidence to suggest that other factors are crucial for 
selection/cleavage by the γ-secretase complex [5]. A greater understanding of the specificity of γ-
secretase substrate selection might be reached by extending the chimaeric approach by exchanging 
each of the domains of these proteins. Indeed, a study (that we discovered while writing this 
manuscript) using a similar domain swap approach but with two unrelated type 1 transmembrane 
proteins (the non γ-secretase substrate Itgβ1 and γ-secretase substrate vasorin) found that both a 
permissive transmembrane and a permissive intracellular domain were required for γ-secretase 
cleavage, confirming our findings [32]. 
 
Other than the prerequisites of being a type 1 membrane protein and of shedding the ectodomain 
it has previously been suggested that dimerisation of substrates and/or the structure of substrate α-
helices may regulate γ-secretase activity [5]. This was not investigated in this study but is 
something that should be considered for future experiments using this assay system. Previous 
studies of the p75NTR dimerisation domain AxxxGxxA found that, while this domain is not 
essential for dimerisation, altering its structure to LxxxLxxA via mutational analyses reduces γ-
secretase cleavage [5, 33]. It was thought that this might be due to a stabilisation of the α-helix, 
inhibiting γ-secretase access by preventing unravelling of the transmembrane domain [5]. 
Zebrafish p75NTF also contains the AxxxGxxA domain. However, in zebrafish Nrh1 the second 
alanine is replaced by leucine (AxxxGxxL) and we suggest this may have a similar effect to the 
LxxxLxxA mutant. It would be interesting to perform site directed mutagenesis on the L256 
residue of the zebrafish Nrh1 dimerisation domain to assess whether this is a key feature preventing 




Another question that can potentially be addressed using this assay is the identity of the enzyme 
performing intramembranous cleavage of Nrh1. Since Kanning et al (2003) established that NRH1 
does in fact produce cleavage products when treated with the PKC activator, PMA, a deeper 
investigation into what cleaves this protein may offer insights into alternative cleavage pathways 
for such substrates [8]. There are four main classes of proteases that perform intramembrane 
proteolysis. The first encompasses the aspartic proteases, including Presenilins (PSENs, the active 
subunit of γ-secretase), signal peptide peptidases (SPPs) and SPP-like proteases [34-36]. While γ-
secretase cleaves proteins with type 1 membrane topology (C-termini towards the cytosol), the 
SPP and SPP-like proteases cleave proteins with type 2 membrane topology (N-termini towards 
the cytosol). Another class of I-CliPs consists of the Site-2 protease (S2P) and S2P-like proteases 
[37]. These are members of the metalloprotease family and cleave type 2 transmembrane proteases. 
Finally, there are the Rhomboid proteases, which are serine proteases [38]. Rhomboid proteases 
are highly specific in their substrate selection. The substrates selected are mostly type 1 
transmembrane proteins, although there is also evidence to suggest they may cleave type 2 and 
multi pass membrane proteins in some cases [39, 40]. If we assume that NRH1 is a type 1 
transmembrane protein like its homologue p75NTR, then we can reasonably exclude two of the 
above classes of membrane cleaving proteases as candidates, namely, SPP (and SPP-like) and S2P 
(including S2P-like). However, the orientation of NRH1 within the membrane has not yet been 
investigated. Our assay could be used to test a range of protease inhibitors to identify which 
enzyme(s) cleave Nrh1. 
 
The question of the effect of the α-helix structure of p75NTR or NRH1 TMD on their cleavage 
susceptibility has not yet been investigated. Previous observations from a study of the effects of 
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the TMD of Gurken found that a β-sheet conformation was required for cleavage by the archaeal 
PRESENILIN homologue, MCMJR1. This raised the question of whether NRH1 can interact with 
PRESENILIN, but perhaps due to its TMD being in an α-helical conformation, cannot be cleaved 
by it. A simple amino acid sequence alignment of the zebrafish p75NTR and Nrh1 TMDs (Figure 
2.6) revealed that, while the p75NTR TMD carries a proline residue that would supposedly allow it 
flexibility to conformationally change between an α-helix and β-sheet, the Nrh1 TMD lacks this 
residue. Interestingly, it has previously been observed that insertion of a single proline into the 
TMD can trigger cleavage of normally un-cleavable TMD’s [31]. It may therefore be of interest 
in future to either insert or substitute a proline residue into the Nrh1 TMD to investigate its ensuing 
γ-secretase cleavage susceptibility. The results of such an experiment using our established assay 
might provide an answer for why Nrh1 is not naturally a γ-secretase substrate, while also 
contributing to the understanding of γ-secretase cleavage susceptibility. Regarding the previously 
observed cleavage of Xenopus NRH1 within its TMD and the question of what protease might be 
responsible for this cleavage, it has been observed that all intramembrane cleaving proteases 
(iCLIPs) prefer to cleave TMDs in their β-strand conformation [41]. If NRH1 is unable to enter 
this conformation, perhaps there is some other unknown enzyme responsible for this cleavage. If 
we wish to understand the cleavage properties of NRH1 it would be important to further investigate 







2.4 Materials and Methods 
Ethics 
This work was conducted under the auspices of the Animal Ethics Committee of the University of 
Adelaide and in accordance with EC Directive 86/609/EEC for animal experiments and the 
Uniform Requirements for manuscripts submitted to Biomedical journals. 
 
Gene orthologue identification 
Alignments and tree building were conducted using the Geneious software suite, version 5.6.7 
(http://www.geneious.com, [13]). Alignments were performed with the following constraints; Cost 
matrix: Identity, Gap open penalty: 10, Gap extension penalty: 3, Alignment: Global. Bayesian 
trees were produced using the “Mr Bayes” program with the following constraints; Substitution 
model: GTR, Outgroup: Lancelet p75NTR, and the rest as default. 
 
Constructs 
ssFLAG-p75NTFC201-dGFP-v2a-mCherry, ssFLAG-Nrh1C191-dGFP-v2a-mCherry and 
ssFLAG-A2C-dGFP-v2a-mCherry DNA sequences were produced by Biomatik (complete DNA 
sequences are provided in supplemental file S4). These DNA sequences in the pBMH vector 
(provided by Biomaitk) were digested using BamHI and ClaI in independent reactions and ligated 
into pT2AL200R150G between the BamHI and ClaI sites. 
 
Replacement of mCherry coding sequence by GFP coding sequence 
GFP was amplified by polymerase chain reaction (PCR) using the following primers; Forward: 5’-
GCTCTAGAATGGTGAGCAAGGGAGAGGA-3’ and Reverse: 
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5’CCATCGATCTACTTGTACAGCTCGTCCATTCC-3’. The thermal cycling parameters were 
as follows: 98°C for 30 s, 15 cycles of 98°C for 10 s, 61°C for 30 s and 72°C for 30 s, followed by 
72°C for 10 mins. mCherry was excised from pT2AL200R150GssFLAG-p75NTFC201-dGFP-v2a-
mCherry, pT2AL200R150G ssFLAG-Nrh1C191-dGFP-v2a-mCherry and pT2ALssFLAG-A2C-
dGFP-v2a-mCherry by restriction digest with Xba1 and Cla1. The amplified GFP was then cloned 
between the Xba1 and Cla1 sites of pT2AL200R150GssFLAG-p75NTFC201-dGFP-v2a-mCherry, 
pT2AL200R150G ssFLAG-Nrh1C191-dGFP-v2a-mCherry and pT2ALssFLAG-A2C-dGFP-v2a-
mCherry. 
 
DNA microinjection of zebrafish embryos and treatment with DAPT. 
Tol2 transposase plasmid (pCS-TP) was linearised using Not1 (NEB) and mRNA was transcribed 
in vitro using the mMESSAGE mMACHINE SP6 Kit (Ambion Inc.). Fertilised embryos were 
injected with a solution containing 100ng/µl plasmid DNA and approximately 50ng/µl Tol2 
transposase mRNA at the one cell stage. ~50 embryos injected with the injection solution above 
were placed into 35mm x 10mm petri dishes with 2ml E3 medium (15mM NaCl, 0.5mM KCl, 
1mM MgSO4, 0.15mM KH2PO4, 0.05mM Na2HPO4, 1mM CaCl2, 0.7mM NaHCO3). At 4hpf 
embryos were treated with 100µM DAPT (In solutionTM γ-secretase inhibitor IX, Calbiochem, San 
Diego, CA, USA) in 1% DMSO in E3 medium. Embryos were maintained at 28°C in a humid 
incubator. At 24hpf embryos were visualised under UV light for GFP expression. Embryos 






Treatment of zebrafish embryos with Z-DEVD-FMK 
Injected embryos were placed into 35mm x 10mm petri dishes with 2mL E3 medium (15mM NaCl, 
0.5mM KCl, 1mM MgSO4, 0.15mM KH2PO4, 0.05mM Na2HPO4, 1mM CaCl2, 0.7mM 
NaHCO3). At 6hpf embryos were treated with 100µM Z-DEVD-FMK (ApexBio Technology 
LLC, Houston, TX, USA) in E3 medium. Embryos were maintained in standard temperature 
conditions in a humid incubator and checked for survival at 24hpf. 
 
Western Immunoblot analyses 
Dechorioned and de-yolked embryos were lysed by placement in sample buffer (2% sodium 
dodecyl sulfate (SDS), 5% β-mercaptoethanol, 25% v/v glycerol, 0.0625 M Tris-HCl (pH 6.8), 
and bromophenol blue) followed immediately by heating to 95°C for 10 min, before storage at -
80°C prior to protein separation on 4-12% SDS polyacrylamide gels. Proteins were transferred to 
nitrocellulose membrane in buffer (25mM Tris, 192mM glycine, 0.1% sodium lauryl sulfate, 20% 
methanol in MilliQ H2O) at 10V for 1hr. When immunoblotting, all membranes were blocked with 
5% Western Blocking Reagent (Roche, Indianapolis, IN, USA) in TBST, incubated with primary 
antibodies in TBST containing 0.5% Western Blocking Reagent (Roche, Indianapolis, IN, USA), 
washed in TBST, and incubated in secondary antibody. Following secondary antibody incubations, 
all membranes were washed three times for 10 minutes in TBST and visualised with luminol 
reagents (Amresco, Ohio, USA or Thermo Scientific, Rockford, USA) by the ChemiDocTM MP 
imaging system (Bio-Rad, Hercules, CA, USA). The p75NTFC201-dGFPx2, Nrh1C191-dGFPx2 
and A2C-dGFPx2 protein bands were visualised at ~61kDa, 57kDa and 57kDa respectively (data 
not shown). Using Image Lab software (Bio-Rad), densitometry analyses were performed on the 
protein bands in each lane of the western immunoblot for each sample and free GFP internal 
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reference. An average value was obtained for the free GFP for each membrane. Each sample value 
was then normalised to the average free GFP value. 
 
GFP immunoblots were incubated in a 1/5,000 dilution of anti-GFP antibodies (Rockland 
Immunochemicals Inc., Gilbertsville, PA, USA) and a 1/10,000 dilution of donkey anti-Goat IgG 
(Rockland Immunochemicals Inc., Gilbertsville, PA, USA). 
mCherry immunoblots were incubated in a dilution of 1/2,000 of anti-mCherry antibody (Abcam, 
Cambridge, UK) and a 1/5,000 dilution of anti-Mouse IgG secondary antibodies (Rockland 
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2.6 Supplementary information 
This section is included in the thesis as information supplementary to Chapter 2. It contains 
additional information not included in the main text of the manuscript. 
 
File S1. Screenshots of results from tblastn searches using the NCBI database 
 The amino acid sequence of human p75NTR was used in a tblastn search of the zebrafish 
genome (constrained to RefSeq_RNA). 
 






Figure S2. Duplication of p75NTR gene on chromosome 3 of Danio rerio, as of GRCz11. The two returned 



















File S2. Supporting table for phylogenetic analyses 
Table S1. Names, NCBI gene names and NCBI accession numbers of all genes used in 
phylogenetic studies 
Organism and gene name NCBI name NCBI Accession nucleotide 
Zebrafish p75NTR ngfr-l NM_001198660.1 
Zebrafish p75NTR like 12 TNF 16-like XM_003199576.1 
Zebrafish p75NTR like 3 ngfr-a XM_003198085.3 
Zebrafish Nrh1 ngfr XM_695893.4 
Xenopus tropicalis NRH1 ngfr NM_001007998.2 
Xenopus p75NTR p75 NTR a NM_001088466.1 
Xenopus laevis NRH1 ngfr NM_001091773.1 
Mouse p75NTR Ngfr NM_033217.3 
Mouse NRH2 Nradd NM_026012.2 
Chicken p75NTR NGFR NM_001146133.1 
Chicken NRH1 TNFR 16-like XM_418509.3 
Human p75NTR TNFR superfamily 16 NM_002507.3 
Human NRH2 NRADDP NR_024046 
Lancelet p75NTR Branchiostoma floridae hypothetical protein XM_002588230.1 
Drosophila p75NTR like 
Drosophila melanogaster rumpelstiltskin 
(rump), transcript variant A NM_141642.3 








File S3. Transmembrane domain predictions for p75NTR and Nrh1 
 
Figure S3. Transmembrane domain predictions for Nrh1 and p75NTR using TMHMM. Plot of 
probabilities generated by TMHMM 2.0. A) p75NTR TMD prediction B) Nrh1 TMD prediction. “outside” 
refers to the prediction that the sequence sits on the cytosolic side of the membrane and “inside” refers to 
the prediction that the sequence sits on the non-cytosolic (lumenal) side of the membrane. 





File S4. Construct overviews and full sequences 
(A)  Sequence design for the pT2ALssFLAG-p75NTFC201-dGFP-v2a-mCherry construct 
Different regions of the sequence are indicated with colours corresponding to the legend below: 
 BamHI-Kozak-START-SS-FlagTag1-FlagTag2-FlagTag3-p75(CTF)-eGFP-BspEI-
MODCPEST-BspEI-v2a-Xba1-mCherry-Xba1-STOP-NotI-ClaI 
 Capitalised C in FlagTag2 = silent mutation, Capitalised T in FlagTag3 = silent mutation 












































(B)  Sequence design for the pT2ALssFLAG-Nrh1C191-dGFP-v2a-mCherry construct 
Different regions of the sequence are indicated with colours corresponding to the legend below: 
 BamHI-Kozak-START-SS-FlagTag1-FlagTag2-FlagTag3-Nrh1(CTF)-eGFP-BspEI-
MODCPEST-BspEI-v2a-Xba1-mCherry-Xba1-STOP-NotI-ClaI 
 Capitalised C in FlagTag2 = silent mutation, Capitalised T in FlagTag3 = silent mutation 












































(C)  Sequence design for the pT2ALssFLAG-A2C-dGFP-v2a-mCherry construct 
Different regions of the sequence are indicated with colours corresponding to the legend below: 
 BamHI-Kozak-START-SS-FlagTag1-FlagTag2-FlagTag3- NRH1 ECD- P75 TMD- 
NRH1 ICD-eGFP-BspEI-MODCPEST-BspEI-v2a-Xba1-mCherry-Xba1-STOP-NotI-
ClaI 
 Capitalised C in FlagTag2 = silent mutation, Capitalised T in FlagTag3 = silent mutation 


































































File S5. Supporting tables for western blot analyses 
 
Table S2. Intensity ratios from western immunoblots for Figure 2.3 
p75NTFC201-dGFP injected, without treatment and collected at 24hpf 
p75NTFC201-dGFP  free mCherry p75NTFC201-dGFP/free 
mCherry 
3355616 2776536 1.208562 
1361151 2087967 0.651903 
2030385 2921364 0.695013 
p75NTFC201-dGFP injected, with DAPT treatment and collected at 24hpf 
p75NTFC201-dGFP  free mCherry p75NTFC201-dGFP/free 
mCherry 
8523834 4229267 2.01544 
10723713 3184398 3.367579 
2570365 2241720 1.146604 
Nrh1C191-dGFP injected, without treatment and collected at 24hpf 
Nrh1C191-dGFP free mCherry Nrh1C191-dGFP/free 
mCherry 
4786670 2897640 1.65192 
5352372 3658428 1.463025 
2862144 4299228 0.665734 
2482850 4824342 0.51465 
Nrh1C191-dGFP injected, with DAPT treatment and collected at 24hpf 
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Nrh1C191-dGFP free mCherry Nrh1C191-dGFP/free 
mCherry 
3344274 2456604 1.36134 
4696055 5235246 0.897008 
3129192 3895992 0.803182 
1659636 4562604 0.363748 
 
 
Table S3. Intensity ratios from western immunoblots for Figure 2.4 
p75NTFC201-dGFPx2 injected, without treatment and collected at 24hpf 
p75NTFC201-dGFPx2  free GFP p75NTFC201-dGFPx2/free GFP 
4099260 21408354 0.191479457 
2265235 18651920 0.121447819 
2760660 13464144 0.205037914 
4012008 31961958 0.125524475 
3141090 24936450 0.1259638 
1371942 7807518 0.175720632 
1161584 6491984 0.178925888 
784560 5346448 0.146744156 
p75NTFC201-dGFPx2 injected, with DAPT treatment and collected at 24hpf 
p75NTFC201-dGFPx2  free GFP p75NTFC201-dGFPx2/free GFP 
9307074 19496964 0.477360167 
11522280 15773135 0.73050031 
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9746802 19327971 0.504284801 
2743486 27871788 0.098432365 
8096400 15898455 0.509257032 
3262120 5782000 0.564185403 
1073216 5489744 0.195494726 
3258768 5566128 0.585464078 
Nrh1C191-dGFPx2 injected, without treatment and collected at 24hpf 
Nrh1C191-dGFPx2 free GFP Nrh1C191-dGFPx2/free GFP 
1491240 259845 5.738959764 
3290364 445676 7.382861092 
3774136 1123326 3.359786918 
14486528 27954624 0.518215806 
9071304 16119450 0.562755181 
2069262 2441270 0.847617019 
7176832 3022704 2.374308566 
4717200 2825728 1.669375113 
Nrh1C191-dGFPx2 injected, with DAPT treatment and collected at 24hpf 
Nrh1C191-dGFPx2 free GFP Nrh1C191-dGFPx2/free GFP 
2157554 286594 7.528259489 
2754024 563472 4.887596899 
1687808 386528 4.366586638 
16519654 30580320 0.5402054 
15641976 20213136 0.773852014 
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6142512 3632768 1.690862725 
4824704 3712496 1.299584969 
6105872 2351728 2.59633427 
 
Table S4. Intensity ratios from western immunoblots for Figure 2.5 
A2C -dGFPx2 injected without treatment and collected at 24hpf 
A2C -dGFPx2 free GFP A2C -dGFPx2/free GFP 
5968380 4111428 1.451656213 
3976478 2930257 1.357040696 
3134032 1885752 1.661953428 
2948385 2764267 1.066606446 
5134025 5889052 0.871791419 
A2C -dGFPx2 injected with DAPT treatment and collected at 24hpf 
A2C -dGFPx2 free GFP A2C -dGFPx2/free GFP 
4955500 2678104 1.850376236 
2455871 1668183 1.472183208 
3267396 3427666 0.953242235 
3248465 2896872 1.121369878 







Chapter 3 – Development and testing of genome editing tools for 
generation of fAD and null mutations in zebrafish appa and appb 
3.1 Introduction 
Missense mutations in the amyloid precursor protein (APP) can lead to an inheritable form of 
Alzheimer’s disease known as familial Alzheimer’s disease (fAD). The proposed mechanism 
through which mutations in APP lead to Alzheimer’s disease involves its processing by the γ-
secretase complex. APP is cleaved sequentially in one of two pathways. In the pathway that leads 
to the formation of the amyloid beta peptide, APP is first cleaved by β-secretase, then γ-secretase. 
fAD mutations in APP are mostly clustered around β- and γ-secretase cleavage sites. There are 
currently 59 known APP mutations involved in fAD (https://www.alzforum.org/mutations/app).  
There are two co-orthologues of the human APP gene in zebrafish, appa and appb [1]. The 
zebrafish has been used previously to study the functions of appa and appb [2]. A search of the 
literature reveals only one paper describing an Alzheimer’s disease zebrafish transgenic model of 
APP. Pu et al’s (2017) approach was to knock in mutant human APP driven by the zebrafish appb 
promoter [3]. This model was used to observe behaviour under mutant APP conditions as well as 
associated histopathology [3]. Other work on the zebrafish app genes has focused on investigating 
its roles in traumatic brain injury and development [4]. 
Although many previous attempts to study AD in mice have focussed on creating transgenic 
models of fAD genes, Hargis and Blalock (2017) observed inconsistent modelling of established 
transcriptomics-based changes detected in human AD in many of these models [5]. Considering 
this, we propose that the best approach to model the disease, and perform meaningful 
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transcriptomics analysis on these models, is to recreate (to the best of our ability) known fAD 
mutations in the equivalent endogenous zebrafish gene, via genome editing. 
In recent years it has become possible to generate targeted mutations in the zebrafish genome. Two 
systems adapted for accomplishing this are: transcription activator-like effector nucleases 
(TALENs) and the clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-
associated (Cas) system. While both systems function by generating double-stranded breaks 
(DSB’s) in the DNA, there are differences in their targeting mechanics and composition. TALENs 
initiate DNA cleavage through the binding of a pair of customisable DNA binding domains, both 
of which are fused to a non-specific Fok1 endonuclease domain, thus allowing Fok1 to dimerise 
and generate DSBs [6]. When used in zebrafish, the type II CRISPR/Cas9 system initiates cleavage 
through a single transcript called “sgRNA”. This sgRNA is a combination of the single 20bp guide 
RNA (gRNA) and tracrRNA used in other systems and is responsible for recruiting the Cas9 
enzyme to the site of interest for DNA cleavage [7].  
DSBs generated by either the TALEN or CRISPR/Cas9 system result in the activation of one of 
two inherent cellular DNA repair mechanisms. Non-homologous end joining (NHEJ), which 
repairs DNA breaks by re-joining the cleaved ends, is known to randomly introduce insertions or 
deletions (indels) and is often exploited for gene editing [8]. Alternatively, homology directed 
repair (HDR) is a process where the cell repairs breaks in DNA using a template with homology 
to the original DNA sequence. This form of repair can be utilised to insert precise mutations using 
an oligonucleotide coding for the desired mutation [9, 10]. By utilising the cell’s HDR machinery, 
both TALENs and CRISPRs can be used to engineer endogenous zebrafish genes to incorporate 
specific single nucleotide mutations. The mutations to be engineered into the zebrafish genome in 
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this study are human fAD APP missense mutations, as well as null mutations in zebrafish appa 
and appb, discussed in more detail below. 
In this study, we designed and analysed sgRNAs targeting 3 fAD missense mutation sites from 
human APP in the equivalent positions of zebrafish appa and appb: the Austrian mutation (human 
APP T714I), found at the γ-secretase cleavage site, which presents with classic AD histopathology 
and increased Aβ-42:Aβ-40 ratio [11]; the Leuven mutation (human APP E682K), found at the 
(lesser known) β’-secretase cleavage site, reduces processing by this anti-amyloidogenic secretase 
and results in increased processing by β-secretase [12]; and the Arctic mutation (human APP 
E693G), occurring close to the α-secretase cleavage site, sees reduced levels of α-secretase 
processing thought to be due to altered APP localisation, with a subsequent shift to processing by 
β-secretase [13]. At the time of this study, we failed to design a sgRNA to target the most 
extensively studied fAD mutation at the γ-secretase cleavage position, the London mutation 
(human APP V717I) [14]. Fortunately, due to different design constraints, we were able to order 
a TALEN to target this residue’s codon. We also designed sgRNAs to target near the start codons 
of both zebrafish appa and appb with the intention of generating null mutations. We found that, 
of the 7 sgRNAs and 1 TALEN tested, only 3 were able to induce DSBs. Unfortunately, with our 
knowledge at the time this study was being undertaken, we were unable to introduce fAD missense 
mutations through HDR. However, we have identified two sgRNAs that can be used to introduce 
fAD mutations, and we discuss ways in which this could be achieved in future studies. Finally, we 
identified a sgRNA that was able to generate DSBs near the start site of appb. This sgRNA was 







Figure 3.1 Overview of the CRISPR/TALEN mutational strategy employed in the work described in this 
chapter. A) Protein alignment of the Aβ peptide region of human APP (isoform hs APP695), zebrafish Appa 
(dr Appa) and zebrafish Appb (dr Appb). Secretase cleavage positions are indicated above the alignment. 
Red text indicates amino acid residues that are not conserved where there is a consensus of two between 
any two sequences. B) Overview of fAD mutations discussed in Chapter 3. Yellow highlighting indicates 
conserved residues. i) Names of potential mutation sites to be targeted by genome editing technology, ii) 
overview of mutational strategy for zebrafish Appa (dr Appa) and iii) zebrafish Appb (dr Appb). Specific 
genome editing technology used in this study to target each mutation position is indicated in text. Successful 
or unsuccessful generation of a DSB at each of the targeted positions is indicated by a green tick or a red 
cross respectively. C) Sequence and representation of TALEN arms designed by ZGeneBio targeting the 
London mutation equivalent position in zebrafish Appb. D) Example of CRISPR design using sgRNA 
targeting near the appb start codon. Grey labelled boxes under the sequence indicate the first Exon, with 
the pale grey box indicating specifically the 5’UTR. The green box indicates the start codon. Yellow and 
red boxes indicate the sgRNA binding site and PAM site respectively. Blue ovals indicate positioning of the 
Cas9 protein and yellow strand indicates the sgRNA position during DSB induction. 
 
3.2 Results and Discussion 
Assessment and selection of APP fAD mutations to target 
The zebrafish has been used comprehensively as a model for human disease research [as reviewed 
in 15]. We aimed to generate several mutations in the zebrafish appa and appb genes, including 
null mutations and fAD-like mutations. We hoped to observe their effects on molecular/signalling 
events and to investigate whether fAD-like mutations in the zebrafish are appropriate models of 
the analogous mutations in humans. We intended to compare the effects of the appa and appb 
fAD-like mutations with the effects of fAD-like mutations in zebrafish psen1, psen2 and sorl1. 
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We also intended to compare the null mutants with the effects of fAD-like mutations in zebrafish 
psen1, psen2, appa, appb and sorl1. Closer inspection of the protein alignment between zebrafish 
Appa, Appb and human APP revealed residues that are conserved within the α-, β- and γ-secretase 
cleavage regions (Figure 3.1, A). A selection of residues that are mutated in fAD have been 
highlighted and relevant cleavage positions marked. 
When selecting human APP fAD mutations to be introduced, three criteria were considered. 
Firstly, the selected mutations should give an even coverage across the length of the Aβ peptide 
region of the APP protein. Secondly, the mutations should be at one of each of the α, β and γ-
secretase cleavage positions within the Aβ peptide region (Figure 3.1, A). Lastly, in order to make 
use of the zebrafish system, the human APP fAD mutant amino acid residues needed to be 
conserved in the equivalent zebrafish App protein sequence. Following these criteria, the Arctic, 
Leuven, Austrian and London human APP fAD mutations were selected for introduction into the 
zebrafish genome by genome editing technologies (Figure 3.1, B). 
The “Swedish” mutation is the most well characterised human APP fAD mutation. An initial 
alignment of the zebrafish Appa and Appb amino acid sequences against human APP revealed a 
lack of conservation of the residues affected by the “Swedish” mutation at the β-secretase sites of 
these proteins (Figure 3.1, B). Therefore, we decided to model the Leuven human APP fAD 
mutation at the alternative β’-secretase site, the equivalent residue of which only occurs in 
zebrafish Appa [12]. The APP fAD mutation at the γ-secretase cleavage position that has been 
most extensively studied is the “London” mutation, hence this is a good candidate [16]. The 
“Austrian” mutation occurs three residues upstream of the “London” mutation and has been quite 
intensively studied due to its effects on Aβ peptide production [11]. Of the reported fAD human 
APP mutations (Alzforum mutations database, https://www.alzforum.org/mutations/app) no 
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pathogenic mutations existed directly at the α-secretase cleavage site. The “Arctic” mutation was 
selected as the closest human APP fAD mutation to the α-secretase site that was also conserved in 
both zebrafish Appa and Appb (Figure 3.2). Later it was discovered that a mutation at the α-
secretase cleavage site (K16N) does exist and is potentially pathogenic [17], however, this 
mutation is only conserved in Appa, hence we proceeded with the “Arctic” mutation (Figure 3.1, 
B). 
Although this mutation is not directly positioned at the site of α-secretase cleavage it does affect 
this cleavage event [18]. It is thought to affect cleavage by reducing the abundance of APP at the 
cell surface, thereby reducing its availability for cleavage by α-secretase. Instead it is cleaved by 
the alternative β-secretase pathway [18]. The relative positions of each mutation of interest can be 
found in Table 3.1 A complete list of APP mutations can be found online at 
https://www.alzforum.org/mutations/app.  
 
Table 3.1 The fAD mutations of the human APP gene to be edited into the zebrafish genome 



















T682I T638I Single AA substitution at γ-sec cleavage 








Design of CRISPR sgRNAs for analysis 
Transcription activator-like effector nucleases (TALENs) are a popular tool used for editing 
genomes by the induction of DSBs. Recently, the CRISPR/Cas9 system has grown in popularity 
for its ability to easily generate mutations of interest in many organisms. One disadvantage with 
ratio in HEK293 cells, mouse primary 
neurons and Plasma [11, 19]. 
E693G 
Arctic 
E661G E617G Single AA substitution between α-sec and 
γ-sec cleavage sites, closer to the α-sec 
site. MOA = 59.7yrs. Decreased A42/40 




E650K N/A Single AA substitution at the B’-sec 
cleavage site. MOA = 61yrs.  
Increased A42/40 ratio in CHO cells and 




V685I V641I Single AA substitution at γ-sec cleavage 
site. MOA = 53.2yrs. Increased A42/40 
ratio in Chinese hampster ovary cells, 
HEK293 cells and mouse primary neurons 
[11, 19, 20]. 
TALEN 
Notes - TM = transmembrane domain, MOA = mean onset age of fAD. AA = amino acid. yrs = years. All 
work will be done with the Tuebingen (TU) strain of fish since this was the strain used to generate the 
zebrafish genome sequence. 
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this system is the additional constraints when designing and using CRISPRs. For Cas9 to 
successfully recognise a target sequence, a protospacer adjacent motif (PAM) sequence is required 
3’ of the sgRNA and upstream of the crRNA binding region [7]. The use of the T7 promoter to 
transcribe gRNAs means that the sequence “GG” is required at the 5’ end of the transcript, which 
reduces the range of targetable sequences [7]. Taken together these constraints would mean that 
any sequence of the form 5’ GG-N(18)-NGG 3’ is available for targeting by CRISPR/Cas9, 
occurring once in every 128bps of random DNA sequence [7]. However, a study by Hwang et al 
(2013) found that this targeting range could be expanded to once in every 8bps by relaxing the T7 
promoter rule [21]. There are currently extensive options for designing and preparing CRISPR 
sgRNAs for generating mutations. During our design phase, we found a method described by 
Hwang et al (2013) which boasted a greater than 10% somatic mutation rate in the zebrafish [7]. 
The online “ZiFit targeter” tool was used to identify potential CRISPR/Cas target sites for each of 
the selected mutations (http://zifit.partners.org/ZiFiT/ChoiceMenu.aspx) [22, 23]. This targeting 
software was originally developed by the Zinc Finger Consortium for Zinc Finger engineering and 
was later updated to identify sequences that fit the standard CRISPR/Cas9 constraints discussed 
above. When using the “CRISPR/Cas9 nuclease” link of the software, the length (in nucleotides) 
of target site of “20” and “T7 promoter” options were selected. A region of approximately 2,000 
nucleotides was run through the software to identify target sites close to the codon of interest 
(supplementary data file S1). 
ZiFit identified oligonucleotides to generate an Arctic-like mutation in Appb but could not identify 
oligos for generating an Austrian-like mutation in Appb or a Leuven-like mutation in Appa. The 
previously mentioned study by Hwang et al (2013) discussed and demonstrated a method to 
overcome the 5’ requirement of the software. Induction of site specific mutations was 
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accomplished by the addition of two guanines (“GG”) to the 5’ end of sgRNA sequences that are 
not complementary to genomic DNA target sequences [21]. This method was adopted when 
designing the Austrian-like Appb and Leuven-like Appa sgRNAs (supplementary data file S2, 
Table S1). 
When designing the initial CRISPR sgRNAs in 2014, there was a limited number of published 
studies using this technology in the zebrafish. As a result, we failed in our attempts to design an 
sgRNA to target the fAD “London” missense mutation in appb. To overcome this, the London 
mutation position was targeted using TALEN technology, which has different targeting 
constraints. Approximately 200 nucleotides up- and down-stream of the London appb TALEN 
target sequence was supplied to ZGeneBio, who designed and constructed appropriate TALEN 
arms (Figure 1, C) (http://www.zgenebio.com/). 
To corroborate the sgRNA target sites suggested by the “ZiFit” targeting software, sequences 
around the sgRNA sites were analysed using the online CRISPRscan software 
[http://www.crisprscan.org/ [24]]. CRISPRscan generates a score calculated using a mathematical 
model that predicts mutagenic activity based on the sgRNA target sequence [24]. Sequences 
containing approximately 50 nucleotides either side of the already designed sgRNAs 
(supplementary data file S2, Table S1) were submitted to the online software. Moreno-Mateos et 
al (2015) found that sgRNAs with a CRISPRscan score above 55 were able to efficiently cleave 
the DNA at the position of interest whereas sgRNAs that scored above 70 were highly efficient 
[24]. CRISPRscan returned sgRNA sequences that matched our previous designs and the scores 
of these are presented in supplementary data file S2, Table S1. Arctic appb sgRNA returned a 
score of 61, suggesting this should cleave efficiently. The appa and appb start site sgRNAs were 
also identified using CRISPRscan. The former returned a score of 70 suggesting it should be highly 
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efficient, while the latter returned a score of 66 suggesting it should also efficiently cleave the 
DNA. The Austrian appb sgRNA was not identified using CRISPRscan. This is perhaps 
unsurprising as this sgRNA required the addition of 5’GG in order to meet design requirements. 
Multiple attempts were made to identify the predicted Austrian sgRNA, including using 50 
nucleotides of genomic DNA sequence either side of the sgRNA sequence without 5’GG, sgRNA 
sequence with additional 5’GG and also using 50 nucleotides of cDNA (exons only) either side of 
the sgRNA sequence equivalent from the NCBI database (one nucleotide difference). None of the 
attempts successfully identified the Austrian sgRNA as an option. Similarly, CRISPRscan was 
unable to identify the Leuven appa sgRNA designed through ZiFit. However, the program did 
return an sgRNA that closely resembled ours, with a score of 34, suggesting cleavage by this 
similar sgRNA would be inefficient. 
The sgRNAs discussed above were designed to be constructed and transcribed via a method 
previously described in zebrafish (The “ADDGene method”) [7]. We also designed an additional 
appa start site sgRNA, Austrian appb sgRNA and an sgRNA to target the Austrian mutation 
position in appa, to be constructed via an adapted “PCR method”, rather than the method 
mentioned above [25] (supplementary data file S2, Table S2). When analysed with CRISPRscan, 
the appa start site sgRNA returned a score of 81 and the Austrian appa sgRNA returned a score 
of 66. Unlike the Austrian appb sgRNA designed for the first method [7], the Austrian appb 
designed at an alternative position returned a score of 79, suggesting it should be highly efficient 





Identifying successful NHEJ events induced by CRISPR/TALENs 
In order to generate mutations by non-homologous end joining (NHEJ) or to engineer mutations 
at a specific site by HDR, there must first be induction of a double-stranded break in the DNA at 
the position of interest. The cell has two major mechanisms for repairing DSBs, NHEJ and HDR. 
NHEJ re-connects DNA breaks, with nucleotides around the break point gained or lost as a part of 
this process. This often results in frameshifts that introduce a premature stop codon around the 
target site [8]. Therefore, NHEJ is often exploited in genome editing as a means of destroying gene 
function. In contrast, HDR allows for precise changes to be made using a template DNA sequence 
that is homologous to the sequence around the DSB [9]. 
 
Table 3.2 Successful or unsuccessful generation of mutations by CRISPRs or TALENs 
App 
isoform 




appb TALEN London/Austrian Addgene - 
appa CRISPR Leuven Addgene - 
appb CRISPR Arctic Addgene + 
appb CRISPR start site (Geneart) Addgene +  
appa CRISPR start site (Geneart) Addgene - 
appa CRISPR start site (PCR) PCR - 
appa CRISPR Austrian (PCR) PCR + 




Each of the sgRNAs (presented in supplementary data file S2, Tables S1 and S2) along with the 
TALEN pair were first tested for whether they could successfully introduce a mutation via NHEJ. 
Mutations induced by injected CRISPR and TALENs were detected using a T7 endonuclease-
based assay and gel electrophoresis. DNA strands of a region approximately 500-1000bp 
(spanning the sites of interest) containing either; 1) insertions or deletions (indels) from NHEJ 
following successful cleavage by CRISPR/Cas9 or TALENs, or, 2) uncleaved WT strands, were 
denatured and re-annealed at random. Non-perfectly matched (i.e. heteroduplex) DNA was 
cleaved by T7 endonuclease and visualised (Figure 3.2)  
Analyses using PCR and T7 endonuclease revealed that the TALEN pair designed to target the 
Austrian and London mutation positions in zebrafish appb was unable to generate a mutation. 
Similarly, sgRNAs designed to target the Leuven mutation equivalent site in appa, Austrian 
mutation equivalent site in appb and the start codon of appa were unable to introduce mutations. 
sgRNAs designed to target the Arctic mutation equivalent site in appb, the Austrian mutation 
equivalent site in appa and the start codon of appb were successful in generating mutations. This 
data is summarised in Table 3.2. 
Note: + indicates successful double-stranded break induction, - indicates that genome editing 
technology was unsuccessful in generating a double-stranded break. The “sgRNA construction 




Figure 3.2 Schematic depiction of the T7 endonuclease I mutation detection assay. (A) 500-1000bp of the 
genomic DNA surrounding the TALEN/CRSIPR target site is amplified via PCR. (B) The PCR amplified 
fragments are denatured and allowed to reanneal slowly, resulting in both homoduplex and heteroduplex 
formation. (C) T7 endonuclease 1 enzyme is applied, cleaving heteroduplexes and leaving homoduplexes 
uncleaved. (D) The T7 treated mix is separated on agarose gel. In this example, two sgRNAs have been 
tested for their ability to generate double-stranded breaks. An identical banding pattern is observed for 
both untreated and T7 endonuclease treated fragments for the example sgRNA 1, suggesting no cleavage 
(all homoduplexes). The * next to the T7 + lane of sgRNA2 represent alternative bands resulting from 
heteroduplex cleavage (suggesting a possible mutation). From top of ladder lane (in descending order), 




Sequencing the APPa 5’UTR region 
In order to test the efficacy of the sgRNA targeting just downstream of the start codon of appa, 
primers that could detect DSBs at this site needed to be designed. However, the 5’UTR region 
identified from database entries (ENSEMBL, NCBI and USCS), was incomplete. When searching 
through the available sequence for appropriate primer sites, highly repetitive regions and blocks 
of undetermined sequence were observed. Therefore, we needed to characterise the genomic 
sequence upstream of the start codon in order to be able to design primers that would bind in this 
region.  
Using the available sequence, primers were first designed to amplify ~1000bp upstream of the start 
codon (supplementary data file S2, Table S3). PCR amplification of the region upstream of the 
start codon was performed on multiple Tübingen-strain fish from different families in order to 
identify common polymorphisms. The PCR-amplified strands were sent for Sanger sequencing 
(Australian Genome Research Facility, SA, AUS). The multiple sequences were combined to 
generate a consensus sequence. The sequence of genomic DNA upstream of the start codon (also 
including Exon 1 and part of Intron 1) can be found in supplementary data file S3. 
 
Attempting to engineer precise fAD mutations into appa and appb 
To engineer a specific mutation using genome editing technologies the appropriate system can be 
co-injected with an oligonucleotide template encoding the desired mutation [21]. The sequence of 
this single-stranded oligonucleotide (ssON) template can then be repaired into the genome via 
HDR. In human APP, the Austrian fAD mutation results from a single substitution of ACA to 
ATA [11]. As can be observed on the Aβ peptide region alignment (Figure 3.1, B, Austrian 
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residue), the Threonine (T) residue at position 714 in human APP695 is conserved in zebrafish 
Appa, while its nucleotide sequence at the equivalent codon is ACC. We designed a custom ssON, 
where the zebrafish appa nucleotide sequence was substituted from ACC to ATA, to emulate the 
substitution that occurs in the human APP Austrian fAD mutant nucleotide sequence 
(supplementary data file S2, Table S4). In order to increase the likelihood of detecting successful 
incorporation of the Austrian-like Appa mutation, silent substitutions were made in some codons 
so that mutation specific primers would be less likely to bind to wildtype sequence (supplementary 
data file S2, Table S4). The Arctic fAD mutation results from substitution of GAA to GGA in 
human APP [26]. The glutamic acid (E) residue at position 693 in human APP695 is conserved in 
zebrafish Appb (Figure 3.1, B). However, the nucleotide sequence corresponding to the Arctic 
residue in zebrafish appb (GAG) is not conserved with human APP (GAA). Therefore, we 
designed a custom ssON where the zebrafish appb nucleotide sequence was substituted from GAG 
to GGA, to emulate the substitution that occurs in the human APP Arctic fAD mutant nucleotide 
sequence (supplementary data file S2, Table S4). 
Oligonucleotides coding the Austrian-like appa and Arctic-like appb fAD missense mutations 
were co-injected with the corresponding sgRNA that had been shown to successfully induce 
mutations via NHEJ. PCR was performed on groups of 10 embryos at 24hpf, using primers that 
had been designed to bind specifically DNA sequences containing the incorporated 
oligonucleotides (supplementary data file S2, Table S5). Neither the Austrian-like appa nor Arctic-




3.3 Conclusion and Future Directions 
In this study, we designed and tested CRISPR/Cas9 sgRNAs and a TALEN for their ability to 
successfully generate mutations in the zebrafish app genes. The single TALEN designed to target 
the Austrian/London mutation positions in appb was unsuccessful. However, 1 of the 4 sgRNAs 
designed to target sites within appa (Austrian) and 2 of the 3 sgRNAs designed to target sites 
within appb (start codon and Arctic) were able to successfully generate DSBs. Single-stranded 
oligonucleotides coding for the Arctic-like and Austrian-like fAD missense mutations were co-
injected with the successful sgRNAs. However, we could not detect incorporation of the 
oligonucleotides into the appa or appb genes by PCR. Therefore, we were unable to introduce the 
Artic-like and Austrian-like fAD missense mutations into the zebrafish genome. 
During our sgRNA design stage, Hwang et al (2013) tested the efficiency of sgRNAs in zebrafish 
and reported successful generation of mutations in 8 of 10 sgRNAs (targeting 10 different 
endogenous genes) tested, with those 8 successful sgRNAs having high mutational frequencies 
[7]. However, our rate of successful double-stranded break induction in the appa and appb genes 
in zebrafish was much lower than that. Only 3 of the 7 CRISPR sgRNAs tested in this study were 
able to generate mutations sufficiently to be detected by our methods. Recent studies suggest that 
local chromatin structure may have an effect on the efficiency of genome editing by CRISPR/Cas, 
as there may be limited access to certain sites in the genome that are more tightly packaged when 
editing is attempted [6, 27, 28]. It is also possible that this limited activity may result from the 
differences between eukaryotic chromatin structures and DNA packaging in the prokaryotes, from 
which the CRSIPR system was originally adapted, as Cas9 was derived from a prokaryotic enzyme 
[28]. In a study investigating the effects of chromatin on efficient Cas9 mutagenesis, Uusi-Mäkelä 
et al (2018) observed that, while a lack of chromatin openness reduced the efficiency of DSB 
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induction, lower gene expression levels were also associated with the inability of CRISPR/Cas9 
to effect mutagenesis [28]. Interestingly, their findings also suggested that genes that become 
active at the maternal to zygotic transition (MZT) are more accessible for Cas9 and therefore 
undergo more efficient mutagenesis. In the zebrafish embryo, MZT spans the period of just after 
fertilisation to the shield stage of gastrulation (i.e 6hpf) [29]. When looking at the expression levels 
of both appa and appb during early developmental stages using the EMBL-EBI “Expression atlas” 
(https://www.ebi.ac.uk/gxa/home, [30]) we observed that both genes had low expression during 
the recorded stages of early development aligning with MZT (blastula 128-cell to gastrula shield) 
(supplementary data file S4, Figure S1). This low expression during MZT may explain our limited 
success in targeting these genes with CRISPR sgRNAs. 
Although two of the CRISPR sgRNAs targeting fAD missense mutation equivalent sites in 
zebrafish appa and appb in our study appeared to generate mutations (and, hence, could generate 
DSBs), sequences from the corresponding oligonucleotide template donor DNAs carrying the 
mutations of interest were unable to be incorporated. This could be due to several factors. One 
such factor is the nature of the HDR process, which has been observed to be inefficient in the 
zebrafish, averaging only 3-4% success when attempting to incorporate specific mutations by 
providing an ssON template [31]. Instead, cells generally prefer to repair breaks in their DNA by 
NHEJ, perhaps dues to the increased activity of NHEJ over HDR in the developing zebrafish 
embryo [32]. Options for overcoming these factors include inhibiting NHEJ and stimulating HDR, 
both of which are discussed in more detail below. Another factor is the optimal length of the HDR 





Enhancing DSB formation 
While CRISPR/Cas9 mediated genome editing has many benefits over alternative methods, there 
are also challenges. Site-specific genome editing can be restricted in some cases due to the absence 
of an NGG (PAM) at the precise position being targeted. When attempting to precisely engineer a 
mutation via HDR, the most efficient position at which to generate the DSB is within 10-20bp of 
the desired change. One group has recently attempted to overcome these challenges by engineering 
Cas9 PAMs with novel specificities [34]. A previous attempt to change the PAM recognition site 
had varying results. Anders et al (2014) mutated the two residues that contact the guanine 
nucleotides of the NGG to R1333Q/R1335Q respectively. However, this mutant Cas9 was unable 
to cleave a site at the newly expected NAA PAM in vitro [35]. It was later confirmed by Kleinstiver 
et al (2015) that this variant is unable to cleave NAA target sites efficiently [34]. They also tested 
both variants separately. However, the expected NAG and NGA PAM’s were also ineffective [34]. 
They investigated the efficiency of two smaller Cas9 orthologues from different bacteria, termed 
St1Cas9 and SaCas9, which have alternative PAM specificities1 with some success [34]. Feng et 
al (2016) have now shown that both SaCas9 and its variant, KKH SaCas9 (that recognises a relaxed 
NNNRRT PAM) can be utilised in zebrafish with a mutational frequency of up to 90% [36]. Such 
studies highlight the potential for finding alternatives for targeting challenging sites in zebrafish 
in the future. 
Another recent development in the field of genome editing is the Cpf1-containing class 2 CRISPR 
system (recently renamed Cas12a [37]), which has been identified as a potential alternative to the 
commonly used type II CRISPR/Cas9 systems [38]. Some of the advantages of this new system 
 
1 Alternate PAM specificities are NNAGAA, NNGGAA, NNAGGA, NNAGCA, NNACCA, NNATAA, NNAAAA, 
NNGGGA (i.e. NNRRRA) for St1Cas9 and NNGGGT, NNGAAT, NNGAGT (i.e. NNGRRT) for SaCas9 
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are as follows: 1) being a single crRNA-guided endonuclease, Cas12a does not require tracrRNA 
to processes crRNA, potentially simplifying design and delivery of this system. 2) DSBs generated 
by Cas12a result in a staggered 5’ overhang. This is advantageous compared to the blunt ends 
generated by Cas9 as it enables the design of DNA templates that can be inserted directionally by 
NHEJ rather than via HDR mechanisms. 3) The PAM site for Cas12a is T rich (5’-TTN) as 
opposed to the G rich Cas9 PAM (5’-GGN). This opens possibilities for targeting regions of the 
genome that are richer in A/T. These are only a few of the many potential advantages of this system 
[38]. Two Cas12a protein variants have been successfully used in mammals previously for genome 
editing, AsCas12a and LbCas12a [39]. One of the benefits of these variants observed thus far has 
been the extension of target recognition to T-rich sequences such as non-coding RNAs, 5’UTR 
and 3’UTR etc (PAM 5’ TTTV), among other things [40]. Despite the benefits of CRISPR-Cas12a, 
previous studies reported reduced activity in Drosophila and plants [41-44]. Moreno-Mateos et al 
(2017) performed a study in which they characterised and optimised CRISPR-Cas12a for zebrafish 
and Xenopus tropicalis [39]. Their study found that the amount of Cas12a activity both in vitro 
and in vivo was temperature sensitive, which could help to explain the previously reported 
reduction of activity in some organisms [41, 44]. Interestingly, they found that incubating injected 
embryos at 34°C for up to 48hpf increases the mutagenic activity of Cas12a [39]. More 
importantly, their study also found that co-injection of CRISPR-LbCas12a along with single 
stranded donor DNA significantly increased the efficiency of homology directed repair (HDR) in 
zebrafish [39]. A recent study by Liu et al (2019) further investigated the use of Cas12a in the 
zebrafish by modifying crRNA in the direct repeat region and stem loop [45]. In the case of 
standard pre-crRNA processing, mature crRNAs are produced with a shorter Direct Repeat (DR) 
sequence. Liu et al (2019) explored the effects of modifying crRNA to have the pre-processing 
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full-length Direct Repeat (DRf-crRNA) and observed higher editing efficiency compared to 
mature crRNA produced by the native system. Interestingly, when they further modified DRf-
crRNA by substituting two of the A:U pairs to G:C within the stem loop region of the DR (DRf-
GC@13-crRNA) they found an even higher editing efficiency than DRf-crRNA [45]. Their study 
also investigated the use of another Cas12a variant, FnoCas12a, which has most recently been 
adapted for use in mammalian cells. FnoCas12a recognises a TTN PAM, which differs from the 
TTTV PAM of the previously discussed LbCas12a and AsCas12a. Their successful use of 
FnoCas12a in the zebrafish adds yet another option for gene editing, offering greater targeting 
flexibility and making it an attractive option for future studies. Cas12a opens new possibilities for 
targeting the zebrafish appa and appb sites that were unsuccessfully targeted in this study. 
 
Enhancing HDR 
While successful incorporation of the single stranded oligonucleotide template DNA carrying the 
mutation of interest was not achieved by co-injection in this study, it is now possible to suppress 
the NHEJ pathway by treating zebrafish embryos with the NHEJ inhibitor SCR7 [19]. Zhang et al 
(2018) saw a significant improvement in HDR mutation incorporation efficiency in zebrafish when 
treating with SCR7 [19]. Very recently, Askoy et al (2019) investigated a different NHEJ inhibitor, 
NU7441. They found that NU7441 improved their CRISPR-mediated genome editing rate by up 
to 13.4-fold [46]. Interestingly (and conversely to the study by Zhang et al), they saw minimal or 
no increase in HDR efficiency with SCR7. They suggested several possible explanations for this 




The HDR pathway can also be stimulated by treatment with RS-1 [46]. Zhang et al (2018) also 
tested RS-1 in the zebrafish and, as with SCR7, found significant improvement in HDR efficiency 
[19]. Most importantly, their study found that a combination of these treatments greatly increases 
the efficiency of HDR, in the case of their target mutation, to around 74% [19]. Applying this 
combination of treatments to the sgRNAs tested in this study may enable successful generation of 
zebrafish carrying the human APP fAD Arctic mutation equivalent in appb and/or the human APP 
fAD Austrian mutation equivalent in appa. 
Finally, other research attempting to improve HDR efficiency used an sgRNA targeting exon 6 of 
the zebrafish albino gene to attempt to revert the mutation. They then tested donor DNA templates 
of various lengths for HDR, finding that only the larger DNA fragments (between 986 bp and 3.8 
kb) gave efficient sequence incorporation [20]. In order to overcome the toxicity sometimes 
observed when co-injecting large linear DNA fragments, they designed circular plasmid donor 
DNAs. These circular donors comprised the linear template DNA fragment flanked by two 
CRISPR target sites that allow the plasmid to be linearised within cells [20]. By employing this 
strategy, they achieved 46% efficiency in detection of reversion in mosaic fish, although only 10% 
of 3-day-old larvae reached adulthood. In this study the linear donor DNA templates tested were 
only 50 bp in length. At the time of design of our study there was no consensus on the most 
appropriate template length for HDR repair. The large circular donor DNA method could easily 
be adapted to carry the Arctic-like appb and Austrian-like appa mutations for delivery into the 






Generating APP fAD mutations in endogenous zebrafish appa and appb is an important step 
towards allowing us to make more meaningful transcriptomic analyses of fAD mutations in the 
APP gene. This study has identified and tested sgRNAs targeting a variety of APP fAD mutation 
loci for their ability generate DSBs. Of the 7 sgRNAs tested, 4 were unable to cleave the DNA at 
their target loci. Similarly, the single TALEN tested in this study failed to generate a DSB at the 
Austrian/London position in zebrafish appb. 3 sgRNAs with the ability to generate DSBs were 
also identified. However, introduction of the desired mutation through HDR was not achieved for 
the 2 sgRNAs targeting fAD APP mutation sites, namely the fAD Arctic (appb) and Austrian 
(appa) mutations. The combined use of SCR7 (or NU7441) and RS-1 treatments, after co-injection 
of sgRNAs and oligonucleotide templates, may allow us to successfully inhibit NHEJ, stimulate 
the HDR machinery and inevitably introduce these fAD APP mutations. The third successful 
sgRNA, targeting the appb start site, was used to generate an appb null mutation which will be 
discussed in detail in the following chapter (Chapter 4).  
Future attempts to generate DSBs at the Austrian/London sites in appb as well as the Leuven site 
in appa should make use of the recently improved understanding of site accessibility and should 
be attempted with new technology, such as Cas12a. The collection of APP fAD mutation models 







This work was conducted under the auspices of the Animal Ethics Committee of the University of 
Adelaide and in accordance with EC Directive 86/609/EEC for animal experiments and the 
Uniform Requirements for manuscripts submitted to Biomedical journals. 
 
Generation of TALEN coding sequences 
TALEN coding sequences were designed by, and purchased from, Zgenebio 
(http://www.zgenebio.com/). The DNA binding sites for the TALEN pair targeting the London 
mutation equivalent site within exon 16 of zebrafish appb were (5’ to 3’): left, 
GGGGGGCGTGGTCATCG and right, GAGCATAACCAGAGTGA (Figure 3.3). 
 
Generation of sgRNA coding sequences 
Oligonucleotide templates for each sgRNA to be constructed (supplementary data file S2, Table 
S1) were provided by SIGMA Aldrich Australia (Castle Hill, NSW). Due to the rapid development 
of CRISPR technology, two different methods were used to construct sgRNAs. In the first method 
(“ADDGene”), oligonucleotides encoding sgRNAs from initial designs (supplementary data file 
S2, Table S1) were cloned into the pDR274 plasmid (https://www.addgene.org/42250/) as 
previously described in [7]. In the second “PCR” based method (adapted from a method developed 
for Drosophila), forward primers for the template synthesis PCR consisted of target sites for 
sgRNAs (that were selected based on their CRISPRscan score) flanked by a T7 polymerase 
binding site and a region complementary to a common reverse primer [25]. These primers, 
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presented in supplementary data file S2, Table S2, were annealed to the common reverse primer 
with sequence: 5’-
AAAAGCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAA
CTTGCTATTTCTAGCTCTAAAAC-3’, and amplified via PCR using Phusion HF DNA 
polymerase (New England BioLabs, Ipswich, MA, USA) with the following cycling conditions; 
98°C for 30 seconds, 34 rounds of 98°C for 10 sec, 60°C for 30 sec, 72°C for 15 sec, then 72°C 
for 10 mins. The resulting template was purified using the Wizard® SV Gel and PCR Clean-Up 
System (Promega, Madison, Wisconsin, USA, A9281). 
 
In-vitro mRNA synthesis 
The coding sequences of the TALENs were provided in the pZGB4 vector for in-vitro mRNA 
synthesis. TALEN-containing plasmids were linearised with Not I and purified using the Wizard® 
SV Gel and PCR Clean-Up System (Promega, Madison, Wisconsin, USA, A9281). Purified 
linearised DNA was used as a template for in-vitro mRNA synthesis using the mMESSAGE 
mMACHINE T7 transcription kit (Thermo Fisher, Waltham, USA) as per the manufacturer’s 
instructions. 
The sgRNA-containing pDR274 plasmid was linearised with HindIII and purified using the 
Wizard® SV Gel and PCR Clean-Up System (Promega, Madison, Wisconsin, USA, A9281). 
Purified linearised DNA or purified PCR reaction product was used as a template for in-vitro 
mRNA synthesis using the HiScribe™ T7 High Yield RNA Synthesis Kit (New England BioLabs, 
Ipswich, MA, USA) as per the manufacturer’s instructions. The mRNA was precipitated using 
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ammonium acetate as described in the “MAXIscript” kit procedure (Thermo Fisher, Waltham, 
USA). 
 
Microinjection of zebrafish embryos 
sgRNA and Cas9 mRNA or Cas9 nuclease (protein) were co-injected into one-cell stage zebrafish 
embryos. Cas9 mRNA was synthesised using the mMESSAGE mMACHINE T7 transcription kit 
(Thermo Fisher, Waltham, USA) as per manufactures instructions. Cas9 protein was purchased 
from ToolGen (ToolGen, Geumcheon-gu, Seoul, South Korea). 
In the first attempt to generate the Arctic, Leuven and Austrian mutations, each embryo was 
microinjected with a ~3 nl solution containing 12.5ng/µl of sgRNA and 300ng/µl of Cas9 mRNA 
or 12.5ng/µl of sgRNA and 500ng/µl of Cas9 nuclease (protein). If a single-stranded 
oligonucleotide was also co-injected with sgRNA and Cas9 (Arctic), it was at a final concentration 
of 50ng/µl. In the second attempt, embryos co-injected with approximately 3 nl of a solution 
containing 200ng/µl of sgRNA and 1.5µg/µl of Cas9 nuclease (protein) (Invitrogen, Carlsbad, 
California, USA). For TALEN injections, embryos were microinjected with an approximately 3 nl 
mixture of 100ng/µl of left and right TALEN mRNA. Embryos were inspected using a light 
microscope at 24 hpf and only embryos that had developed normally were selected for analysis of 






Genomic DNA extraction from zebrafish embryos and tail clips 
A random selection of 10-25 injected embryos was collected at 24 hpf. Once grown into adults (~3 
months old), a small section of the dorsal fin (~3 mm) was removed with a sterile scalpel blade 
under anaesthesia (Tricaine solution, 1.68 μg/mL). 
Embryos or tail fin tissue were placed in 50µl of a 17mg/ml solution of Proteinase K (Roche, 
Basel, Switzerland) with 1XTE and then incubated at 55-65°C until digestion was complete (2-4 
hours). The solution was then placed at 95°C for 5 mins to inactivate the Proteinase K. This was 
then centrifuged at maximum speed for 2 mins to sediment cellular debris. The supernatant was 
transferred into a clean microfuge tube ready for subsequent PCR [47]. 
 
Mutation detection assays 
Mutation due to NHEJ of double-stranded DNA breaks was detected by either the GeneArt 
Genomic Cleavage Detection Kit or the T7 endonuclease I method adapted from Reyon et al 
(2012) [48]. Targeted genomic loci were amplified from the pooled genomic DNA of ten injected 
embryos using primers designed to anneal ~500 base pairs upstream and downstream from the 
expected cut site using the GeneArt Kit (Thermo Fisher, Waltham, USA) as per manufacturer’s 
instructions. In the T7 endonuclease I method, loci were amplified with GoTaq polymerase (New 
England Biolabs, Ipswich, Massachusetts, USA) and the resulting DNA was re-annealed under the 
following conditions; 95°C for 5 mins then ramped down from 95°C-85°C at a rate of -2°C/sec, 
followed by ramping down from 85°C-25°C at a rate of -0.1°C/sec. After reannealing, 1µl of T7 
endonuclease I (New England Biolabs, Ipswich, Massachusetts, USA) was added to the PCR 
133 
 
products and the entire mixture was incubated at 37°C for 15 mins. The mixture was then analysed 
by electrophoresis on a 2% agarose gel that was run at 90V for 1hr. 
 
Sanger sequencing 
The genomic region surrounding the Arctic mutation sgRNA target site was PCR amplified using 
“Arctic and Austrian appb F” and “Arctic and Austrian appb R” primers (supplementary data file 
S2, Table S5). The purified appb Arctic genomic DNA fragments were then used for Sanger 
sequencing with the “Arctic appa” sequencing primer (supplementary data file S2, Table S5) 
(Australian Genome Research Facility, SA, AUS).  The genomic region surrounding the appa 
5’UTR/Exon 1 region was PCR amplified using appa 5’UTR amplification forward and reverse 
primers (supplementary data file S2, Table S3). The appa 5’UTR PCR fragments were cloned into 
pGEM-T Easy (Promega, Madison, Wisconsin, USA) and sequenced with M13 forward and 
reverse primers (Australian Genome Research Facility, SA, AUS). 
 
Multiple sequence alignment to identify an appa consensus sequence upstream of the start codon 
The appa nucleotide sequences generated by Sanger sequencing were aligned to each other along 
with the appa genomic DNA sequence from the zebrafish SANGER database (SSS10789, 
https://www.sanger.ac.uk/) using the online tool “MUSCLE” 
(https://www.ebi.ac.uk/Tools/msa/muscle/). Differences between the Tübingen fish sequenced for 
this study and the available database sequence were identified by eye and a consensus sequence 
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2.3 Supplementary Information 
This section is included in the thesis as information supplementary to Chapter 3. It contains 
additional information not included in the main text of the manuscript. 
 
File S1. Sequences run through Zifit targeter software to identify sgRNA sequences 
(A)  The ~2000bp of the zebrafish appb sequence that was used to identify sgRNA sequences 
to target the fAD “Arctic” mutation is included below: 











































(B)  The ~2000bp of the zebrafish appb sequence that was used to identify sgRNA sequences 
to target the fAD “Austrian” mutation is included below: 












































(C) The ~2000bp of the zebrafish appa sequence that was used to identify sgRNA sequences 
to target the fAD “Leuven” mutation is included below: 












































(D)  The ~1300bp of the zebrafish appa sequence that was used to identify sgRNA sequences 
to target the start codon is included below: 





























(E)  The ~450bp of the zebrafish appb sequence that was used to identify sgRNA sequences 
to target the start codon is included below: 


















File S2. Supporting tables. 
Table S1. sgRNAs designed for the ADDGene method using Zfit targeter, with respective 
CRISPRscan scores. 
 N/A indicates that an sgRNA was not identified via CRISPRscan software.  























































Table S2. sgRNA primers designed for the PCR method using CRISPRscan software. 
 Red text highlights guanine nucleotides artificially inserted to fit CRISPR/Cas9 
requirements.  
 Blue text indicates the identified sgRNA target sites 
 
 
Table S3. Primers used for appa 5’UTR amplification and sequencing 
 F = forward, R = reverse 
Primer name Use Direction Primer Sequence (5’-3’) 
appa 5’UTR Amplification F ATAACGAACACATCCCTGACTGA 
appa 5’UTR Amplification R CCCACTGACACCAGCATAGC 
M13 F Sequencing F GTAAAACGACGGCCAGT 



















Table S4. Single-stranded donor DNA oligonucleotide templates for homology-directed 
repair 
 The codon incorporating the mutation is underlined. 
 Bold lettering indicates nucleotides that were substituted from the original genomic DNA 
sequence to give the desired mutation upon incorporation via HDR.  
 Bold red text indicates silent substitutions that were made to aid specific binding of the 
primer. 







Table S5. Primers used to identify double-stranded breaks induced by TALEN/CRISPR and 
to detect successful incorporation of ssONs carrying the mutation of interest. 
 F = forward, R = reverse 
Primer name Use Direction Primer sequence (5’-3’) 
Arctic and Austrian 
appb F 
T7 assays F GAACCTGTAGATGCCCGTCCAA 
Arctic and Austrian 
appb R 
T7 assays R CGCTGCTCAGTAGGTATTCACTTGC 
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Arctic appa Sequencing F CCGTCCAATTCCCGAAAG 
London appb F T7 assays F CCTGTAGATGCCCGTCCAA 
London appb R T7 assays R GCTGCTCAGTAGGTATTCACTTGC 
Leuven appa F T7 assays F CAGTGTCTGGACTGAAGCCTG 
Leuven appa R T7 assays R TTTCCCTCACACAACCACAG 
appa start codon F T7 assays F GGCTCTGATTCTCACCGCA 
appa start codon R T7 assays R CTTCACCGAATAATCCACACCAG 
appb start codon F T7 assays F CTCCAACCTCCGAGTCCATTCT 
appb start codon R T7 assays R TGCGTTTTCCCTTCACTCCC 
Arctic appb F ssON detection F AATCAGATGTTCCTCGCGGGAG 
Arctic appb R ssON and WT 
detection 
R CGCTGCTCAGTAGGTATTCACTTGC 
Arctic appb WT F WT detection 
(ssON expt) 
F AATCAGATGTTCCTCGCGGAGG 
Austrian appa F ssON detection F GATAATCATCGTCATCACCTTGG 
Austrian appa R ssON detection R CATTTCTGACCGTGATCTGGC 
Austrian appa WT F WT detection 
(ssON expt) 
F GCAACCATCATCGTCATCAC 








File S3. Sequence containing the region of genomic DNA just upstream of the start codon of 
appa generated by Sanger sequencing 
 Blue text indicates exon 1 sequence.  






























File S4. Expression levels of appa and appb during early development 
  
Figure S1. Screen shots from the EMBL-EBI “Expression atlas” showing expression levels of appa and 







Chapter 4 – Preliminary analysis of a putative null mutation in zebrafish 
appb 
4.1 Introduction 
γ-secretase is an important protease complex due to its cleavage of over 100 substrates within their 
transmembrane domains [1, 2]. γ-secretase plays a role in Alzheimer’s disease (AD) through its 
processing of APP to produce the aggregation-prone Aβ peptide [3]. Sequential processing of APP 
that produces the Aβ peptide is thought to be a major mechanism affected in AD disease 
progression, as described by the amyloid cascade hypothesis [4]. In this hypothesis, when APP is 
processed by β-secretase (BACE1) followed by γ-secretase, the Aβ peptide is released. This is in 
contrast to the processing of APP by α-secretase followed by γ-secretase, which releases the non-
amyloidogenic P3 peptide [5]. However, as mentioned previously, although Aβ accumulation into 
plaques is evident in the disease, there is no quantitative relationship between this and other factors 
of the disease [6]. There are many alternative hypotheses that attempt to explain this disparate 
relationship between Aβ plaques and other factors. One such hypothesis is the Hypoxia/Ischemia 
hypothesis. 
 
Local hypoxia refers to a state in which part of the body lacks adequate oxygen supply to tissue. 
Ischemia is one of the more common causes of hypoxia and refers to times where there is 
insufficient blood flow to a tissue. Interestingly, ischemia has been observed in the brains of 
individuals experiencing Mild Cognitive Impairment (MCI), which is a condition considered a 
precursor to dementia [7]. APP, β-secretase (BACE1) and γ-secretase expression have all 
previously been found to be increased during hypoxia while α-secretase expression is decreased 
[7, 8]. It is presumably this shift that results in an observed increase in Aβ production under 
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hypoxic stress. Some studies have also suggested that oxidative stress, induced by acute hypoxia, 
may increase APP cleavage by γ-secretase [8]. Furthermore, stimulation of oxidative stress due to 
accumulation of Aβ peptides has also been found to occur, which would create a positive feedback 
loop potentially accelerating brain aging [8]. Hypoxia-inducible factor 1 (HIF-1) is considered the 
master transcriptional regulator of the cell’s responses to hypoxia. HIF-1 is a transcription factor 
consisting of both an oxygen-regulated α subunit and a constitutively expressed β subunit. The 
oxygen-regulated HIF1-α subunit is degraded under normal oxygen conditions (normoxia), 
whereas, under hypoxia this subunit is stabilised and translocated to the nucleus. Once in the 
nucleus, HIF1-α and HIF1-β dimerise and can induce expression of hypoxia-regulated genes 
[reviewed in 9]. During hypoxia, HIF-1 induces transcription of over 70 HIF-1 responsive genes 
(HRGs) including IGFBP3 and EDN1 [10]. These HRGs can be used to measure the hypoxic 
response in genetically modified organisms. 
 
Zebrafish are widely used to study genetic influences on diseases as their genome is approximately 
70% conserved with humans [11]. A study by Moussavi Nik et al (2012) found that transcription 
of zebrafish genes encoding Bace1 and Appa and Appb, along with Psen1 and Psen2 (the active 
components of γ-secretase), are also induced by hypoxia [12]. This finding suggests that regulation 
of these genes by hypoxia is conserved in the zebrafish, making it a good model for studying the 
mechanisms by which hypoxia/ischemia might lead to AD. Recently, observations by Newman et 
al (2019) revealed an interesting response to hypoxia in the brains of zebrafish carrying fAD-like 
mutations in the psen1 gene [13]. When measuring HRGs, they saw an acceleration of normal age-
dependent changes in the brains of their mutant zebrafish. This supports the idea that age is one of 
the major risk factors for AD. Further investigation of the hypoxic response of fAD-like mutations 
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in other fAD mutant genes (psen2, appa, appb and sorl1), may provide further support to the notion 
that, not only is age a risk factor for AD, but AD is actually an inevitable consequence of aging. 
In Chapter 3, it was established that sgRNAs designed to target the Arctic mutation in appb, the 
Austrian mutation in appa and the start site of appb were successful in generating double-stranded 
breaks (DSBs). The purpose of targeting the start site of appb was to generate a null mutation. One 
original aim for this project was to generate zebrafish null models both for appa and appb, so that 
the effects of complete loss of these proteins could be compared to the effects of fAD-like 
mutations in zebrafish psen1, psen2, appa, appb and sorl1 using transcriptomic analyses. A long-
term goal of the laboratory is to perform these analyses in the hopes of identifying common 
molecular changes between fAD-like mutations, to assist in our understanding of the molecular 
progression into AD. 
 
In this study, the identification of a null mutation of appb will be outlined, along with some 
preliminary experiments conducted to investigate whether loss of appb expression, and therefore 
a loss of Appb protein, affects the response to acute hypoxia in zebrafish brain. Furthermore, 
successful breeding of the putative appb null to produce homozygous mutant fish was achieved. 
These fish can now be utilised in future transcriptomic analyses to contribute to the wider 
laboratory program, to identify the molecular “signature” of AD. 
 
4.2 Results and Discussion 
Screening F0 founders for potential null mutations 
The appb start site sgRNA, that was shown to induce DSBs in Chapter 3, was co-injected with 
Cas9 protein into fertilised one cell stage embryos. Embryos injected with appb sgRNA were 
155 
 
raised to adulthood and will henceforth be referred to as “F0” or “founder” fish. At ~3 months of 
age, founder fish were screened across the 5’UTR/Exon 1 region for potential mutations that would 
prevent translation of Appb protein. Screening was performed using primers amplifying a 345bp 
fragment spanning the 5’UTR/Exon 1 region of the appb gene, ~216bp upstream and ~129bp 
downstream of the PAM site (Figure 4.1). 
 
Figure 4.1 appb start site, sgRNA binding site, and primer design. – a) region of 5’UTR and exon 1 
sequence within which primers were designed to amplify genomic DNA for T7 cleavage assays. The appb 
start site sgRNA binding site is represented by the black bar, the PAM by the red bar. The green box 
highlights the start codon in exon 1 of appb. The forward primer sequence is highlighted in blue and the 
reverse primer binding site is highlighted in yellow. Lowercase letters represent 5’UTR sequence, while 
uppercase represent sequence from exon 1. The sequence in this figure reads 5’-3’. 
 
Of the 15 adult fish that were biopsied by tail clipping in the initial founder screen, T7 
endonuclease 1 assays identified 11 individuals that were positive for what could potentially be an 
appb null mutation (Figure 4.2 B). As CRISPR/Cas9 can generate DSBs continuously as the 
embryo develops, zebrafish founders injected with the CRISPR/Cas9 system are generally mosaic 
for mutations [14]. Therefore, founders that were positive for mutations were outcrossed to wild 




3 of the 11 founder fish were selected to be outcrossed to wildtype for mutation screening. Fish 
F0-1, F0-3, F0-6, F0-7, F0-10 and F0-13 displayed a banding pattern corresponding to the cleavage 
fragment sizes predicted from the DSB test (figure 4.2 B). Fish F0-3 and F0-6 from this cohort 
were initially selected for further breeding and analysis. Interestingly, our screen also revealed a 
single band above the larger of the predicted (216bp) cleavage fragments in fish F0-5, F0-12 and 
F0-13 (figure 4.2 B). It was suspected that this discrepancy may be indicative of a larger 
deletion/insertion introduced through NHEJ. Fish F0-5, displaying this unexpected banding pattern 
was therefore selected for further breeding and analysis. Fish F0-11, F0-14 and F0-15 also 
displayed aberrant banding patterns to those described above, that were not present in the wildtype 
and did not correspond to the predicted fragments but were not selected for further analysis. 
 
 
Figure. 4.2. Analysis of F0 founder fish generated from appb start site sgRNA injections – a) appb start 
site sgRNA binding site at the boundary of 5’UTR and exon 1 (Ex1). The sgRNA sequence is indicated in 
blue text and is underlined. The 3bp PAM sequence is indicated in red text; b) T7 endonuclease I assay of 
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F0 founders. Each label number above the gel image represents an arbitrarily numbered adult zebrafish 
and the wildtype control is labelled WT; c) the sequence of zebrafish appb around the sgRNA binding site 
for founder fish F0-3, F0-5 and F0-6 (from the gel images in b), above). Dashes indicate deleted 
nucleotides; red and lowercase text indicates an inserted nucleotide. 
 
 
Attempting to identify appb mutations in F0-5 and F0-6 founder fish 
In order to identify potential mutations in our selected founder fish, a random pool of 10 embryos 
from the separate outcrossing of wildtype to F0-5 or F0-6 were first screened to confirm germline 
transmission (supplementary data file S1, Figure S2). A further screen of 6 adult F1 progeny from 
fish F0-5 revealed that approximately 67% (4/6) were positive for the same banding pattern that 
was observed in Figure 4.2 B, indicating that these fish are transmitting a mutation (supplementary 
data file S1, Figure S3). These positive F1 progeny (F1-5.2, F1-5.3, F1-5.4 and F1-5.6) of F0-5 
outcrossed to wildtype were sequenced using the Sanger method to identify any mutations present 
near the start codon. Unfortunately, Sanger sequencing did not reveal any mutations at or around 
the start codon (supplementary data file S2, Figure S6). The absence of a mutation at the start 
codon in these F1 fish suggests that potential mutations observed from tail clippings of F0-5 fish 
do not exist in both tail fin cells and the germline. However, it is also possible that only a few of 
the embryos in the original random pool that was used for screening carried the detected mutant 
genotype. Therefore, as individual adult F1 generation zebrafish were selected for sequencing 
randomly, it could be purely chance that this genotype was not represented in the sequencing. This 
result could be due to the mutation not being carried through to all cells in the germline of the F0 
fish. Another possibility to explain this result may be the presence of a natural polymorphism 
within the 5’UTR and exon 1 region that was used for screening. 
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Screening of 39 adult F1 progeny from fish F0-6 crossed with wildtype, revealed that 
approximately 8% (3/39) carry a banding pattern identical to that of the founder fish, which aligns 
with the predicted fragments expected from DSB induction by this sgRNA (Figure 4.2 B). 
Interestingly, some fish showed faint bands that do not align with the original cleavage pattern as 
seen in Figure 4.2 B (supplementary data file S1, Figure S4). Sanger sequencing of F1 fish 6-13, 
that carries the same banding pattern as F0-6, revealed a 3bp deletion within the 5’UTR/Ex1 region 
(Figure 4.2 C, supplementary data file S2, Figure S7). Unfortunately, the 3bp deletion isolated in 
this mutant fish would not result in the appb transcript being read out of frame hence an (almost) 
full length Appb protein would be generated (supplementary data file S2, figure S9). Since neither 
of the F0-5 or F0-6 lines carried a mutation that would result in an Appb null protein they were 
not included in further analyses. 
 
Identification of a putative appb null mutation in founder fish F0-3 
A pool of 10 randomly selected embryos from the outcrossing of F0-3 to a wildtype fish was also 
screened, confirming germline transmission (supplementary data file S1, Figure S5 a). Further 
screening of 20 adult F1 fish from this mating by T7 endonuclease 1 assay, showed that 10% (2/20) 
of these F1 progeny carry the same banding pattern as F0-3 as shown in Figure 4.2 B 
(supplementary data file S1, Figure S5 b-e). Sanger sequencing performed on F1 fish F1-3.8 of 
this mating identified a single C-insertion mutation at position 13 in the 5th codon (supplementary 
data file S2, Figure S8). In silico translation of cDNA containing the C-insertion using the ExPASy 
software [15] revealed a frameshift, resulting in replacement of the arginine for proline at position 
5 in the amino acid sequence, followed by replacements of all amino acids up until the premature 
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stop codon (PTC) at position 26 in the amino acid sequence. Therefore, the appb C-insertion 
mutant will henceforth be referred to as appbR5PfsTer26 (Figure 4.3).  
 
Figure 4.3. Outline of appbR5PfsTer26 mutation. Red star indicates position of the single C insertion that 
shifts the protein out of frame, resulting in an early stop codon, indicated by black box and star. 
 
Prediction of alternative start site priming for this mutant using the NetStart 1.0 prediction software 
[16], suggests that the start site that gives the truncated protein is preferred (supplementary data 
file S3, Figure S10). An additional search for alternative methionine (start codons) within the first 
and second exons of zebrafish appb that could re-initiate translation, as displayed on the Ensembl 
genome browser (https://asia.ensembl.org/index.html), revealed that there are no alternative start 
codons in either of these exons. Also, translation of appbR5PfsTer26 obtained from the ExPASy 
software (supplementary data file S3, Figure S11) showed that there are no alternative start codons 
for the correct reading frame downstream of the PTC. 
 
 
Breeding the appb null mutant to generate families of WT, heterozygous and homozygous fish for 
analysis of mutational effects 
103 F1 fish from the mating of F0-3 x TU were screened for the appbR5PfsTer26 mutation. The initial 
20 fish were screened by T7 endonuclease 1 assay, while the remainder were screened using 
mutation-detecting primers. Designing primers to detect the single base pair change of the 
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appbR5PfsTer26 mutation was challenging. The appbR5PfsTer26 mutation consists of three consecutive 
cytosines, where previously there were only two. Therefore, a mutation-detecting primer was 
designed that placed the triple cytosine as close to the 3’ end of the primer as possible, as DNA 
polymerase can only synthesis in the 5’-3’direction and thus will first bind strongly to the 3’ end 
to commence replication. Approximately 13% of the 103 F1 fish screened positive for germline 
transmission of the mutation (13/103, as shown in supplementary data file S4, Table S2). Fish F1-
3.30, that was genotyped as heterozygous for the null mutation using mutation detecting primers, 
was confirmed by Sanger sequencing to carry appbR5PfsTer26. In order to minimise off target 
mutations carried through to further experiments, fish F1-3.08 (that had been confirmed by Sanger 
sequencing to carry appbR5PfsTer26) was outcrossed to a wildtype fish from a different family to 
generate an F2 family. Approximately 36% of the 33 (12/33) F2 fish that were tested, screened 
positive for a heterozygous mutation. 
 
In zebrafish, appb has previously been observed to play a role in convergent extension movements, 
development of body length and neural development [17, 18]. Involvement in these processes 
suggests a key role for appb in zebrafish development. Interestingly, we observed no obvious 
developmental abnormalities in zebrafish heterozygous for the appb null mutation. The lack of an 
observable phenotype in individuals heterozygous for this putative null mutation (as had 
previously been observed with morpholino knockdown) is perhaps not surprising, as previous 
studies have shown that phenotypes caused by morpholino knockdown are most often different to 





Generating homozygous appb nulls for phenotypic analysis and future transcriptomic analyses 
Further breeding of appbR5PfsTer26 mutant zebrafish was conducted in order to; 1) investigate the 
potential of generating zebrafish that were homozygous viable for appbR5PfsTer26, and 2) generate 
families containing a combination of heterozygous, homozygous and wildtype genotypes for 
multiple three-way comparisons (i.e. pairwise comparisons between heterozygous/homozygous, 
heterozygous/wildtype and homozygous/wildtype for later transcriptomic and other analyses). 
Therefore, a pair of heterozygous appbR5PfsTer26 fish were mated to produce an F2 generation family 
that should contain a combination of heterozygous, homozygous and wildtype in a 2:1:1 ratio. The 
progeny of this original mating were raised to 5dpf, at which point we observed their phenotype 
to look for any changes that might be associated with homozygous siblings. 
 
Since we previously observed no phenotype in heterozygous individuals, we were surprised to 
observe phenotypic changes from this mating. We classified larvae from this mating into 3 
phenotypic groups (supplementary data file S5, Figures S12, S13 and S14): severe (with 
phenotypic traits ranging from: tail curved down, edema, short tail and up curved fish [20]), 
mild/moderate (up curved tail, down curved fish (mild) [20] and under-developed swim bladder) 
and wildtype (normal). These larvae were then harvested for genomic DNA and genotyped to 
determine whether genotypes correlated with the observed phenotype groups. Unexpectedly, 
genotypes did not align with our predictions from the observed phenotypes. We expected larvae 
displaying severe phenotypes to be homozygous for appbR5PfsTer26, whereas mild/moderate 
phenotypes might be homozygous or heterozygous and normal phenotypes might be heterozygous 
or wildtype. However, we observed no correlation between genotype and phenotype. Of the 21 
larvae genotyped, ~33% (7/21) were heterozygous, ~38% (8/21) were homozygous mutant and 
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~29% (6/21) were wildtype. Interestingly, no obvious phenotype was observed in the F2 offspring 
from additional mating’s of two alternative zebrafish heterozygous for the appb null mutation. 
Since the progeny of only a single pair mating was observed in this analysis, the phenotypical 
differences observed in the F2 family may have been due to individual fish variability or genetic 
impacts at genome editing other than generation of appbR5PfsTer26. For example, an off-target 
mutation may unintentionally have been created during the process of generating this mutant fish 
line. Alternatively, our laboratory has previously observed poor quality embryos produced from 
the pairing of two non-mutant TU fish. This may be due to homozygosity for deleterious recessive 
mutations present in this inbred fish line. The observation of the F2 offspring from additional 
mating’s of two alternative zebrafish heterozygous for the appb null mutation having no 
observable phenotype better fits what we would expect from the genetic compensation response. 
 
Investigating the hypoxic response of young appbR5PfsTer26 mutant zebrafish by examining HRGs  
Zebrafish are a versatile model for the genetic analysis of the response to acute hypoxia [12]. A 
previous study in our laboratory used digital real-time polymerase chain reactions (dqPCRs) to 
compare transcript levels of five HIF-1 responsive genes (HRGs) in 6-month-old zebrafish brains, 
carrying two different fAD-like mutations in psen1, after treatment with normoxia or acute 
hypoxia [13]. In the study, an expected increase in expression of HRGs was observed in wildtype 
zebrafish after treatment with acute hypoxia. Interestingly, the expression of HRGs in psen1 fAD-
like mutant zebrafish under normoxia was raised to levels similar to that of the wildtype hypoxia-
treated zebrafish, suggesting hypoxic-like stress in the young mutant brain [13]. Treatment of 6-
month-old psen1 fAD-like mutant zebrafish with acute hypoxia further exacerbated the observed 
increase in HRGs expression [13]. 
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A study using mouse embryonic fibroblasts (MEFs) suggested that the APP intracellular domain 
(AICD), generated by cleavage of the APP protein by PSEN1/2, can induce Hif1a gene expression 
and HIF-1α protein stability [21]. Furthermore, it has also been demonstrated that hypoxia 
upregulates both APP mRNA and protein expression, resulting in accumulation of Aβ [reviewed 
in 22]. If APP plays an integral role in the hypoxic response through generation of its AICD, one 
would expect that knocking out APP would reduce the brain’s ability to respond to hypoxia. Our 
study also utilised dqPCR to establish the effects that our appb putative null allele asserts on the 
HIF-1 hypoxic response, by comparing transcript levels from two HRGs: edn1 and igfbp3 [23], in 
6-month-old zebrafish brains that had been exposed to either normoxia or acute hypoxia. Unlike 
the study with psen1 fAD-like mutant zebrafish, we did not observe increased levels of HRGs in 
the normoxia treated heterozygous appb putative null mutation fish, nor did we observe the 
decrease in hypoxic response we would expect from loss of the Appb AICD. However, expression 
of both HRGs was raised under acute hypoxia in the 6-month-old brains of both wildtype and appb 
putative null zebrafish (although there was an upwards trend observed, edn1 did not reach 
significance in the wildtype) (Figure 4.4).  
 
The human APP protein has been identified in three different isoforms that occur due to alternative 
splicing of exons 7 and 8 of APP transcripts [24], the full-length isoform APP770, isoform APP751 
lacking exon 8, and isoform APP695 which lacks both exon 7 and exon 8. In zebrafish there are 
two co-orthologues of the human APP gene, appa and appb [25]. The appa orthologue shares 
greater identity to APP770 and APP751, while the appb orthologue is more closely related in 
structure to APP695. The human APP695 isoform is nearly exclusively expressed in the CNS (the 
site of increased hypoxia in AD), while APP770 and APP751 are expressed elsewhere [26]. 
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Although, structurally, appb resembles more closely the human APP695 isoform, while appa is 
closer to the APP751 and APP770 isoforms, physiologically these zebrafish genes are both 
expressed widely throughout the developing embryo. A study by Kaiser et al (2012) found that 
appa and appb were mostly redundant during zebrafish development, where messenger RNA 
(mRNA) of appa rescued the phenotype induced by Appb morpholino knockdown, and vice versa 
[27]. Hence, the observed lack of decrease of the hypoxic response in our heterozygous appb 
putative null mutants is perhaps not unexpected, as in zebrafish two healthy copies of the appa 
allele may be able to compensate for loss of the Appb AICD. Another possibility is that a single 
wildtype copy of the appb allele may be enough to sufficiently respond to hypoxia. Zebrafish 
homozygous for the appb putative null mutation should therefore be tested to investigate whether 
knocking out both copies of appb is sufficient to decrease the hypoxic response. Furthermore, the 
lack of statistical significance in induction of the hypoxic response observed when measuring edn1 
in our wildtype zebrafish brains is consistent with what has previously been observed in our 
laboratory, where recent experiments have shown that edn1 expression is only increased under 
very severe acute hypoxia (unpublished data). This variability suggests that edn1 is perhaps not 





Figure 4.4. Hypoxia response gene expression in 6-month-old zebrafish brains under normoxia and 
hypoxia. Data points on the graph indicate relative transcript levels of edn1 (●) and igfbp3 (■) in 50ng of 
cDNA generated from a single zebrafish brain RNA sample. The genotype of each sample is indicated at 
the bottom of the graph. Normoxia treated samples are indicated with “N”, while hypoxia treated samples 
are indicated with “H” on the x-axis. 
 
4.3 Conclusions and Future Directions 
In this study, we utilised the appb start site sgRNA that was demonstrated to generate DSBs in 
Chapter 3 in an attempt to isolate appb null mutations. Three zebrafish founders were screened for 
potential appb null mutations. Of these founders, F0-5 and F0-6 did not carry a null mutation. 
Therefore, neither of these fish were selected for further breeding and analysis. However, we 
successfully identified a founder carrying a putative null mutation in appb when sequencing F1 
progeny from the F0-3 founder fish crossed with TU. This appbR5PfsTer26 mutation was carried 
through to the germline and successfully bred to produce heterozygous and homozygous families. 
In future, western blot analyses could be performed on these homozygous fish, to confirm that our 
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putative appb null leads to loss of Appb protein. A study by Kaiser et al (2012) previously used 
the 22C11 APP antibody to detect changes in the amount of zebrafish Appa or Appb protein after 
morpholino knockdown [27]. They demonstrated that the 22C11 antibody binds both Appa and 
Appb in zebrafish. Unfortunately, preliminary western blot analyses we performed using this 
antibody to detect protein changes in response to our putative appb null mutation were 
unsuccessful (data not shown). In their paper, Kaiser et al (2012) did not provide details of their 
methods using the 22C11 antibody with zebrafish protein material, hence our preliminary tests 
utilised conditions that had previously been used in mouse studies. Further testing and adaptation 
of antibody conditions in zebrafish may lead to more successful identification of the effect of 
appbR5PfsTer26 on Appb protein levels. 
 
Nonsense mediated decay (NMD) is a mechanism through which mRNAs harbouring PTCs are 
rapidly degraded [28]. The single cytosine insertion in the appbR5PfsTer26 mutant creates a PTC at 
amino acid position 26, therefore we expect that this transcript would be down-regulated by NMD. 
To measure the effect of NMD on the appbR5PfsTer26 transcript, dqPCR could be employed. Allele-
specific primers that amplify either mutant or wildtype would be utilised to directly compare 
transcript expression levels in cDNA synthesised from total RNA extracted from wildtype, 
heterozygous and homozygous mutant fish brains. If appbR5PfsTer26 is a true null, we would expect 
to see decreased, or complete loss of, expression of this allele in heterozygous and homozygous 
mutants due to NMD of the mutant transcripts. Unfortunately, preliminary attempts to design 
allele-specific dqPCR primers that could differentiate between our mutant appb fish carrying a 
single cytosine insertion and wildtype were unsuccessful (data not shown). In future, further 
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primers may be designed and conditions tested in attempts to better differentiate between these 
two very similar sequences. 
 
Previous experiments in zebrafish that used morpholinos to block appb expression resulted in 
several developmental phenotypes [17, 18]. Despite this, we observed no obvious phenotypical 
difference in our appbR5PfsTer26 putative null mutants (heterozygous or homozygous) compared to 
wildtype. However, the observed lack of phenotype in our mutant versus the developmental 
phenotypes observed for the previously studied morphants was not unexpected, as this 
phenomenon has now been observed for many genes. Rossi et al (2015) showed that phenotypic 
differences that are now commonly observed between morphants and mutants are due to the 
phenomenon of “genetic compensation” [19]. In their experiments, genetic compensation was only 
observed in zebrafish when a loss of protein function was achieved by mutation, not morpholino 
knockdown. Therefore, it is probable that the lack of phenotype observed in our appbR5PfsTer26 
heterozygous and homozygous fish is due to genetic compensation, most likely by the appb co-
orthologue appa, but also possibly by another member of the large APP family of genes such as 
aplp1 or aplp2 [29]. 
 
6-month-old wildtype and heterozygous siblings from an F2 family generated by outcrossing a 
zebrafish heterozygous for appbR5PfsTer26 to TU, were treated with either normoxia or hypoxia and 
their hypoxic response measured by dqPCRs detecting the levels of two HRGs (edn1 and igfbp3). 
We observed an increase in the transcript levels of both HRGs under hypoxia to the same extent 
as observed for wildtype fish at the same age. However, we did not observe an increase in the 
transcript levels of HRGs in the normoxia treated appb null mutants, as had been observed 
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previously for two psen1 mutants in our laboratory at the same age point [13]. In their study, 
Newman et al (2019) measured the hypoxic response in both wildtype and psen1 fAD-like mutant 
zebrafish brains at 24-months-old (which we consider to be an aged brain in zebrafish as the fish 
are no longer fertile) with some interesting findings. At 6-months-old, their mutant fish showed 
increased HRG expression under normoxia like that of 24-month-old wildtypes, suggesting that 
this psen1 fAD-like mutation accelerates brain aging. Under hypoxia, HRG transcript levels in 
wildtype fish are increased twofold relative to that of fish remaining under normoxia, while the 
HRGs of normoxic 24-month-old psen1 fAD-like mutants are expressed at very similar levels to 
HRGs in the hypoxia-treated wildtype brains. If 24-month-old psen1 fAD-like mutant brains are 
already under hypoxic stress prior to hypoxia treatment, it would be interesting to observe the 
effect our appb putative null on brain aging. As previously mentioned, the APP AICD can directly 
upregulate HIF-1α [21]. If this interaction is important for the cells ability to respond to hypoxia, 
we would expect our appb putative null zebrafish to have a decreased hypoxic response. Although 
we did not observe the expected decrease in our experiments presented in this study, the 
importance of this interaction cannot be discounted for a number of reasons. Firstly, as we 
measured the hypoxic response in zebrafish brains heterozygous for appbR5PfsTer26, there may be 
enough AICD generated by the second wildtype appb allele to sufficiently respond to hypoxia in 
these brains. This could be further investigated by measuring the hypoxic response in zebrafish 
brains homozygous for appbR5PfsTer26. Secondly, zebrafish have two co-orthologues of the APP 
gene, appa and appb. Therefore, it is possible that in our appbR5PfsTer26 zebrafish, the AICD of 
Appa can compensate for loss of Appb. Indeed, AICD is highly conserved between human, mouse 
and both zebrafish APP’s, supporting this suggestion. Analysis of the hypoxic response in a double 
knockout model of zebrafish appa and appb might be able to resolve this question. 
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In a previous mouse study, Koike et al (2012) observed a higher mortality rate when APP knockout 
mice were subjected to hypoxia. They suggested that loss of APP, or one of its cleavage fragments, 
may have increased mortality in these animals by increasing their vulnerability to hypoxia [30]. In 
their case, complete knockout of APP would mean a complete loss of the AICD, hence 
observations from their study may provide support to the idea that the interaction between AICD 
and HIF1-α is critical for the cell to respond to hypoxia. Alternatively, BACE1 expression is also 
upregulated in response to hypoxia [ref], so it is also possible that one or more β-secretase-specific 
APP cleavage fragments (such as sAPPβ or even Aβ) play an important role in the hypoxic 
response. Expression of APP in the vasculature has been observed experimentally [reviewed in 
31] and vascular dysfunction in the aging brain has been suggested to be a major risk factor for 
AD [32]. Although APPs role in the vasculature remains incompletely understood, hypoxia (in the 
form of ischemia) has been shown to upregulate both the mRNA and protein levels of APP, with 
subsequent Aβ accumulation [reviewed in 22]. It is therefore possible that APP can act as a stress 
response protein that protects the brain against hypoxia, although further investigation is needed 
to confirm this. 
 
Finally, transcriptomic analyses should eventually be performed to identify changes that are 
specific to an appb null mutation and can be excluded from our developing understanding of 








This work was conducted under the auspices of the Animal Ethics Committee of the University of 
Adelaide and in accordance with EC Directive 86/609/EEC for animal experiments and the 
Uniform Requirements for manuscripts submitted to Biomedical journals. 
 
Genomic DNA extraction from zebrafish embryos and tail fin clips 
A small section of the dorsal fin (~3 mm) of adult fish was removed with a sterile scalpel blade 
under anaesthesia (Tricaine solution, 1.68 μg/mL). 
Embryos, or, tail fin tissue, were placed in 50µl of a 17mg/ml Proteinase K (Roche, Basel, 
Switzerland), 1XTE solution and then incubated at 55-65°C until dissolved (2-4 hours). The lysis 
buffer was then placed at 95°C for 5 mins to inactivate the Proteinase K. Either mixture was then 
centrifuged at 12,000 rpm for 2 mins to pellet cellular debris. The supernatant was transferred into 
a clean microfuge tube ready for subsequent PCR [33]. 
 
Mutation detection assays 
Mutations generated by CRISPR or TALEN were detected by the T7 endonuclease 1 method 
adapted from Reyon et al (2012) [34]. In the T7 endonuclease 1 method, loci were amplified using 
primers presented in supplementary data file S4, Table S1, with GoTaq polymerase (New England 
Biolabs, Ipswich, Massachusetts, USA) and the resulting DNA was re-annealed under the 
following conditions; 95°C for 5 mins then ramped down from 95°C-85°C at a rate of -2°C/sec, 
followed by ramping down from 85°C-25°C at a rate of -0.1°C/sec. After reannealing, 1μl of T7 
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endonuclease I (New England Biolabs, Ipswich, Massachusetts, USA) was added and the entire 
mixture was incubated at 37°C for 15 mins. 
 
Sanger sequencing 
The genomic region surrounding the appb start site sgRNA target site was PCR amplified using 
appb Ex1 forward and reverse primers (supplementary data file S4, Table S1). The purified appb 
5’UTR/Exon1 genomic DNA fragments were then used for Sanger sequencing with the appb Ex1 
sequencing F primer (supplementary data file S4, Table S1) (Australian Genome Research 
Facility, SA, AUS). 
 
Detecting appbR5PfsTer26 mutations via PCR 
We identified a single base pair insertion that resulted in a frameshift at nucleotide position 14 in 
exon 1 of appb (Figure 4.3#). PCR primer pairs were designed to detect either the appbR5PfsTer26 
allele or wildtype allele at this position (supplementary data file S4, Table S1). Loci were amplified 
with GoTaq polymerase (New England Biolabs, Ipswich, Massachusetts, USA) with PCR 
conditions varying between primer pairs: The PCR conditions for wildtype-specific (WTF2-R1) 
detection were 95°C, 2min; 30 cycles of [95°C, 30 s; 64°C, 30 s; and 72°C 40s]; 72°C, 5 min and 
the anticipated length of the PCR product was 326 bp. The PCR conditions for mutant-specific 
(F4R2) detection were 95°C, 2min; 30 cycles of [95°C, 30 s; 60°C, 30 s; and 72°C 40s]; 72°C, 5 






Hypoxia treatment and whole brain removal 
Oxygen-depleted water was first generated by bubbling nitrogen into recirculated tank water. 6-
month-old zebrafish were treated in low oxygen levels (0.9 ± 0.5mg/L of oxygen) or normal 
oxygen levels (6.6 ±0.5 mg/L of oxygen) by placing them inside a 500ml bottle of the respective 
water conditions for approximately 3 hours. Directly following hypoxia or normoxia treatment, 6-
month-old zebrafish were euthanised in an ice water slurry for ~30 seconds and the brain 
subsequently removed for immediate RNA extraction.  
 
RNA extraction from whole adult zebrafish brain and cDNA synthesis  
Total RNA was isolated from mutant and WT siblings using the mirVana miRNA isolation kit 
(Thermo Fisher, Waltham, Massachusetts, USA). RNA isolation was performed according to the 
manufacturer’s protocol. First the brain is lysed in a denaturing lysis solution. The lysate is then 
extracted once with acid-phenol:chloroform leaving a semi-pure RNA sample. A glass-fiber filter 
is utilised to further purify the sample and return total RNA.  
cDNA was generated from 500ng of 6-month-old zebrafish brain RNA using random primers 
following the First-Strand cDNA Synthesis protocol (Invitrogen, Life Technologies, Carlsbad, 
CA, USA). After inactivation the cDNA was treated with RNase H (New England Biolabs, 
Ipswich, Massachusetts, USA) and incubated at 37°C for 30 minutes, the RNase H was then 
inactivated by heating at 65°C for 20 minutes. 
 
Assaying the hypoxia response by digital PCR 
Primers for dqPCR of known hypoxia response genes, including a forward and reverse primer 
(supplementary data file S4, Table S3) detecting the igfbp3 gene (NM_205751), and a forward and 
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reverse primer (supplementary data file S4, Table S3) detecting the edn1 gene (NM_131519), were 
previously designed for analysis of these genes in response to hypoxia in the presence of fAD-like 
mutations. HRG gene transcript levels were measured using the QuantStudio™ 3D Digital PCR 
System (Life Sciences, Waltham, MA, USA) with the QuantStudio™ 3D Digital PCR 20K Chip 
Kit v2 and Master Mix (Life Sciences, Waltham, MA, USA, A26317) and SYBR™ Green I 
Nucleic Acid Gel Stain (Life Sciences, Waltham, MA, USA, S7563). The dqPCR conditions for 
assays of edn1 or igfbp3 expression in response to hypoxia were 96°C, 10 min; 49 cycles of [62°C, 
2 min; 98°C, 30 s]; 62°C, 2 min. 50ng of total cDNA from each sample was loaded into one chip 
for the dqPCR. Chips were read using QuantStudio™ 3D AnalysisSuite Cloud Software (Life 
Sciences, Waltham, MA, USA). 
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4.6 Supplementary Information 
This section is included in the thesis as information supplementary to Chapter 4. It contains 
additional information not included in the main text of the manuscript. 
 
File S1. Mutation screening 
 
Figure S1. Confirmation of the ability of the appb start site sgRNA to generate mutations. Image shows 
T7 endonuclease treated genomic DNA from appb sgRNA microinjected zebrafish. Primers were used to 
amplify a region of 345bp with the predicted cleavage site (PAM) positioned so that cleavage products of 
~200bp and ~100bp would be generated that could be separated using gel electrophoresis. Fragments 
observed with sizes of approximately 200pb and 100 bps (black arrows) indicate that the sgRNA was 





Figure S2. Screening for germline transmission of mutations in the embryos produced from of an 
outcross of fish F0-5 to wildtype and an outcross of fish F0-6 to wildtype. The 3 arrows on the right 
indicate cleavage products from a T7 endonuclease assay on DNA amplified across the cleavage site of the 
appb sgRNA in embryos from F0-6 outcrossed to wildtype. The single arrow on the left indicates the 
cleavage product from a T7 assay on DNA amplified across the cleavage site of the appb sgRNA in embryos 
from F0-5 outcrossed to wildtype. 
 
 
Figure S3. Screening for mutations in the adult progeny of an outcross of fish F0-5 to wildtype. Fish F1-
5.2, F1-5.3, F1-5.4 and F1-5.6 carry a potential germline mutation indicated by arrow. Fish F1-5.1 and 




Figure S4. Screening for mutations in the adult progeny of an outcross of fish F0-6 to wildtype. Fish F0-
6.13 (a), F0-6.37 and F0-6.38 (h) carry a potential germline mutation indicated by arrows, while the 





Figure S5. Screening for mutations in the adult progeny of an outcross of fish F0-3 to wildtype. Fish F0-
3.8 (c) and F0-3.17 (d) carry a potential germline mutation (indicated by black arrows), while the 
remaining fish are wildtype. Black star (fish F0-3.4, b) indicates a faint band that suggests the fish may 




File S2. Raw sequencing data files 
 
Figure S6. Sanger sequencing of a single adult from the progeny of an outcross of fish F0-5 to wildtype 
– Single peaks observed throughout the sequence suggest that both strands are wildtype. This same 
observation was made for sequencing of fish F0-5.2 (this image), F0-5.3, F0-5.4 and F0-5.6 from 
supplementary data file S1, Figure S3. 
 
 
Figure S7. Sanger sequencing of a single adult from the progeny of an outcross of fish F0-6 to wildtype 
– Single peaks indicate wildtype sequence. Sequence with double peaks indicates a difference in the 
composition of the two strands (purple and black). Red arrow indicates mutation position. This same 
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observation was made for sequencing of fish F0-6.13 (this image), F0-6.37 and F0-6.38 from 
supplementary data file S1, Figure S4. 
 
 
Figure S8. Sanger sequencing of a single adult from the progeny of an outcross of fish F0-3 to wildtype 
– Single peaks indicate wildtype sequence. Scrambled sequence with double peaks indicates a difference in 
the composition of the two strands (purple and black). Red arrow indicates mutation position. This same 
observation was made for sequencing of fish F0-3.8 (this image) and F0-3.17 from supplementary data file 
S1, Figure S5. 
 
 
Figure S9. Outline of appb 3bp deletion mutation identified in progeny of an outcross of fish F0-6 to 




File S3. Investigation of translation and start codons for appbR5PfsTer26 
 
Figure S10. Netstart 1.0 prediction (screenshots) for alternative start codons in R5PfsTer26 mutant. a) 
sequence run through software, output is below sequence with start codon (methionine) positions indicated 
by “i” if initiation is possible and “N” if not. b) individual scores given to each start codon that could 





Figure S11. ExPASy translations for primary reading frame of a) wildtype and b) R5PfsTer26 mutant 




File S4. Supporting tables. 
Table S1. Primers used in sequencing and mutation detection. 
 F = forward, R= reverse 
Primer name 
 
Primer sequence (5’-3’) 
Appb Ex1 Sequencing F 
 
CTCCAACCTCCGAGTC 
Appb Ex1 F CTCCAACCTCCGAGTCCATTCT 
Appb Ex1 R TGCGTTTTCCCTTCACTCCC 
C insertion F4 CAGGAATACCGTGCGGG 
C insertion R2 TATTTGGGTCTCAGGAGGATAA 
Appb Ex1 WT F2 CATGGGTATGGACCGCA 
C insertion R1 (used with WT F2) CGCTACACTACGCCTGATACT 
 
 
Table S2. Mutations detected in the progeny of an outcross of fish F0-3 to wildtype via 
genotyping PCR  
 Fish were genotyped with T7E1 assay up to F1-3.20, then genotyped with the C insertion 
detecting primers up to F1-3.103. 
 Orange shading indicates no mutation, Green shading indicates positive signal for a 
mutation and Yellow indicates faint bands that might be a signal 
F1-3.1 F1-3.2 F1-3.3 F1-3.4 F1-3.5 F1-3.6 F1-3.7 F1-3.8  F1-3.9 
F1-3.10 F1-3.11 F1-3.12 F1-3.13 F1-3.14 F1-3.15 F1-3.16 F1-3.17  F1-3.18 
F1-3.19 F1-3.20 F1-3.21 F1-3.22 F1-3.23 F1-3.24 F1-3.25 F1-3.26  F1-3.27 
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F1-3.28 F1-3.29 F1-3.30 F1-3.31 F1-3.32 F1-3.33 F1-3.34 F1-3.35  F1-3.36 
F1-3.37 F1-3.38 F1-3.39 F1-3.40 F1-3.41 F1-3.42 F1-3.43 F1-3.44  F1-3.45 
F1-3.46 F1-3.47 F1-3.48 F1-3.49 F1-3.50 F1-3.51 F1-3.52 F1-3.53 F1-3.54 
F1-3.55 F1-3.56 F1-3.57 F1-3.58 F1-3.59 F1-3.60 F1-3.61 F1-3.62 F1-3.63 
F1-3.64 F1-3.65 F1-3.66 F1-3.67 F1-3.68 F1-3.69 F1-3.70 F1-3.71 F1-3.72 
F1-3.73 F1-3.74 F1-3.75 F1-3.76 F1-3.77 F1-3.78 F1-3.79 F1-3.80 F1-3.81 
F1-3.82 F1-3.83 F1-3.84 F1-3.85 F1-3.86 F1-3.87 F1-3.88 F1-3.89 F1-3.90 









     
 
 























Table S4. Expression levels of edn1 in 50ng total 6-month-old adult brain cDNA. (Assuming 
complete reverse transcription of total brain RNA). 
edn1 














Table S5. Expression levels of igfbp3 in 50ng total 6-month-old adult brain cDNA. (Assuming 
complete reverse transcription of total brain RNA). 
igfp3 


















File S5. Classification of F2 generation larvae, from a pair mating of heterozygous F1 
appbR5PfsTer26 fish, into 3 phenotypic groups (wildtype, mild/moderate and severe). 
 
Figure S12. F2 progeny from a pair mating of two heterozygous F1 appbR5PfsTer26 fish with the wildtype 
phenotype. Larvae were subsequently genotyped, and their genotypes are included below each image as 




Figure S13.  F2 progeny from a pair mating of two heterozygous F1 appbR5PfsTer26 fish with the 
mild/moderate phenotype. Larvae were subsequently genotyped, and their genotypes are included below 




Figure S14. F2 progeny from a pair mating of two heterozygous F1 appbR5PfsTer26 fish with the severe 
phenotype. Larvae were subsequently genotyped, and their genotypes are included below each image as 





Chapter 5 – Analysing the aggregation propensity of putative zebrafish 
APPa and APPb Aβ-42-like peptides 
5.1 Introduction 
The aggregation of proteins or peptides into β-sheets (i.e amyloid fibrils) occurs in several human 
diseases, such as: Alzheimer’s disease (AD) and Parkinson’s disease [1]. The amyloid precursor 
peptide (APP) has a diverse range of functions [2] but is perhaps most well-known for its predicted 
role in AD neuropathogenesis. APP is processed sequentially by the metalloprotease BACE (aka 
β-secretase) followed by the γ-secretase complex to release amyloid beta (Aβ) peptide [3]. The Aβ 
peptide varies in length between 38-43 amino acids, depending on the proteolysis by γ-secretase 
[4]. The two predominant Aβ species observed in the human brain are the soluble Aβ-40 peptide 
and the less soluble, more aggregation prone variant, Aβ-42, that is often observed in increased 
concentrations in AD brains. The Aβ-42 variant is concentrated in the senile/neuritic plaque 
deposits observed in AD patient’s brain parenchyma [reviewed in 5]. Furthermore, mutations 
within the transmembrane domain of human APP that cause the rare, genetic form of AD, familial 
AD (fAD), have been demonstrated to increase the Aβ-42 to Aβ-40 ratio, which is thought to be a 
cause of neuronal cell death in the disease [4]. Both the Aβ-40 and Aβ-42 peptides have been 
shown to aggregate into amyloid fibrils [6] – which have also previously been defined as “fibrillar 
polypeptide aggregates that consist of a cross-β structure” [7].  
 
In our laboratory, we have used the zebrafish as a model to study genetic and biochemical 
processes involved in fAD, such as: hypoxia, autophagy and APP processing. The zebrafish is an 
excellent model for studying these processes for several reasons. Firstly, genes that carry mutations 
in humans that are implicated in fAD pathogenesis are conserved in the zebrafish (human PSEN1 
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and PSEN2 orthologs psen1 and psen2, APP co-orthologs appa and appb, and SORL1 ortholog 
sorl1) along with other genes involved in the Aβ cascade (other γ-secretase complex component 
genes psenen, ncstn and aph1b, and β-secretase orthologs, bace1 and bace2) [reviewed in 8]. 
Zebrafish are also genetically manipulable through microinjection with a range of technologies, 
including: morpholinos, mRNA, transgenes and genome engineering tools, such as TALENs and 
CRISPR/Cas. Furthermore, zebrafish have neuroanatomical similarity with the human brain, fAD 
behavioural similarity with humans, and pathophysiological resemblance to fAD [reviewed in 9].  
Previous research has investigated the Aβ peptide in zebrafish in a variety of ways. Donnini et al 
(2010) administered human-derived Aβ peptides directly to the water containing developing 
zebrafish embryos to examine toxicity [10]. Cameron et al (2012) treated zebrafish embryos with 
monomeric human Aβ and observed induced branching in cerebrovascular blood vessels in the 
zebrafish hind brain [11]. Newman et al (2010) fused the sequence of human Aβ-42 to the mitfa 
gene promoter and utilised this to generate a zebrafish transgenic toxicity model of Aβ [12]. 
Bhattarai et al (2016) generated an Aβ-42 toxicity model in zebrafish by injecting human Aβ-42 
linked or unlinked to two peptides with the ability to penetrate cells, transportan and poly-arginine 
[13]. Sivaji et al (2019) injected human Aβ-42 peptide into the midbrain region of 24 hour old 
zebrafish, to study the relationship between Aβ and osteogenesis over Sox9a expression during 
early development [14]. 
 
To our knowledge there are no published studies that have investigated aggregation of endogenous 
Aβ peptides that would theoretically be produced from sequential processing of Appa or Appb in 
zebrafish. The Aβ peptide region, along with the secretases that produce Aβ from APP, are 
conserved in zebrafish. Also, it has previously been demonstrated that zebrafish psen1 (γ-
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secretase) is capable of processing human APP to secrete the Aβ-42 peptide, suggesting that this 
role of psen1 (γ-secretase) is conserved in the zebrafish [15]. Despite this, there has not yet been 
identification of a zebrafish-specific Aβ peptide, nor has it been established whether the zebrafish 
equivalent β-secretase and γ-secretase enzymes process endogenous appa or appb as they do 
human APP [16]. One study performed sequence alignments of APP across all animal taxa and 
observed that the “normal” β-secretase cleavage site (EVKMDAE) is not completely conserved in 
zebrafish Appa or Appb [17]. However, this does not necessarily mean that zebrafish Appa and 
Appb will not be cleaved by β-secretase as; 1) the amino acid residues in zebrafish Appa and Appb 
that do not share conservation with the human APP sequence are still highly similar in chemical 
structure, and 2) it has previously been demonstrated that mutation of the β-secretase site in a 
Swedish fAD family (from EVKMDAE to EVNLDAE [18]) creates a peptide sequence that is 
actually preferentially cleaved by β-secretase [19]. One gap in the knowledge of presenilin 
function in zebrafish, in the context of generating fAD-like mutations in the equivalent endogenous 
zebrafish genes, is our lack of understanding of (or knowledge of the existence of) zebrafish-
specific Aβ peptides. In order to utilise our existing fAD-like mutant zebrafish to study aggregation 
in response to these mutations, we first need to investigate a) whether zebrafish-specific Aβ 
peptides are released, and b) whether these peptides aggregate in a similar manner to human Aβ 
peptides. 
 
In this study, we aimed to determine whether the putative Aβ-42 equivalent peptides from 
zebrafish Appa and Appb would aggregate with a similar propensity to that of human Aβ-42. We 
first predicted Aβ-42-like peptides for zebrafish Appa and Appb. We then analysed these Aβ-42-
like peptides using three forms of different aggregation/fibril formation propensity predicting 
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software: TANGO, Zyggregator and Zipper DB. During these analyses, we observed two distinct 
regions of the human Aβ-42 peptide that are prone to fibril formation, one in the mid-peptide 
region and another at the C-terminal end of the peptide sequence. When comparing the predicted 
Aβ-42-like peptides of zebrafish Appa and Appb to the human Aβ-42 peptide, our analyses 
revealed similar aggregation propensities in the C-terminal ends across all peptides. However, we 
observed that the predicted Aβ-42 equivalent peptide of zebrafish Appb had distinctly lower, or 
even non-existent, aggregation propensity in the mid-peptide region. In contrast, the predicted Aβ-
42 equivalent peptide of zebrafish Appa showed an aggregation propensity in this mid-peptide 
region similar to that of human Aβ-42. These findings suggest that both the Aβ-42-like peptides 
of zebrafish Appa and Appb have similar aggregation potentials to human Aβ-42. However, further 
investigation is required 1) to determine whether the lack of aggregation potential observed in the 
mid-peptide region of the predicted Aβ-42-like peptide of zebrafish Appb prevents it from forming 
amyloid fibrils, and 2) to demonstrate that the Aβ-42-like peptide of Appa does aggregate as 
predicted by the analyses in this chapter. 
 
5.2 Results and Discussion 
Determining Aβ-42-like peptide equivalents in zebrafish Appa and Appb 
To investigate the amyloidogenic propensity of zebrafish-equivalent Aβ-42 peptides, we first 
identified Aβ-42 equivalents by performing a protein sequence alignment with human and mouse 
APP. Alignment of zebrafish Appa and Appb with human and mouse APP revealed the equivalent 
Aβ-42 peptide regions in these genes (Figure 5.1). While the Aβ-42-like peptide in zebrafish Appb 
maintained the same length as mouse and human Aβ-42, the zebrafish Appa peptide is only 39 
amino acids in length due to three missing amino acids near the N-terminal end of the polypeptide 
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chain. The predicted amyloidogenic propensities of the identified zebrafish Appa and Appb Aβ-
42-like peptides were then investigated using a variety of software tools, whose algorithms employ 




Figure 5.1. Alignment of Aβ-42 peptides of human and mouse and Aβ-42-like peptides of zebrafish Appa 
and Appb used in aggregation analyses. Green boxes indicate regions of sequences that are identical 
across all peptides. The three amino acid residues that are different between mouse and human (and the 
equivalent amino acid residues in zebrafish Appa and Appb) are indicated by red boxes.   
 
Investigating amyloidogenic propensity of zebrafish Aβ-40 and Aβ-42 using TANGO 
The TANGO algorithm tests whether residues in a peptide sequence of interest occupy a β-
aggregation conformation. One of the definitions of amyloid fibrils is that they consist of a cross-
β structure [7], hence this method should give an indication of the propensity to form these fibrils. 
Only sections of five or more consecutive amino acid residues in the β-aggregation conformation 
are included in TANGO’s analysis. TANGO has previously been used to predict the β-sheet 
aggregation propensity of Alzheimer's Aβ-40 and Aβ-42 variants [20]. TANGO identified two 
aggregation prone regions for both peptides: one region comprised of residues 17-21 in the middle 
of the peptide and a second region towards the C-terminus of the peptide containing residues 31-
36 of Aβ-40 and residues 30-42 of Aβ-42. Interestingly, they found that Aβ-42 had a much higher 
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propensity to aggregate between residues 30-42 than Aβ-40 between residues 31-36 [20]. They 
also compared in vivo experimentally determined values of Aβ aggregation for four fAD mutations 
(Arctic, Dutch, Italian and Flemish) to predictions of β-sheet aggregation propensity using 
TANGO and found that three of the four predictions closely resembled the experimentally derived 
data thereby validating their algorithm [20]. 
 
Table 5.1. Combinations of physio-chemical conditions input into TANGO software 
Experiment pH Temperature (K) Ionic Strength Concentration 
1 7.2 310.15 0.3 9x10-12 
2 7 298.15 0.3 9x10-12 
5 7.2 310.15 0.2 9x10-12 
6 7 298.15 0.2 9x10-12 
9 7.44 298.15 0.2 9x10-12 
10 7.44 298.15 0.3 9x10-12 
Notes: The experiments presented here are a subset of the experiments conducted. For a 




In the zebrafish, APP exists as two co-orthologs, appa and appb [8], whereas in humans and mice 
there is only a single APP gene. We therefore analysed our predicted Aβ-42-like peptides for both 
zebrafish Appa and Appb, along with human and mouse Aβ-42, using the TANGO software under 
varying conditions. TANGO allows for input variations in pH, temperature, ionic strength and 
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concentration. Each of these parameters have been shown to affect protein folding or misfolding 
[20] and, therefore, their effect on these processes has been accounted for in TANGO’s algorithm. 
The Aβ-42 peptides were each run through the TANGO software program using conditions laid 
out in Table 5.1. pH, ionic strength and concentration values for human and zebrafish were 
identified from the literature. For human pH conditions, we wished to use the pH of the brain as 
this is where the Aβ-42 peptide’s function in fAD is predominantly studied. Orlowski et al (2011) 
stated the pH of human brain to be 7.2, hence we used this value in our analyses [21]. The in vivo 
pH for the brain ventricle of 5-day-old zebrafish larvae has previously been reported as ~7.0-7.44, 
hence we compared both the upper and lower limit of this range in our analysis [22]. For the 
temperature settings, we used values known to represent the standard in vivo temperature for 
humans (310.15K, 37°C) and zebrafish (298.15K, 25°C). The concentration value was derived 
from a study by Wang et al (1999), that measured Aβ-42 levels in pathological aging brain at 9 
pmol/g wet tissue [23]. Animals maintain an intracellular ionic strength of 200-300 nM, therefore, 
we used the upper and lower limits of these values in our analyses [24]. The specific combinations 
of conditions presented in Table 5.1 were selected since we wanted to understand: a) whether each 
peptide would aggregate (and if these values would differ) with zebrafish or human-specific 
temperatures and pH, and b) whether the aggregation propensity would change with differing 






Figure 5.2. TANGO predictions of the aggregation propensity of Aβ-42 peptides for human, mouse, 
zebrafish Appa and zebrafish Appb under each set of experimental conditions (presented in Table 5.1). 
The blue line indicating aggregation propensity of human Aβ-42 is obscured by the mouse Aβ-42 line 
(orange) as they have highly similar values. Both human and mouse Aβ-42 lines are obscured in most 
sections by the zebrafish Appb line (green). Numbers corresponding to positions of the amino acid residues 
in each Aβ-42 peptide are on the x-axis. 
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During our analyses of the four Aβ-42 peptides using TANGO, we observed two regions of high 
β-aggregation propensity in each (Figure 5.2). As with the Aβ-40 and Aβ-42 study described 
above, the first region encompassed residues 17-21, and the second residues 30-41 for the Aβ-42 
peptides of human APP, mouse APP and zebrafish Appb. For the shorter, zebrafish Appa Aβ-42-
like peptide, the first region was comprised of residues 14-18, while the second region was 
composed of residues 27-38. Interestingly, while the Aβ-42 peptides of human, mouse and 
zebrafish Appa all returned highly similar β-aggregation scores in the mid-peptide region, the Aβ-
42 peptide of zebrafish Appb returned distinctly lower scores in this region for all experimental 
conditions tested. Despite this, all four peptides returned highly similar scores in the C-terminal 
region across all conditions investigated. Finally, each of the peptides run through the varying 
conditions gave what the TANGO authors term an “Agg” score. Agg is a parameter indicating β-
sheet aggregation propensity of the whole peptide being analysed, rather than at each section of 5 
amino acids [20]. For each of the conditions tested, the Aβ-42-like peptide of zebrafish Appb had 
a lower Agg score than that of human, mouse or zebrafish Appa Aβ-42 equivalents (supplementary 
data file S1, Table S8). Taken together, the results of our TANGO analysis suggest that, while 
zebrafish Appa is three amino acids shorter than the human or mouse Aβ-42 peptide, it has a much 
more similar β-aggregation propensity than that of zebrafish Appb. 
 
Investigating amyloidogenic propensity of zebrafish Aβ-40 and Aβ-42 using Zyggregator 
To confirm the observations made using the TANGO software, we decided to utilise a similar 
aggregation predicting software, Zyggregator [1]. While TANGO predicts the β-aggregation 
propensity of peptides, Zyggregator calculates a Ziagg score at each position of the peptide sequence 
from each specific amino acid’s physio-chemical properties. This can be otherwise described as a 
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prediction of the most important peptide sequence regions for promotion of aggregation and 
amyloid fibril formation [25]. The three physio-chemical properties Zyggregator calculates as a 
part of its algorithm are: hydrophobicity, charge, and the propensity to adopt α-helical or β-sheet 
structures [1]. Importantly, if a Ziagg score of 0 is recorded this suggests that the aggregation 
propensity at that position equals that of a random sequence (i.e. not likely to aggregate), whereas, 
if a score of 1 is recorded it is considered aggregation prone. 
 
Tartaglia and Vendruscolo (2008) previously used their Zyggregator algorithm to predict the 
aggregation propensity of the human Aβ-42 peptide [1]. Similar to what was observed using the 
TANGO algorithm, Zyggregator revealed two regions with a high propensity to aggregate 
(identified by Ziagg values of >1, Figure 5.3). Also like the TANGO study, one region was identified 
in the middle of the peptide between residues 18-22 and another at the C-terminal end of the 
peptide between residues 32-42. Our analysis of human Aβ-42 using the Zyggregator algorithm 
complemented the Tartaglia and Vendruscolo study. We also analysed mouse Aβ-42 and the 
predicted Aβ-42-like peptides for zebrafish Appa and Appb. While the zebrafish Appa Aβ-42-like 
peptide is shorter than the others, the Ziagg profile of this peptide closely resembled that of human 
Aβ-42, with two regions identified: one at position 15-19 and the other at position 29-39 (Figure 
5.3). Worthy of note is that the mouse Aβ-42 Ziagg profile is less similar to the human Aβ-42 profile 
than zebrafish Appa, with an additional aggregation prone residue close to the N-terminus (which 
is not represented in any other profile) and a slight shift in the positions of amino acid residues 
with high aggregation propensity in the mid peptide region (Figure 5.3). As was previously 
observed for the zebrafish Appb Aβ-42 peptide using the TANGO algorithm, its Ziagg profile 




Figure 5.3. Aggregation propensity profiles of human, mouse, zebrafish Appa and zebrafish Appb Aβ-
42 equivalent peptides. Vertical lines show the intrinsic aggregation propensity profile, Ziagg. The horizontal 
dashed line indicates the threshold which the Ziagg score must reach for the amino acid residue at that 
position to be considered to have high aggregation propensity. 
 
Investigating amyloidogenic propensity of zebrafish Aβ-40 and Aβ-42 using Zipper DB 
While the previously discussed algorithms, TANGO and Zyggregator, both rely purely on 
sequence-based information to calculate aggregation/fibril formation potential, Zipper DB utilises 
structural information to assess the possibility that a peptide will form fibrils. The Zipper DB 
algorithm focuses on the factors that permit a protein to convert to the amyloid state, by attempting 
to identify “steric zipper” forming segments [25]. In a study investigating their newly developed 
method, Goldschmidt et al (2009) validated their approach using pancreatic ribonuclease A 
(RNase A) as a model system [25]. The Zipper DB algorithm measures fibril formation potential 
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based on the RosettaDesign potential energy function, with low Rosetta energy numbers indicating 
high fibril forming propensity. 
 
The authors established what they termed an “energetic threshold for high fibrillation propensity” 
(HP), where high fibrillisation potential is predicted for Rosetta energies of less than -23 kcal/mol. 
In our study, we used Zipper DB to assess the amyloid fibril forming propensity of human and 
mouse Aβ-42 along with our predicted Aβ-42-like peptides in zebrafish Appa and Appb. The 
Rosetta energies predicted for hexapeptides in each of these peptide sequences are presented in 
supplementary data file S3, Table S10. 
 
Zipper DB analysis of the predicted zebrafish Appa and Appb Aβ-42 peptide equivalents revealed 
fibrillisation propensity profiles similar to the established aggregation prone human Aβ-42 peptide. 
Once again, Zipper DB identified two regions that appear to have high aggregation propensity, as 
was observed for TANGO and Zyggregator. For human, mouse and zebrafish Appa Aβ-42 
sequences, the regions that are predicted to have high fibrillation propensity are mostly at the C-
terminus of the peptide (hexapeptides 27-31, 33 and 35-37 for human and mouse, and hexapeptide 
24-28, 30 and 32-34 for zebrafish Appa). Complementary to our findings from the analyses with 
TANGO and Zyggregator, the profile for the zebrafish Appa Aβ-42-like peptide most closely 
resembled that of human Aβ-42, even though its shorter length of 39 amino acids resulted in less 
hexapeptides analysed in this region. Also complementary to our previous two analyses, while the 
fibrillisation propensity profile of zebrafish Appb resembles human Aβ-42 at the 25th-37th 
hexapeptide positions, it lacks the aggregation prone hexapeptide that exists at position 15 in 
human and mouse profiles and position 12 in zebrafish Appa (Figure 5.4, Table S10). This 
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difference in its fibrillisation propensity profile may suggest that the zebrafish Appb Aβ-42-like 
peptide is less likely to aggregate. Interestingly, a separate analysis of the human APP Aβ-40 
peptide with Zipper Db revealed a similar fibrillisation propensity to human, mouse and zebrafish 
Appa Aβ-42 in the mid-peptide (15th hexapeptide). However, due to it being two peptides shorter 
at the C-terminal end, it is missing the hexapeptides with high aggregation propensity at positions 
36 and 37 (supplementary data file S4, Figure S1). Also worth noting is that, while there are several 
hexapeptides that are close to reaching the -23 kcal/mol threshold in the N-terminal region of both 
the human Aβ-42 peptide and zebrafish Appa Aβ-42-like peptide, the mouse Aβ-42 peptide 
hexapeptides have much higher energies in this region (and thus have less aggregation potential). 
 
 
Figure 5.4. Zipper DB fibrillation propensity profiles of Aβ-42 peptide regions. – A) human Aβ-42 peptide, 
B) mouse Aβ-42 peptide, C) zebrafish Appa predicted Aβ-42 peptide and D) zebrafish Appb predicted Aβ-
42 peptide. Red histogram bars correspond to hexapeptides with energy < −23 kcal mol and are predicted 
to form fibrils. 
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5.3 Conclusions and future directions 
In this study, we have predicted the Aβ-42-like peptides for the zebrafish co-orthologs, Appa and 
Appb. We performed aggregation analyses of these peptides using several software programs, 
namely; TANGO, Zyggregator and Zipper DB. Our analyses demonstrate that the zebrafish Appa 
Aβ-42 equivalent has a very similar aggregation propensity to that of the known aggregation-prone 
human Aβ-42 peptide. Interestingly, while the zebrafish Appb Aβ-42 equivalent peptide was 
observed to have comparable aggregation potential at its C-terminal end, each of the analyses 
suggested that the middle of this peptide did not have the same aggregation propensity as that of 
human and mouse Aβ-42, or the predicted Appa zebrafish Aβ-42-like peptide. In our TANGO 
analysis, this mid-peptide region had a much lower β-aggregation score, suggesting it was less 
likely to aggregate, whereas the analyses with Zyggregator and Zipper DB showed no aggregation 
propensity in this region. Although a region of high aggregation propensity appears to be missing 
in the zebrafish Appb Aβ-42-like peptide, it is still possible that it may form similar aggregates to 
the human Aβ-42 peptide. Further testing using in vitro analyses could confirm this. Another 
interesting observation from the Zipper DB analysis is that of the high fibrillisation propensity 
profile for human Aβ-40, similar to that of human Aβ-42, with the exception of the final two amino 
acid residues. Human Aβ-40 has long been thought to be less aggregation prone than the longer 
Aβ-42 variant, although more recent studies have demonstrated that Aβ-40 fibrils have common 
structural principles to Aβ-42 fibrils [6]. However, numerous other studies have demonstrated that 
the difference in the C-terminal regions of Aβ-40 or Aβ-42 results in variable aggregation 
mechanisms, suggesting that this C-terminal region is important in the dimer formation process of 
aggregation [26]. Considering this, we can speculate that perhaps the mid-peptide region, which is 
conserved between human Aβ-42, mouse Aβ-42 and Appa Aβ-42-like peptides, also has some 
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important (currently unknown) role to play in the aggregation process, making it possible that the 
Aβ-42-like peptide of Appb would not aggregate in the same way as the other Aβ-42 peptides. It 
is also worth noting that, while our TANGO analyses were performed using ionic strength values 
reflecting the zebrafish intracellular environment (200-300nM), peptide aggregation can also occur 
in the extracellular space where ionic strengths are typically in the mM range [27, 28]. In future, 
additional TANGO analyses could be conducted utilising ionic strength values representative of 
the extracellular environment. This should allow us to determine whether the aggregation 
propensities of these peptides in extracellular conditions remain consistent with the results of our 
analyses. The TANGO analysis could also potentially be improved by utilising a scrambled Aβ-
42 peptide sequence to investigate whether random peptides with equivalent sequence composition 
are equally as aggregation prone. 
 
Another interesting observation from our analysis was the differences between Mouse Aβ-42 
profiles and human Aβ-42 profiles in the early-mid peptide region for both the Zyggregator and 
Zipper DB software analyses. Interestingly, zebrafish Appa Aβ-42-like peptide profiles were 
actually more similar to human Aβ-42 profiles than those of mouse Aβ-42. This is consistent with 
existing observations in vitro and in vivo, that mouse Aβ does not have as high an aggregation 
propensity as human Aβ, nor do mouse brains form Amyloid plaques [29, 30]. Interestingly, the 
altered aggregation propensity of mouse Aβ has previously been attributed to the three amino 
residues that differ in the mouse peptide (5, 10, and 13) (Figure 5.1) and the involvement of these 
residues in binding of metal ions [31]. When comparing these residues to those of the equivalent 
residues in the zebrafish Appa and Appb Aβ-42-like peptides, zebrafish Appa Aβ-42-like peptide 
shows no conservation with the equivalent human or mouse residues, while zebrafish Appb Aβ-
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42-like peptide is conserved with human Aβ-42 at residues 5 and 10, but not 13 (it is instead 
conserved with mouse Aβ-42 at this position) (Figure 5.1). What does this mean regarding the 
aggregation propensities of these two putative zebrafish peptides? Further investigation of both 
zebrafish Aβ-42-like peptides is likely needed to address this observation. It is also worth noting 
that other studies have reported that residues 6 and 13 are most important for binding metal ions 
[32]. If these alternative studies are correct, and mouse Aβ-42 shares the same residue at position 
6 as human Aβ-42, does this suggest that the residue at position 13 alone is critical for aggregation 
propensity? Further research is needed to address this question, although, if this is in fact the case 
then all three of mouse Aβ-42, zebrafish Appa Aβ-42-like and zebrafish Appb Aβ-42-like are not 
conserved at this residue, which may suggest that none of these peptides have the same aggregation 
propensity as the human Aβ-42 peptide. 
 
Although human Aβ-40 also forms fibrils, these aggregates are considerably less toxic in AD. It 
follows that the toxicity of both zebrafish Aβ-42-like peptides should also be analysed. Regarding 
the observation by Moore et al (2014) of a lack of conservation in the putative β-secretase cleavage 
sites of zebrafish Appa and Appb and what this might mean for production of Aβ from these 
proteins, a study in our laboratory is currently investigating this using tagged forms of Appa and 
Appb. To confirm the observations made in this study, the Aβ-42 equivalent peptides that we have 
predicted for zebrafish Appa and Appb should be produced and used in in vitro aggregations 
studies. Future work should also include further investigation of these peptides in vivo. In order to 
confirm the existence of endogenous Aβ in the zebrafish brain, immunoprecipitation of Aβ peptide 
from the zebrafish brain should be attempted using existing Aβ antibodies. Zebrafish whole brain 
lysates could be incubated with the well documented 4G8 antibody. Aβ peptides could then be 
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sequestered from the lysates using protein A sepharose (or protein G sepharose) beads. The 
purified Aβ peptides would then be examined by western immunoblot. If these peptides could be 
isolated successfully from the zebrafish brain, we could investigate further the effects of our fAD-
like mutation model zebrafish on Aβ aggregation. 
 
5.4 Methods 
Protein sequence alignments 
Alignments were conducted using the Geneious software suite, version 5.6.7 
(http://www.geneious.com, [29]) Alignments were performed with the following constraints; Cost 
matrix: Identity, Gap open penalty: 10, Gap extension penalty: 3, Alignment: Global. 
 
Predicting β-aggregation propensity with TANGO 
The β-aggregation propensities of human and mouse Aβ-42, along with our predicted Aβ-42 
peptides for zebrafish Appa and Appb (Figure 5.1), were assessed with TANGO [20] using pH, 
temperature, ionic strength and concentration conditions presented in Table 5.1 and default 
parameters for Nterm and Cterm.  
 
Predicting amyloidogenic regions with other software 
The amino acid sequences of human and mouse Aβ-42, along with our predicted Aβ-42 peptides 
for zebrafish Appa and Appb were entered into the input windows of Zyggregator [1] and Zipper 
DB [25] to predict aggregation-prone regions of these peptides. When using Zyggregator, the pH 
was set to 7 as the input only allows for whole numbers and 7 is the closest to the pH of human 
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5.6 Supplementary information 
This section is included in the thesis as information supplementary to Chapter 5. It contains 
additional information not included in the main text of the manuscript. 
 
File S1. Supplementary tables for TANGO analyses 
Table S1. Combinations of physio-chemical conditions input into TANGO software 
 Highlighted cells indicate experiments not included in the final analysis. 
Experiment pH Temperature (K) Ionic Strength Concentration 
1 7.2 310.15 0.3 9x10-12 
2 7 298.15 0.3 9x10-12 
3 7.2 298.15 0.3 9x10-12 
4 7 310.15 0.3 9x10-12 
5 7.2 310.15 0.2 9x10-12 
6 7 298.15 0.2 9x10-12 
7 7.2 298.15 0.2 9x10-12 
8 7 310.15 0.2 9x10-12 
9 7.44 298.15 0.2 9x10-12 
10 7.44 298.15 0.3 9x10-12 
11 7.44 310.15 0.2 9x10-12 






Table S2. Experiment 1 - β-aggregation (β-agg) values at each amino acid residue position of 
the Aβ-42 peptides as generated by the TANGO software 










1 D 0 D 0 E 0 D 0 
2 A 0 A 0 A 0 I 0 
3 E 0 E 0 E 0 E 0 
4 F 0 F 0 E 0 E 0 
5 R 0 G 0 R 0 R 0 
6 H 0 H 0 H 0 H 0 
7 D 0 D 0 S 0 N 0 
8 S 0 S 0 E 0 A 0 
9 G 0 G 0 V 0 G 0 
10 Y 0 F 0 Y 0 Y 0 
11 E 0 E 0 H 0 D 0 
12 V 0 V 0 Q 0 V 0 
13 H 0 R 0 K 0 R 0 
14 H 0 H 0 L 77.261 D 0 
15 Q 0 Q 0 V 77.261 K 0 
16 K 0 K 0 F 77.261 R 0 
17 L 77.204 L 77.157 F 77.261 L 31.515 
18 V 77.204 V 77.157 A 77.261 M 31.515 
19 F 77.204 F 77.157 E 0 F 31.515 
20 F 77.204 F 77.157 D 0 L 31.515 
21 A 77.204 A 77.157 V 0 A 31.515 
22 E 0 E 0 S 0 E 0 
23 D 0 D 0 S 0 D 0 
24 V 0 V 0 N 0 M 0 
25 G 0 G 0 K 0 G 0 
26 S 0 S 0 G 5.481 S 0 
27 N 0 N 0 A 66.588 N 0 
28 K 0 K 0 I 89.595 K 0 
29 G 5.482 G 5.481 I 91.842 G 5.500 
30 A 66.644 A 66.630 G 92.047 A 66.782 
31 I 89.623 I 89.607 L 94.336 I 89.776 
32 I 91.867 I 91.852 M 94.731 I 92.020 
33 G 92.072 G 92.057 V 94.988 G 92.225 
34 L 94.360 L 94.345 G 92.814 L 94.509 
35 M 94.755 M 94.741 G 92.620 M 94.903 
36 V 95.012 V 94.998 V 92.609 V 95.159 
37 G 92.836 G 92.821 V 92.397 G 92.990 
38 G 92.642 G 92.627 I 88.996 G 92.796 
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39 V 92.631 V 92.615 A 0 V 92.785 
40 V 92.420 V 92.404   V 92.574 
41 I 89.016 I 89.001   I 89.168 
42 A 0 A 0   A 0 
 
 
Table S3. Experiment 2 - β-aggregation (β-agg) values at each amino acid residue position of 
the Aβ-42 peptides as generated by the TANGO software 










1 D 0 D 0 E 0 D 0 
2 A 0 A 0 A 0 I 0 
3 E 0 E 0 E 0 E 0 
4 F 0 F 0 E 0 E 0 
5 R 0 G 0 R 0 R 0 
6 H 0 H 0 H 0 H 0 
7 D 0 D 0 S 0 N 0 
8 S 0 S 0 E 0 A 0 
9 G 0 G 0 V 0 G 0 
10 Y 0 F 0 Y 0 Y 0 
11 E 0 E 0 H 0 D 0 
12 V 0 V 0 Q 0 V 0 
13 H 0 R 0 K 0.042 R 0 
14 H 0 H 0 L 86.290 D 0 
15 Q 0 Q 0 V 86.290 K 0 
16 K 0.042 K 0.042 F 86.290 R 0 
17 L 86.238 L 86.191 F 86.290 L 47.333 
18 V 86.238 V 86.191 A 86.290 M 47.333 
19 F 86.238 F 86.191 E 0.042 F 47.333 
20 F 86.238 F 86.191 D 0 L 47.333 
21 A 86.238 A 86.191 V 0 A 47.333 
22 E 0.042 E 0.042 S 0 E 0 
23 D 0 D 0 S 0 D 0 
24 V 0 V 0 N 0 M 0 
25 G 0 G 0 K 0 G 0 
26 S 0 S 0 G 5.728 S 0 
27 N 0 N 0 A 69.168 N 0 
28 K 0 K 0 I 93.371 K 0 
29 G 5.729 G 5.727 I 95.463 G 5.740 
30 A 69.212 A 69.202 G 95.635 A 69.278 
31 I 93.388 I 93.378 L 97.541 I 93.449 
32 I 95.478 I 95.469 M 97.832 I 95.537 
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33 G 95.649 G 95.640 V 97.957 G 95.708 
34 L 97.555 L 97.547 G 96.138 L 97.609 
35 M 97.846 M 97.837 G 95.971 M 97.899 
36 V 97.970 V 97.962 V 95.958 V 98.023 
37 G 96.150 G 96.141 V 95.766 G 96.209 
38 G 95.984 G 95.974 I 92.544 G 96.043 
39 V 95.970 V 95.961 A 0.010 V 96.030 
40 V 95.779 V 95.769   V 95.838 
41 I 92.555 I 92.545   I 92.616 
42 A 0.010 A 0.010   A 0.010 
 
 
Table S4. Experiment 5 - β-aggregation (β-agg) values at each amino acid residue position of 
the Aβ-42 peptides as generated by the TANGO software 










1 D 0 D 0 E 0 D 0 
2 A 0 A 0 A 0 I 0 
3 E 0 E 0 E 0 E 0 
4 F 0 F 0 E 0 E 0 
5 R 0 G 0 R 0 R 0 
6 H 0 H 0 H 0 H 0 
7 D 0 D 0 S 0 N 0 
8 S 0 S 0 E 0 A 0 
9 G 0 G 0 V 0 G 0 
10 Y 0 F 0 Y 0 Y 0 
11 E 0 E 0 H 0 D 0 
12 V 0 V 0 Q 0 V 0 
13 H 0 R 0 K 0.043 R 0 
14 H 0 H 0 L 77.436 D 0 
15 Q 0 Q 0 V 77.436 K 0 
16 K 0.043 K 0.043 F 77.436 R 0 
17 L 77.376 L 77.321 F 77.436 L 36.469 
18 V 77.376 V 77.321 A 77.436 M 36.469 
19 F 77.376 F 77.321 E 0.043 F 36.469 
20 F 77.376 F 77.321 D 0 L 36.469 
21 A 77.376 A 77.321 V 0 A 36.469 
22 E 0.043 E 0.043 S 0 E 0 
23 D 0 D 0 S 0 D 0 
24 V 0 V 0 N 0 M 0 
25 G 0 G 0 K 0 G 0 
26 S 0 S 0 G 5.81 S 0 
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27 N 0 N 0 A 70.513 N 0 
28 K 0 K 0 I 90.602 K 0 
29 G 5.811 G 5.809 I 92.562 G 5.831 
30 A 70.57 A 70.554 G 92.733 A 70.724 
31 I 90.629 I 90.612 L 94.714 I 90.793 
32 I 92.586 I 92.569 M 95.055 I 92.749 
33 G 92.757 G 92.74 V 95.266 G 92.926 
34 L 94.737 L 94.72 G 93.244 L 94.901 
35 M 95.079 M 95.062 G 93.064 M 95.242 
36 V 95.289 V 95.273 V 93.053 V 95.452 
37 G 93.266 G 93.249 V 92.856 G 93.436 
38 G 93.085 G 93.068 I 89.445 G 93.256 
39 V 93.074 V 93.057 A 0 V 93.245 
40 V 92.877 V 92.86   V 93.048 
41 I 89.464 I 89.447   I 89.627 
42 A 0 A 0   A 0 
 
 
Table S5. Experiment 6 - β-aggregation (β-agg) values at each amino acid residue position of 
the Aβ-42 peptides as generated by the TANGO software 










1 D 0 D 0 E 0 D 0 
2 A 0 A 0 A 0 I 0 
3 E 0 E 0 E 0 E 0 
4 F 0 F 0 E 0 E 0 
5 R 0 G 0 R 0 R 0 
6 H 0 H 0 H 0 H 0 
7 D 0 D 0 S 0 N 0 
8 S 0 S 0 E 0 A 0 
9 G 0 G 0 V 0 G 0 
10 Y 0 F 0 Y 0 Y 0 
11 E 0 E 0 H 0 D 0 
12 V 0 V 0 Q 0 V 0 
13 H 0 R 0 K 0.056 R 0 
14 H 0 H 0 L 86.411 D 0 
15 Q 0 Q 0 V 86.411 K 0 
16 K 0.056 K 0.056 F 86.411 R 0 
17 L 86.357 L 86.302 F 86.411 L 52.898 
18 V 86.357 V 86.302 A 86.411 M 52.898 
19 F 86.357 F 86.302 E 0.056 F 52.898 
20 F 86.357 F 86.302 D 0 L 52.898 
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21 A 86.357 A 86.302 V 0 A 52.898 
22 E 0.056 E 0.056 S 0 E 0 
23 D 0 D 0 S 0 D 0 
24 V 0 V 0 N 0 M 0 
25 G 0 G 0 K 0 G 0 
26 S 0 S 0 G 6.052 S 0 
27 N 0 N 0 A 73.051 N 0 
28 K 0 K 0 I 94.114 K 0 
29 G 6.053 G 6.051 I 95.934 G 6.066 
30 A 73.097 A 73.085 G 96.082 A 73.172 
31 I 94.131 I 94.12 L 97.729 I 94.198 
32 I 95.948 I 95.938 M 97.98 I 96.012 
33 G 96.096 G 96.086 V 98.079 G 96.16 
34 L 97.743 L 97.733 G 96.393 L 97.802 
35 M 97.993 M 97.984 G 96.239 M 98.052 
36 V 98.092 V 98.083 V 96.226 V 98.15 
37 G 96.405 G 96.395 V 96.048 G 96.47 
38 G 96.251 G 96.241 I 92.818 G 96.317 
39 V 96.238 V 96.228 A 0.002 V 96.304 
40 V 96.061 V 96.05   V 96.127 
41 I 92.829 I 92.818   I 92.896 
42 A 0.002 A 0.002   A 0.002 
 
 
Table S6. Experiment 9 - β-aggregation (β-agg) values at each amino acid residue position of 
the Aβ-42 peptides as generated by the TANGO software 










1 D 0 D 0 E 0 D 0 
2 A 0 A 0 A 0 I 0 
3 E 0 E 0 E 0 E 0 
4 F 0 F 0 E 0 E 0 
5 R 0 G 0 R 0 R 0 
6 H 0 H 0 H 0 H 0 
7 D 0 D 0 S 0 N 0 
8 S 0 S 0 E 0 A 0 
9 G 0 G 0 V 0 G 0 
10 Y 0 F 0 Y 0 Y 0 
11 E 0 E 0 H 0 D 0 
12 V 0 V 0 Q 0 V 0 
13 H 0 R 0 K 0.047 R 0 
14 H 0 H 0 L 86.271 D 0 
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15 Q 0 Q 0 V 86.271 K 0 
16 K 0.047 K 0.047 F 86.271 R 0 
17 L 86.220 L 86.195 F 86.271 L 52.840 
18 V 86.220 V 86.195 A 86.271 M 52.840 
19 F 86.220 F 86.195 E 0.047 F 52.840 
20 F 86.220 F 86.195 D 0 L 52.840 
21 A 86.220 A 86.195 V 0 A 52.840 
22 E 0.047 E 0.047 S 0 E 0 
23 D 0 D 0 S 0 D 0 
24 V 0 V 0 N 0 M 0 
25 G 0 G 0 K 0 G 0 
26 S 0 S 0 G 6.048 S 0 
27 N 0 N 0 A 73.027 N 0 
28 K 0 K 0 I 94.092 K 0 
29 G 6.049 G 6.048 I 95.913 G 6.064 
30 A 73.071 A 73.066 G 96.061 A 73.160 
31 I 94.106 I 94.102 L 97.71 I 94.186 
32 I 95.925 I 95.920 M 97.961 I 96.001 
33 G 96.073 G 96.068 V 98.06 G 96.149 
34 L 97.721 L 97.717 G 96.371 L 97.792 
35 M 97.972 M 97.968 G 96.217 M 98.041 
36 V 98.071 V 98.067 V 96.204 V 98.140 
37 G 96.381 G 96.376 V 96.026 G 96.458 
38 G 96.227 G 96.222 I 92.795 G 96.305 
39 V 96.214 V 96.209 A 0.002 V 96.292 
40 V 96.036 V 96.031   V 96.115 
41 I 92.803 I 92.799   I 92.883 
42 A 0.002 A 0.002   A 0.002 
 
 
Table S7. Experiment 10 - β-aggregation (β-agg) values at each amino acid residue position 
of the Aβ-42 peptides as generated by the TANGO software 










1 D 0 D 0 E 0 D 0 
2 A 0 A 0 A 0 I 0 
3 E 0 E 0 E 0 E 0 
4 F 0 F 0 E 0 E 0 
5 R 0 G 0 R 0 R 0 
6 H 0 H 0 H 0 H 0 
7 D 0 D 0 S 0 N 0 
8 S 0 S 0 E 0 A 0 
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9 G 0 G 0 V 0 G 0 
10 Y 0 F 0 Y 0 Y 0 
11 E 0 E 0 H 0 D 0 
12 V 0 V 0 Q 0 V 0 
13 H 0 R 0 K 0.036 R 0 
14 H 0 H 0 L 86.167 D 0 
15 Q 0 Q 0 V 86.167 K 0 
16 K 0.036 K 0.036 F 86.167 R 0 
17 L 86.135 L 86.099 F 86.167 L 47.283 
18 V 86.135 V 86.099 A 86.167 M 47.283 
19 F 86.135 F 86.099 E 0.036 F 47.283 
20 F 86.135 F 86.099 D 0 L 47.283 
21 A 86.135 A 86.099 V 0 A 47.283 
22 E 0.036 E 0.036 S 0 E 0 
23 D 0 D 0 S 0 D 0 
24 V 0 V 0 N 0 M 0 
25 G 0 G 0 K 0 G 0 
26 S 0 S 0 G 5.724 S 0 
27 N 0 N 0 A 69.146 N 0 
28 K 0 K 0 I 93.351 K 0 
29 G 5.725 G 5.724 I 95.444 G 5.738 
30 A 69.189 A 69.184 G 95.616 A 69.268 
31 I 93.366 I 93.361 L 97.524 I 93.438 
32 I 95.457 I 95.453 M 97.815 I 95.526 
33 G 95.628 G 95.624 V 97.94 G 95.697 
34 L 97.536 L 97.532 G 96.118 L 97.6 
35 M 97.826 M 97.823 G 95.951 M 97.889 
36 V 97.951 V 97.948 V 95.938 V 98.014 
37 G 96.128 G 96.124 V 95.746 G 96.198 
38 G 95.962 G 95.958 I 92.524 G 96.032 
39 V 95.948 V 95.944 A 0.01 V 96.019 
40 V 95.756 V 95.752   V 95.827 
41 I 92.533 I 92.528   I 92.605 









Table S8. Agg scores for all TANGO experiments 
Experiment Human Mouse Zf Appa Zf Appb 
1 1475.38 1474.96 1475.35 1248.76 
2 1560.55 1560.20 1560.62 1366.66 
5 1486.19 1485.71 1486.18 1283.58 
6 1568.84 1568.44 1568.91 1402.22 
9 1567.84 1567.67 1567.93 1401.79 













File S2. Supplementary tables for Zyggregator analyses 
Table S9. Raw Zygg residue score data output from Zyggregator 

























1 D 0.0619504 D 0.06195 D -0.588424 E -1.29325 
2 A -0.437954 A 0.223669 I -1.11194 A -1.84235 
3 E -0.303041 E 0.205307 E -0.820887 E -1.38209 
4 F -0.494487 F 0.094332 E -0.964486 E -1.64632 
5 R -0.335666 G 0.253154 R -0.880837 R -1.64632 
6 H -0.16945 H 0.41937 H -1.04779 H -1.2646 
7 D 0.693793 D 1.38153 N -0.184546 S -0.401354 
8 S -0.268368 S 0.41937 A 0.163942 E 0.0878349 
9 G 0.564591 G 0.634872 G 0.996902 V 0.48241 
10 Y 0.564591 F 0.126579 Y 0.488608 Y 0.0939694 
11 E 0.705292 E 0.267279 D 0.329613 H 0.173497 
12 V 0.283972 V -0.1254 V -0.10356 Q 0.510175 
13 H -0.401329 R -0.8107 R -0.908714 K 0.658481 
14 H -0.490038 H -0.99833 D -0.997422 L 0.945095 
15 Q 0.323818 Q -0.18448 K -0.508714 V 1.26344 
16 K 0.284427 K -0.03617 R -0.548104 F 0.700269 
17 L 0.757399 L 0.945095 L 0.0578379 F 0.948009 
18 V 1.07574 V 1.26344 M 0.329183 A 1.17503 
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19 F 0.700269 F 0.887965 F 0.228435 E 1.05618 
20 F 0.948009 F 1.1357 L 0.596027 D 0.601327 
21 A 1.17503 A 1.36272 A 0.65869 V 0.146649 
22 E 1.14722 E 0.959523 E 0.419846 S -0.18474 
23 D 0.692369 D 0.504673 D -0.0350047 S 0.413613 
24 V 0.237692 V 0.237692 M 0.0733369 N 0.309566 
25 G -0.0936972 G -0.0937 G -0.445748 K 0.261015 
26 S 0.504656 S 0.504656 S 0.340301 G 0.51901 
27 N 0.400608 N 0.400608 N 0.236253 A 0.610052 
28 K 0.352058 K 0.352058 K 0.352058 I 0.689407 
29 G 0.51901 G 0.51901 G 0.51901 I 1.23816 
30 A 0.610052 A 0.610052 A 0.610052 G 1.64136 
31 I 0.689407 I 0.689407 I 0.689407 L 1.80757 
32 I 1.23816 I 1.23816 I 1.23816 M 1.64062 
33 G 1.64136 G 1.64136 G 1.64136 V 1.68917 
34 L 1.80757 L 1.80757 L 1.80757 G 1.90467 
35 M 1.64062 M 1.64062 M 1.64062 G 2.08314 
36 V 1.68917 V 1.68917 V 1.68917 V 1.86578 
37 G 1.90467 G 1.90467 G 1.90467 V 1.18629 
38 G 2.08314 G 2.08314 G 2.08314 I 1.38345 
39 V 1.86578 V 1.86578 V 1.86578 A 1.18111 
40 V 1.18629 V 1.18629 V 1.18629   
41 I 1.38345 I 1.38345 I 1.38345   




File S3. Supplementary tables for Zipper DB analyses 
Table S10. Rosetta energies (Re) of all possible hexapeptides within the Aβ-42 peptide regions 
of human APP, mouse APP and zebrafish Appa and Appb proteins. 
 Yellow highlight indicates positions that are likely to aggregate (based on Re < -23 
kcal/mol) 
 H.sapiens APP M.musculus APP D.rerio Appa D.rerio Appb 
Position Sequence Re Sequence Re Sequence Re Sequence Re 
1 DAEFRH -12.5 DAEFGH -14.7 EAEERH -14.4 DIEERH -16.3 
2 AEFRHD -17.5 AEFGHD -17.9 AEERHS -17.8 IEERHN -15.3 
3 EFRHDS -14.6 EFGHDS -17.4 EERHSE -16.8 EERHNA -19.8 
4 FRHDSG -15.5 FGHDSG -17.9 ERHSEV -17.7 ERHNAG -17.2 
5 RHDSGY -17 GHDSGF -19.2 RHSEVY -19.8 RHNAGY -18 
6 HDSGYE -19.9 HDSGFE -18.8 HSEVYH -22 HNAGYD -18.8 
7 DSGYEV -17.2 DSGFEV -14.4 SEVYHQ -21.9 NAGYDV -18.4 
8 SGYEVH -20.5 SGFEVR -17.5 EVYHQK -22.7 AGYDVR -15.5 
9 GYEVHH -22.2 GFEVRH -17.9 VYHQKL -21.3 GYDVRD -15.5 
10 YEVHHQ -21.1 FEVRHQ -19.4 YHQKLV -21.3 YDVRDK -14 
11 EVHHQK -21.6 EVRHQK -18.7 HQKLVF -22.6 DVRDKR -12.1 
12 VHHQKL -19.9 VRHQKL -16.5 QKLVFF -24 VRDKRL -12.9 
13 HHQKLV -21.1 RHQKLV -17.6 KLVFFA -22.2 RDKRLM -10.5 
14 HQKLVF -22.6 HQKLVF -22.6 LVFFAE -7.5 DKRLMF -18.7 
15 QKLVFF -24 QKLVFF -24 VFFAED -18.7 KRLMFL -18.4 
16 KLVFFA -22.2 KLVFFA -22.2 FFAEDV -19.3 RLMFLA -12.8 
17 LVFFAE -7.5 LVFFAE -7.5 FAEDVS -18.2 LMFLAE -21.4 
221 
 
18 VFFAED -18.7 VFFAED -18.7 AEDVSS -20.9 MFLAED -18.1 
19 FFAEDV -19.3 FFAEDV -19.3 EDVSSN -18.8 FLAEDM -19.3 
20 FAEDVG -18 FAEDVG -18 DVSSNK -21.2 LAEDMG -16.9 
21 AEDVGS -20.4 AEDVGS -20.4 VSSNKG -20.9 AEDMGS -18.6 
22 EDVGSN -17.9 EDVGSN -17.9 SSNKGA -22.3 EDMGSN -17.5 
23 DVGSNK -22 DVGSNK -22 SNKGAI -22.4 DMGSNK -20.6 
24 VGSNKG -19.9 VGSNKG -19.9 NKGAII -23.5 MGSNKG -21.3 
25 GSNKGA -22.3 GSNKGA -22.3 KGAIIG -23.3 GSNKGA -22.3 
26 SNKGAI -22.4 SNKGAI -22.4 GAIIGL -26 SNKGAI -22.4 
27 NKGAII -23.5 NKGAII -23.5 AIIGLM -25.7 NKGAII -23.5 
28 KGAIIG -23.3 KGAIIG -23.3 IIGLMV -23 KGAIIG -23.3 
29 GAIIGL -26 GAIIGL -26 IGLMVG -21.9 GAIIGL -26 
30 AIIGLM -25.7 AIIGLM -25.7 GLMVGG -23.1 AIIGLM -25.7 
31 IIGLMV -23 IIGLMV -23 LMVGGV -21.7 IIGLMV -23 
32 IGLMVG -21.9 IGLMVG -21.9 MVGGVV -23.4 IGLMVG -21.9 
33 GLMVGG -23.1 GLMVGG -23.1 VGGVVI -25.1 GLMVGG -23.1 
34 LMVGGV -21.7 LMVGGV -21.7 GGVVIA -27.8 LMVGGV -21.7 
35 MVGGVV -23.4 MVGGVV -23.4   MVGGVV -23.4 
36 VGGVVI -25.1 VGGVVI -25.1   VGGVVI -25.1 








File S4. Supplementary figures for Zipper DB analyses 
 
Figure S1. Zipper DB fibrillation propensity profile of human Aβ-40 peptide. – Red histogram bars 
correspond to hexapeptides (6 amino acid residues, starting from the residue directly above the bar and 
read C-terminally, i.e. the hexapeptide for the first red bar would be GAIIGL) with energy < −23 kcal mol 




Chapter 6 - Further Discussion, Conclusions and Future directions 
6.1 Introduction 
γ-secretase is an important protease complex as it is responsible for the cleavage of over 100 
substrates within their transmembrane domains [1, 2]. Although many substrates of γ-secretase are 
known, the specificity by which γ-secretase selects its substrates remains a mystery. γ-secretase 
plays a role in Alzheimer’s disease (AD) through its processing of APP to produce the aggregation-
prone Aβ peptide [3]. This sequential processing of APP that produces the Aβ peptide is considered 
a major pathological event in AD disease progression, as described by the amyloid cascade 
hypothesis [4]. Other than its role in AD disease, γ-secretase also has numerous roles in 
development and adulthood through regulating many cellular events, including axon guidance and 
formation, neurite outgrowth, cell fate determination and maintenance of synapses. Due to its 
involvement in this wide array of important physiological processes, defects in γ-secretase 
mediated signalling pathways can lead to numerous pathologies, such as: Neurodegeneration in 
AD, Acne inversa, Autoimmune disease, Breast cancer and Dilated cardiomyopathy [reviewed in 
5]. Thus, it is important to gain a better understanding of substrate selection by γ-secretase, to 
facilitate more efficient drug design that allows for targeting only the specific substrate involved 
in each disease. 
 
In this thesis we aimed to investigate γ-secretase and two of its substrates, p75NTR and APP, on 
three different fronts; 1) selection of substrates by γ-secretase using an assay-based system, 2) the 
molecular effects of fAD-like and null mutations in zebrafish appa and appb, by generating 
mutations in endogenous genes with genome editing technologies, and 3) the predicted aggregation 
propensity of Aβ-42-like peptides of Appa and Appb using predictive software. 
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6.2 How does γ-secretase select specific substrates? 
The amyloid cascade hypothesis continues to dominate the field of AD research, mostly due to the 
observation of plaques composed of oligomerised Aβ peptide in the brains of AD sufferers. γ-
secretase is a key component of this hypothesis, due to its processing of APP to release the Aβ 
peptide. The observation that γ-secretase-cleavage of APP results in the release of Aβ peptides, 
led many researchers to develop inhibitory drugs targeting this protease in the hopes of preventing 
Aβ aggregation into plaques [6]. Our current knowledge suggests that γ-secretase is responsible 
for cleaving more than 100 substrates (including APP and Notch), so it should come as no surprise 
that drugs designed to inhibit this protease cause severe side effects [7]. A better understanding of 
substrate selection by γ-secretase may assist in the design of drugs to target more specifically its 
processing of select substrates.  
 
As there is still no clear answer to the question of substrate selection by γ-secretase, we sought to 
investigate this using the known γ-secretase substrate, p75NTR, and its homolog NRH1. We 
leveraged the structural and sequence similarities (especially in the transmembrane domain 
(TMD)) of these two homologues to design an assay system with which we could attempt to 
elucidate structural determinants that enable p75NTR to be cleaved by γ-secretase while NRH1 is 
not. Our assay determined that the TMD of p75NTR alone was insufficient to confer γ-secretase 
cleavage to its homolog Nrh1. Therefore, we posited that there must be structures other than the 
TMD that are also required for cleavage by γ-secretase. Interestingly, another study employing a 
similar strategy to ours, found that γ-secretase cleavage of their substrate required both a 
permissive transmembrane and a permissive intracellular domain (ICD) [8]. Suggesting that the 
ICD is just as important as the TMD to confer γ-secretase cleavage. Furthermore, a study by Sykes 
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et al (2012) suggested that dimerisation of substrates or the structure of substrate α-helices may 
regulate γ-secretase cleavage [9]. While zebrafish Nrh1 has a different dimerisation domain to that 
of p75NTR, replacing the Nrh1 dimerisation domain by the swapping its TMD with the p75NTR 
TMD in our study, did not confer γ-secretase cleavage. This suggests that the p75NTR dimerisation 
domain alone is also not sufficient to confer γ-secretase cleavage.  
 
In Chapter 2 we discussed some options for investigating the question of which enzyme is 
responsible for cleavage of the TMD of Nrh1. We suggested that a range of protease inhibitors 
could be employed to identify the class of iCLIP responsible. Investigation into what causes the 
previously observed cleavage within the Nrh1 TMD could be further extended as follows: 
 
(1) Site directed mutagenesis could be used to alter Leucine (Figure 6.1) to Proline in the TMD of 
our existing Nrh1 assay construct, as this residue supposedly assists the TMD of p75 in 
changing confirmation from an α-helix to a β-sheet, thereby allowing γ-secretase access for 
proteolysis. The altered construct could then be injected into single cell embryos and DAPT 
inhibitor applied to assess whether cleavage by γ-secretase is conferred, thereby confirming 
whether this residue contributes to proteolysis through allowing relaxation of the α-helix into 
β-sheet for better access for γ-secretase. 
 
(2) Antisense morpholino oligonucleotides (MOs) could be used to block psen1 and psen2 
expression to confirm that Nrh1 cleavage is presenilin-independent. MOs are a type of 
oligomer molecule that can be injected into zebrafish embryos to block expression of proteins 
through binding to mRNAs [10]. Previous work in our laboratory has involved inhibition of 
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Psen1 and Psen2 translation with MOs that bind over the start codons of their mRNA 
transcripts. These existing MOs could be co-injected with the previously described Nrh1 assay 
construct at the 1-cell-stage and western immunoblot analysis could then be performed on 
embryos at 24hpf to determine the effect of presenilin inhibition.  
 
(3) Subcellular localisation of both NRH1 and p75NTR cleavage events could also be investigated. 
Combined evidence suggests the principal sites of γ-secretase cleavage to be endosomes, TGN 
and at the plasma membrane [reviewed in 3, 11], so it is reasonable to assume that p75NTR 
cleavage may occur in one or all of these compartments. However, the subcellular localisation 
of NRH1 and whichever enzyme is responsible for its proteolysis is more of a mystery. With 
a current lack of open source software that can accurately predict the subcellular localisation 
of proteins in the zebrafish, more traditional methods could be employed to investigate the 
location of p75NTR and Nrh1. Fluorescence microscopy might be employed by synthesising 
GFP labelled recombinant p75NTR and Nrh1 zebrafish proteins, injecting them at the 1-cell-
stage, and monitoring their localisation at different time points. Alternatively, subcellular 
fractionation followed by western immunoblotting with p75NTR- and Nrh1-specific antibodies 
could also be attempted. Knowledge of the respective subcellular cleavage locations of Nrh1 
and p75NTR may also assist in identifying the enzyme responsible for the non-γ-secretase 
cleavage event of Nrh1. 
 
(4) Another extension of this project could be a deeper investigation of the evolution of γ-secretase 
dependence or independence of proteins. Kanning et al (2003) proposed an evolutionary model 
for the existence of the p75NTR and NRH1 homologues [12]. Their hypothesis was that a gene 
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duplication event within a common ancestral sequence led to formation of the p75NTR and 
NRH1 sequences. NRH2 lacks the ECD motif observed in both p75NTR and NRH1, hence it 
may have arisen by a deletion mutation around the time that the avian and mammalian lineages 
diverged [12, 13]. Considering this, one can assume the existence of a common ancestral 
sequence encoding a protein either cleaved or not by γ-secretase and from which a γ-secretase 
dependence or independence evolved (Figure 6.2). Therefore, identification of a common 
ancestral sequence that gave rise to p75NTR and NRH1 through additional phylogenetic 
analyses would allow us to develop an assay specifically to test whether this ancestor is cleaved 
by γ-secretase. This could give us insight into whether p75NTR’s dependence on γ-secretase is 
a characteristic that has evolved recently. 
 
Understanding the basis for γ-secretase substrate selection is important for understanding disease 
processes, such as those involved in Alzheimer’s disease, and for rational drug design. A specific 
recognition and/or cleavage site for γ-secretase-mediated proteolysis has not yet been established. 
This makes designing drugs to prevent, specifically, proteolysis of APP and release of Amyloid 
beta particularly challenging and may contribute to the explanation of why so many drugs targeting 
this mechanism in attempts to alleviate and/or slow the progression of Alzheimer’s Disease 
symptoms have failed. We do not yet understand what makes a γ-secretase substrate unique for 
selection/targeting for proteolysis by this protease complex. As it stands there are many substrates 
of this protease with varied roles in cell biology which makes targeted drug design even more 
important as widespread disruption of these processes would be expected to have deleterious 
effects. The unique design of our assay system may allow us to gain a deeper understanding to the 
question of what structures define a γ-secretase substrate. Information gleaned from the 
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experiments proposed in the discussions above could be used to design new drugs that target 
specifically γ-secretase’s ability to cleave specific substrates. 
 
 
Figure 6.2 Suggested evolutionary development of p75NTR and NRH genes. The high degree of 
conservation between the sequences of p75NTR and NRH1 suggests that these two sequences arose via 
a gene duplication event in an ancestral sequence. As mammalian NRH2 lacks an extracellular domain 




6.3 What are the molecular effects of fAD-like and null mutations in zebrafish appa and 
appb? 
The overarching goal of the ADGL laboratory is to develop a catalogue of fAD-like mutations and 
null mutations in each of the fAD gene equivalents in zebrafish to identify the molecular changes-
in-common that contribute to AD pathology. One key question to be answered from this larger 
project is, what are the effects of APP fAD mutations on key molecular processes in the brain that 
eventually lead to AD? We originally aimed to generate several fAD-like mutations spanning the 
Aβ peptide region of human APP at equivalent residues in the zebrafish appa and appb genes, 
along with null mutations in both genes, to contribute to this larger project.  
 
In Chapter 3, we utilised current genome editing techniques and attempted to generate a suite of 
fAD-like and null mutations in appa and appb with limited success. While we were able to achieve 
double-stranded break generation with an sgRNA targeting a fAD mutation site in appa (Austrian 
mutation site) and one fAD mutation site in appb (Arctic mutation site), introduction of mutations 
of interest using engineering oligonucleotides was not achieved. We also discussed how future 
work should utilise recent developments in CRISPR technologies to successfully generate these 
fAD-like mutations in appa and appb.  
 
In Chapter 4, successful generation of a putative null mutation in zebrafish appb using an sgRNA 
that successfully generated a DSB near the start codon was described (appbR5PfsTer26) and 
preliminary analyses of the hypoxic response to this mutation performed. We observed no 
phenotype in our heterozygous appbR5PfsTer26 putative null mutants and proposed that this is 
possibly due to the phenomenon of “genetic compensation”.  
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Previous studies using MEFs have shown that the AICD induces Hif1a gene expression and HIF-
1α protein stability [14]. Along with this, hypoxic conditions have been shown to upregulate 
mRNA and protein expression of APP [15]. This may indicate a possible positive feedback loop, 
whereby increased production of APP under hypoxic conditions results in increased AICD release, 
which in turn results in an increased hypoxia response through increased Hif1a expression. 
Therefore, we proposed that loss of appb in our putative null mutant should have resulted in a 
reduction in the hypoxia response. 
 
APP is also connected to the hypoxia response through its involvement in cellular iron homeostasis 
[16]. Interestingly, both APP and its cleavage product, sAPPα, have been shown to bind 
FERROPORTIN 1 (FPN1) to improve the process by which neurons export excess iron (Fe2+). 
HIF is stabilised under hypoxia and degraded under normoxia. During normoxia, Fe2+ (together 
with oxygen and other factors) is needed to hydroxylate HIF1α to target it for degradation. In 
Chapter 4 we discussed how loss of the AICD from Appb in our putative null mutant would be 
expected to reduce the hypoxia response by potentially reducing expression of the Hif1a gene. As 
APP is also involved in the movement of Fe2+ out of the cytosol, we would expect that the cytosol 
of our appbR5PfsTer26 putative null mutants would accumulate excess Fe2+. This excess of available 
Fe2+ may result in increased destabilisation or degradation of HIF1α, thereby decreasing the 
hypoxia response. Therefore, we would also expect to observe decreased induction of HRG 
expression in hypoxia treated appbR5PfsTer26 putative null mutants compared to wildtype, due to 




Previous experiments in the ADGL measuring the hypoxic response of a fAD-like mutation in 
psen1, saw increased expression of HRGs in 6-month-old psen1 mutant brains under normoxia. 
PSEN1 plays an important role in the acidification of lysosomes through chaperoning a protein 
whose eventual role is lysosomal acidification [16]. Interestingly, fAD mutations in PSEN1 have 
previously been observed to decrease the acidity of lysosomes [17]. If lysosomes are not acidified 
(as may be the case in psen1 fAD-like mutants [18]) iron cannot be recycled from its ferric form 
(Fe3+) into its ferrous form (Fe2+) for release into the cytosol. A lack of cytosolic Fe2+ in psen1 
fAD-like mutants could explain the observed increase in HRG expression as HIF1α would not be 
degraded but stabilised to induce the expression of hypoxia response genes. If we crossed the 
existing psen1 fAD-like mutant with our appb putative null mutant we might expect this to 
alleviate the increased hypoxic response, as Appb would no longer be available to bind FPN1 to 
increase export of Fe2+ out of the cytosol of neurons. If we observed HRG expression levels in 
psen1 fAD-like/appbR5PfsTer26 mutants like that of wildtype fish, this would further confirm the 
critical roles of both Psen1 and Appb in the hypoxia response pathway through their involvement 
in iron homeostasis. 
 
There is also significant other work that could be performed to further explore the biological effects 
of our appbR5PfsTer26 putative null mutation, including: 
 
(1) In Chapter 4 we observed no obvious phenotype in either heterozygous or homozygous 
appbR5PfsTer26 mutants. Whereas, previous studies of appb in the zebrafish using morpholinos 
to knockdown gene function reported developmental phenotypes [19, 20]. We suggested that 
this discrepancy in phenotype is most likely due to the phenomenon of “genetic 
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compensation”. In order to confirm this assumption, primers detecting wildtype appa, aplp1 
and aplp2 could be designed and dqPCR performed to measure their transcript levels in 
heterozygous and homozygous appbR5PfsTer26 mutants. If one or all of these genes from the 
larger APP family are compensating for loss of appb in our mutants, we would expect to see 
increased expression of these transcripts. RNA sequencing of our appb null mutants could also 
be used to identify other genes that may be compensating for loss of appb. 
 
(2) INTERLEUKIN 1 (IL1) is a pro-inflammatory cytokine that stimulates APP translation, 
possibly so that it can participate in the inflammatory response by assisting in iron export from 
the cytosol [16]. This coupled with the observation that APP transcription is upregulated by 
oxidative stress (hypoxia), suggests that APP plays an important role in regulation of iron 
during these states of stress. If APP’s role in iron homeostasis and the hypoxic response is 
critical as we suspect, then we might also expect to observe increased transcription of appa in 
our appbR5PfsTer26 putative null mutants, as appa may compensate for loss of appb during 
hypoxic stress. This anticipated increase in appa transcription in our appbR5PfsTer26 putative null 
mutants could be measured in samples previously treated with hypoxia via dqPCR. 
 
 
(3) Transcriptomics allows for a detailed analysis of the molecular phenotype of cells or tissues. 
Previous work in our laboratory has analysed the transcriptome of zebrafish brains that carry 
fAD-like mutations in the psen1 gene [21]. Our current goal is to extend this approach to 
compare the molecular changes observed by transcriptomic analyses of fAD-like mutations in 
psen1, psen2, appa, appb and sorl1 and to exclude changes shared with null mutations in each 
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of these genes. Therefore, RNA sequencing (RNA-seq) should be performed on both normal 
zebrafish adult brains and adult zebrafish brains heterozygous for the appb null mutation, to 
allow comparison of their transcriptomes. RNA-seq would be performed on brains of 
heterozygous mutant zebrafish at 6-months-old and 24-months-old. This would be followed 
by gene interaction network analysis, gene ontology analysis, and promoter analysis to identify 
the time/sex/mutation-dependent changes in cell biology caused by the null mutation in appb. 
This would contribute to the identification of the signature molecular changes in AD by 
allowing us to exclude those molecular changes that are shared between fAD-like mutations 
and null mutation (Figure 6.2). 
 
 




Confirming that appbR5PfsTer26 is a true loss-of-function mutation as discussed in Chapter 4 is 
important, as this will allow us to compare the effects of appbR5PfsTer26 to fAD-like mutations in 
appa and appb generated in the future. Such comparisons may allow us to identify whether fAD-
like mutations in appa and appb are gain- or loss-of-function. Our appbR5PfsTer26 putative null 
mutant may also prove useful in gaining new insights into the function of Appb in the zebrafish, 
and perhaps APP in general, as we could use this mutant to further investigate the molecular 
pathways/mechanisms that are affected by loss of Appb in the zebrafish. The transcriptomic 
analyses of appbR5PfsTer26 suggested above should allow for exclusion of the non-fAD-causative 
effects caused by loss of Appb, thereby allowing us to discover the changes in future fAD-like 
mutants that are unique to those mutations. Finally, the latest techniques in genome editing, as 
discussed in Chapter 3, have significantly improved our ability to generate specific mutations into 
the zebrafish genome. Thus, it is highly feasible for the suggested future work discussed both here 
and in Chapter 4 to be completed. 
 
6.4 Do the Aβ-42-equivalent peptides that would be generated from zebrafish Appa and 
Appb have the same aggregation propensity as human Aβ-42? 
One of the key concepts that has persisted in the field of AD research is that the Aβ-42 peptide 
produced by sequential processing of APP is neurotoxic. This is mostly due to the observations 
that 1) mutations causing fAD are mostly in genes that are important for amyloid production, 2) 
many fAD mutations in APP increase production of Aβ-42 over the more soluble Aβ-40 variant 
and 3) senile/neuritic plaques (one of the histological hallmarks of AD) containf aggregated Aβ-
42 fibrils. There are currently no studies that have investigated the aggregation of endogenous Aβ-
42-equivalent peptides that would be generated by the same processing of Appa or Appb in the 
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zebrafish. We therefore performed analyses using a range of software to investigate the possible 
aggregation properties of theoretical Aβ-42-like peptides for both Appa and Appb. We observed 
extremely similar aggregation propensity in the C-terminal regions of both Aβ-42-like peptides of 
Appa and Appb. Interestingly, the Aβ-42-like peptide of Appb did not have the same level of 
aggregation propensity in its mid-peptide region as was observed for human, mouse and Appa. It 
is therefore possible that the Aβ-42-like peptide of Appb does not aggregate in the same way that 
is observed for human Aβ-42. Furthermore, we also observed some minor differences in the N-
terminal and mid-peptide regions of mouse Aβ-42 in both the Zyggregator and Zipper DB 
analyses. In Chapter 5 we discussed how this is consistent with studies that have observed lower 
aggregation propensity for mouse Aβ compared to human Aβ both in vitro and in vivo [22, 23]. 
 
Some further questions to address regarding the Aβ-42-like peptides of Appa and Appb would be;  
 
(1) Do the Aβ-42-like peptides of Appa and Appb aggregate in vitro?  
To address this, overexpression constructs harbouring the putative zebrafish Appa and Appb 
Aβ-40-like and Aβ-42-like peptides could be designed and synthesised. These constructs could 
then be transfected into cells, where each respective peptide would be overexpressed, and its 
aggregation propensity then measured in vitro. We could also potentially utilise this system to 
observe toxicity of the Aβ-42-like peptides of Appa and Appb. 
 
(2) Are zebrafish-specific Aβ peptides generated from Appa and Appb in vivo?  
A current Honours project in the ADGL has included the design of DNA constructs that encode 
Appa and Appb, human APP and BACE1 that will be used to determine if BACE1 cleaves 
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zebrafish Apps. The constructs will be injected into zebrafish embryos at the single cell stage 
and protein will be collected from these embryos at 24hpf to investigate whether β-CTF-
equivalent peptides are produced. The results of this study should allow us to answer the 
question of whether zebrafish Appa And Appb produce peptides that resemble Aβ since we 
know that Appa and Appb can be cleaved by γ-secretase [24].  
 
Confirmation of whether Aβ is produced from zebrafish Appa and Appb and whether these 
peptides have aggregation potential and/or toxicity similar to that of human Aβ will be important 
for future analyses of our fAD-like mutants of each of the fAD genes (psen1, psen2, appa, appb 
and sorl1). If Aβ equivalent peptides are not found to be produced from zebrafish Appa and Appb, 
this would suggest that the molecular changes we observe in our fAD-like mutants are occurring 
in an Aβ independent manner. We may actually be able to utilise such an observation to 
confirm/deny involvement of this peptide in certain AD-like molecular phenotypes, and in doing 
so, gain a deeper understanding of Aβ-independent contributions to AD. 
 
6.5 Concluding remarks 
The phenomenon known as “population aging” is currently shifting the distribution of the world’s 
populations to a more elderly composition, with predictions suggesting that more than 100 million 
individuals will develop AD by 2050 [6]. Despite this, the AD research community still has not 
reached a consensus on the underlying pathological mechanism(s) that leads to the development 




While γ-secretase processing of APP has been the major focus of research efforts surrounding this 
protease, processing of more than 100 other substrates by this protease highlights its involvement 
in many other important roles in development and other processes, that are still poorly understood. 
There remains a vast gap in our knowledge of γ-secretase biology, physiology, and structural 
biology [25]. A greater understanding of substrate selection specificity by γ-secretase would allow 
for more precise investigation of the importance of the 100+ known substrates in biological 
processes. It should also increase the potential for designing new drugs to treat the various disease 
processes that have been linked to defects in γ-secretase-mediated signalling pathways, by 
ensuring that only γ-secretase processing of the specific substrate involved is inhibited. Further 
research into many aspects of γ-secretase will be paramount if researchers wish to further pursue 
this protease as an option for treating AD. 
 
There are currently numerous hypotheses that attempt to explain the development of AD, some of 
which have been discussed in detail in this thesis. Both the validity and importance of these 
hypotheses in explaining the progression into AD remain in question. Furthermore, the lingering 
question of how or whether some or all of these hypotheses might fit together to form a single, 
unifying hypothesis remains. A unifying hypothesis will not be reached unless we can garner a 
better understanding of the larger picture regarding the early and late changes that occur in the 
brain as it transitions into AD. The generation of an appb putative null mutation as described in 
this thesis, coupled with suggested future work and current work in the ADGL, should allow us to 
address these issues, by identifying common changes between zebrafish carrying fAD-like 
mutations in each of the early onset fAD causing genes. 
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While Aβ-42 (through its aggregation and deposition into amyloid plaques) is thought to contribute 
to neurodegeneration in AD, many of the other hypotheses discussed throughout this thesis place 
its proposed role as the major underlying cause of neurodegeneration in dementia in doubt. By 
further investigating whether Aβ peptides are produced from zebrafish Appa and Appb as 
suggested in this thesis, we may be able to leverage the result to gain more insight into the role of 
this peptide in the aging or fAD mutant brain. 
 
Finally, applying our existing zebrafish fAD-like mutation models in psen1, psen2 and sorl1, along 
with the appa and appb fAD-like mutants proposed as future works continued from this thesis, to 
these questions may help us to identify new information regarding the molecular changes caused 
by such mutations. With the information gathered from such analyses, we might bring together the 
many individual hypotheses surrounding AD and gain greater insight into the complex molecular 
changes that underpin the disease. 
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